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Preface
Phantom limb pain (PLP) is a frequent consequence of amputation, and
it is notoriously difficult to treat. Despite isolated reports of success, no
medical/non-medical treatments have been beneficial on more than a tem-
porary basis. While the majority of the treatments currently offered seek
to actively suppress the pain, we emabarked on a journey back in 2008 to
challenge the status-quo of PLP treatment by instead supplying meaningful
sensations that will restore the neuroplastic changes in the cortex and thereby
control and alleviate pain. We designed, implemented and tested a novel
‘human-machine interface’ that included a ‘first-in-human’ clinical trial of
the system. In this book we report on the first steps and results from this
journey to demonstrate and provide a proof of concept of our ideas.
xiii
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Introduction
Winnie Jensen
Department of Health Science and Technology, Aalborg University,
Denmark
E-mail: wj@hst.aau.dk
Amputation of a limb is a surgical intervention used as a last resort to
remove irreparably damaged, diseased, or congenitally malformed limbs
where retention of the limb is a threat to the well-being of the individual. The
procedure traumatically alters the body image, but often leaves sensations
that refer to the missing body part, the phantom limb. In 50–80% of cases,
these sensations are perceived as painful and referred to as “phantom limb
pain” (PLP). Today, it is still not completely understood why the pain occurs,
and there are no effective treatments.
A Possible Path for Combatting PLP?
Cortical reorganization has been found to be related to PLP. Amputation
of a hand is immediately followed by significant reorganization in the
somatosensory pathway and cortex, i.e. the hand area in the brain is invaded
by neighboring areas, such that the normal homunculus is shifted. Painful
sensations appear to be related to reorganization of the primary somatosen-
sory cortex (S1), and a correlation was demonstrated between the number
of sites in the stump from where stimuli evoked referred sensations, the
PLP experienced and the amount of cortical reorganization (Grüsser et al.,
2001; Knecht et al., 1996). Several studies have demonstrated the favor-
able effect of enhancing the sensory feedback related to the missed limb
to alleviate PLP in the recent years. For example, patients with PLP, who
intensively used myoelectric prosthesis (Lotze et al., 1999) or used daily
discrimination training of surface electrical stimuli applied to the stump
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2 Introduction
Figure 1 Overview of the main hypothesis of the TIME project.
experienced significant reduction of PLP (Floor et al., 2001). Intrafascicular,
electrical stimulation of severed nerves proved to be capable of eliciting
tactile or proprioceptive sensations by implanted LIFE electrodes in human
subjects (Rossini et al., 2010). Rossini et al. also demonstrated that training
for control of a robotic hand (with a limited amount of sensory feedback)
significantly reduced PLP in a human amputee volunteer implanted with four
LIFE. The reduction in PLP lasted several weeks after the LIFE electrodes
were removed and changes in sensorimotor cortex topography were shown
electrodes (Rossini et al., 2010). We therefore hypothesized that given appro-
priate control over a sufficient number of nerve fibers, a neural interface
may be able to artificially evoke sensations and eventually relieve PLP (see
Figure 1).
Why is a HMI-System is Needed to “Solve” the Problem of
PLP?
As anybody who has felt a static electric discharge can attest, electrical
impulses can be used to evoke sensations. These sensations are a result of
the direct but nonspecific activation of peripheral nerves by the electrical
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discharge. If this basic principle is refined to specifically and focally activate
only those nerve fibers projecting to sensory fibers related to pressure on the
skin on the side of the index finger, for example, the evoked sensation would
be that of pressure on the side of the hand. Given sufficient control over a
large enough set of nerve fibers and types, the neural interface would be able
to artificially evoke sensations of touch, vibration, heat, etc., and illusions
of limb/finger/joint movement. The holy grail of human-machine interfaces
has been considered a device that can directly interface to the body’s nervous
system. It has been the topic of popular science fiction but is based upon
current experimental research in neuroprostheses. It is considered important
because almost all interactions between the brain, the body, and the environ-
ment are relayed through information flowing through the nervous system.
The ability to intercept information from, or artificially place the information
into the nervous system can revolutionize the way the brain interacts with
the body and the environment. But more importantly, such a technique may
provide currently nonexistent treatment modalities to those who have lost or
have pathological function due to traumatic injury or disease. Because of the
sizes of the cells and constraints on dimensions of devices to minimize tissue
damage, the only way to obtain high-density multichannel interfaces to the
nervous system is through the application of micro/nanotechnologies to this
medical device problem.
The TIME Prototype System for Treatment of PLP
Our aim was to develop such a Human Machine Interface (HMI) by means
of the application of multichannel microstimulation to the nerve stump of
an amputee volunteer to manipulate his/her the phantom limb sensations and
explore the possibility of using the method as a treatment for clinched fist
phantom limb pain.
This book provides an overview of our experiences and results with the
design, development, and test of the hardware and software components,
and our ambition to safely implant and evaluate the system in an amputee
volunteer subject (see Figure 2).
4 Introduction
Figure 2 Overview of the TIME prototype system for preclinical evaluation in amputee
subjects.
The “TIME prototype system” (see Figure 3) consists of the Thin-film
Intrafascicular Multichannel Electrodes (TIME) (Chapter 3), a multichan-
nel stimulator system (Chapter 7), and a psychophysical testing platform
(Chapter 8). Theoretical modeling was carried out to drive electrode design
(Chapter 4). The TIME electrodes underwent in vivo characterization in ani-
mals to test the biocompatibility, stability, and chronic safety (Chapters 5 and
6) before the system was tested in one human volunteer subject (Chapter 9).
We also speculate on the future of the TIME electrodes and TIME prototype
system (Chapter 10). Finally, to provide the reader with a broad back-
ground, we introduce the pathophysiology of pain (Chapter 2) and provide an
overview of the current understanding and treatment of phantom limb pain
(Chapter 1).
References 5
Figure 3 Overview of elements in the development and test of the TIME prototype system
for preclinical evaluation in amputee subjects.
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With amputation comes many new experiences and sensations. Most credit
the discovery and early characterization of phenomena associated with
amputation to Ambroise Paré (16th century) and, nearly 250 years later,
Silas Weir Mitchell in 1866 (Finger and Hustwit, 2003; Kline, 2016). Since
then, substantial research has been conducted to further understand the con-
sequences, mechanisms, and phenomena associated with amputation through
the investigation of physical and psychological changes after amputation.
This chapter has several goals. The first is to introduce the topic of amputation
and the associated sequelae. Second, discuss the epidemiology and several
proposed etiologies of the sequelae, focusing on phantom limb pain (PLP).
Third, review methods for measuring the manifestation of PLP, specifically
with respect to psychophysical aspects and cortical representation. Fourth,
explore the proposed treatments of PLP and consider a potential new therapy
paradigm.
Multiple studies have estimated the prevalence of limb loss and the sub-
sequent effects of amputation. As many as 185,000 amputations occur every
year in the United States (Owings and Kozak, 1998; Ziegler-Graham et al.,
2008). It was estimated that 1.6 million Americans were living with the loss of
a limb in 2005, which translates to a ratio of 1:190 Americans; 65% of these
individuals have lower extremity amputations (Ziegler-Graham et al., 2008).
Fifty-four percent of amputation cases occur after diagnosis of dysvascular
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disease and 70% of amputees with dysvascular disease (or 38% of the
amputee population) were noted to have a comorbidity of diabetes (Ziegler-
Graham et al., 2008). An unfortunate reality for many amputees is a relatively
high rate of reamputation (26% among those with dysvascular amputation
(Dillingham et al., 2005; Ziegler-Graham et al., 2008)). Reamputation refers
to those who underwent an additional procedure or additional procedures to
the previously amputated limb or the contralateral limb within 12 months
of the original procedure. In 1996, US medical care costs exceeded $4
billion yearly for dysvascular amputations alone (Dillingham et al., 2005),
which is only about half (54%) of the amputee community (Ziegler-Graham,
2008). Ziegler-Graham et al. predict the number of amputees in the United
States will reach beyond 3 million by the year 2050. This, coupled with the
high prevalence of postamputation pain (PAP) and the high degree of pain
experienced, easily makes the case that phantom pain is a relevant problem.
To further complicate the issue, the amputee community is ill-informed in
regards to PLP; 41.6% of amputees have never heard of the phenomenon
(Kern et al., 2012).
1.1 Epidemiology and Etiology of Phenomena and
Sequelae Associated with Amputation
Individuals commonly notice the presence of a phantom limb shortly after
amputation. This phenomenon, known as phantom limb sensation (PLS), is
the mental construction of the limb that is no longer present postamputation.
The phantom limb, or phantom, can be represented in a number of forms,
from normal orientations to those that are not easily described or even
physically possible. The phantom can also present pain to the amputee in
many varieties, such as tingling, burning, stabbing, etc. This phenomenon
is known as PLP or phantom pain. PLP is a subset of PLS where the
sensations specifically cause discomfort. Amputees also experience other
common painful phenomena, such as neuropathic pain (NP) and residual
limb pain (RLP; also known as stump pain). NP is pain due to the damage
or dysfunction of the somatosensory nervous system and RLP is pain in the
remaining portion of the amputated limb. All of these painful phenomena fall
under the umbrella of PAP.
1.1.1 Phantom Limb Sensation (PLS)
While the mechanism of the PLS phenomenon is not clear, it is common
among amputees; as many as 80–90% of amputees experience PLS (Jensen
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et al., 1983; Ehde et al., 2000; Casale et al., 2009). In arm or leg amputees,
PLSs are generally localized to the distal region of the phantom, i.e., the
hand, foot, fingers, or toes, and are typically not constant (Jensen et al.,
1985). Rather, the sensations peak intermittently, sometimes on a monthly
basis and sometimes several times a week (Ehde et al., 2000; Kooijman
et al., 2000). Sensations can be provoked in various ways, such as stump
movement, touching the stump, and urination (Jensen et al., 1983). In a
study involving 255 amputees, 79% reported nonpainful PLS, and of those
individuals 27% (most common) described the sensations as tingling, 26% as
itching, 13% as feeling asleep, among others (Ehde et al., 2000). Another
related phenomenon is perceived movement of the phantom, where the
amputee is able to consciously move the orientation or sense movement of
the phantom. Eight days after amputation, 36% of amputees felt movement of
the phantom with 19% feeling spontaneous movements (i.e., movements that
were not consciously driven) (Jensen et al., 1983). Similarly, another study by
Kooijman et al. found 38% to experience movement (Kooijman et al., 2000).
For some amputees, electromyogram (EMG) patterns in the stump during
imagined movements of the phantom limb are distinguishable and non-
random, indicating hand motor commands are preserved after amputation
and there exists an inherent understanding of how to manipulate/move the
phantom (Reilly et al., 2006). The modulation of signal seen in the stump
did not appear in experiments with the intact limb, which supports current
theories postamputation reorganization at some level.
The efforts to move the phantom were not only observed through muscle
movements, but also through peripheral nerve activity, i.e., Dhillon et al.
recognized nerve activity in the residual limb during attempted move-
ments. Furthermore, they recognized activity in the central nervous system
(CNS), specifically in the motor cortex, during phantom movements (Dhillon
et al., 2004). These findings emphasize the current understanding of phenom-
ena associated with amputation; the sensorimotor cortices and related periph-
eral innervation are actively involved in the perception of the phantom limb.
An altered kinesthesia is also common. For example, as many as 30%
of amputees experience telescoping, which is the gradual shortening or
retraction of the phantom limb, as depicted in Figure 1.1 (Jensen et al.,
1983; Hill, 1999). In some amputees, the phantom limb no longer reflects the
original anatomy. In this example, the phantom limb shortens and is drawn
into the stump. In these situations, the residual limb and phantom hand or
foot are no longer in an orientation that matches the original volume or limb,
which causes confusion and concern to many amputees. Telescoping has also
been linked to increased levels of phantom pain (Flor et al., 2006).
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Figure 1.1 Among the peculiar potential pathological changes that occur after amputation is
telescoping. Telescoping is a phenomenon in which the amputees sensory body image changes
resulting in an alteration in the phantom sensations with respect to the sensations from the
normal parts of the body. With time, the phantom sensation gradually moves or shrinks, for
example as shown above, into odd or impossible positions or joint angles. This results in a
state of sensory confusion, and concern for the amputee that potentially contributes to the
increase in phantom limb pain.
In some circumstances, PLSs can be helpful in adjusting to the use
of a prosthetic device, where the phantom limb embodies the prosthesis
(Gallagher et al., 2008). Murray describes the embodiment phenomenon as a
transition of a prosthesis from an extracorporeal structure to a corporeal one,
meaning the prosthesis becomes part of the identity of self. This fits into the
field of psychoprosthetics, which uses a psychological framework to analyze
and explain the phenomena associated with prostheses and the amputation
rehabilitation process. Corporeal embodiment does not occur in all amputees,
which is not well understood. Murray attributes this embodiment transforma-
tion to practice, i.e., increased use of the prosthesis (Gallagher et al., 2008).
Despite the possible utility of PLSs, in many cases the phantom sensation
evolves into the form of PLP, which can be not only a hindrance, but also a
phenomenon that has a strong negative effect on the amputee’s quality of life
(Knežević et al., 2015).
The phantom limb can also be debilitating when the sensations are
painful; 54% of amputees who experience painful phantom sensations,
or PLP, regarded the pain as somewhat bothersome (27% said extremely
bothersome) (Ephraim et al., 2005).
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Phantom sensations are not pathognomonic to amputation of a limb
(Buonocore, 2015). In fact, studies have recognized phantom sensations in
other sensory systems. Phantom eye syndrome has been found to affect as
many as 51% of patients with orbital exenteration with 26% feeling pain
(Roed Rasmussen et al., 2009). Phantom eye sensations most commonly
came in the form of elementary visual hallucinations such as white light
or colored light and were triggered by darkness, stress, and fatigue, among
others (Roed Rasmussen et al., 2009).
Another argued case of phantom sensation is tinnitus, where individuals
experience phantom auditory sensations, most commonly described as ring-
ing in the ears, steady tones, or hissing. Tinnitus has been linked to hearing
loss, i.e., up to 90% of cases are linked to hearing loss (Shore et al., 2016).
Like PLS, tinnitus describes false perceptions; however, tinnitus is unique
because it also occurs in individuals who are otherwise healthy. Sectioning of
relevant cranial nerves has not proven successful for the treatment of tinnitus,
lending to support the current proposed mechanism of maladaptive neural
plasticity (House and Brackmann, 1981; Shore et al., 2016).
1.1.2 Phantom Limb Pain (PLP)
The prevalence of PLP, or phantom pain, widely varies in literature. A survey
by Ephraim et al. (with 914 respondents), phantom pain was reported in
79.9% of amputees with 38.9% reporting the pain as severe (≥7 on a 0–10
analog scale) (Ephraim et al., 2005). Ephriam et al. recognized no significant
difference of the rates of phantom pain based on etiology, age, or level of
amputation; they also noted that the rate of PLP for upper limb amputees
was 83%, consistent with the rest of the study population. Eleven percent of
the amputees in this study were upper limb (10% unilateral), leaving 89% as
lower limb (79% unilateral). The mean pain intensity for phantom pain of all
study participants was 5.5 ± 2.6 (Ephraim et al., 2005). Others have found
prevalence rates ranging between 40% and 85% (Sherman and Sherman,
1983; Ehde et al., 2000; Kooijman et al., 2000; Schley et al., 2008; Kern
et al., 2012). Various explanations have been offered for discrepancies in the
prevalence, such as response rates and bias from choice of study population.
However, the clear cause of the differences is not known. The range for PLP
prevalence in amputees generally referenced in literature is 50–80%.
The quantification and description of PLP is important in understanding
the effectiveness of treatment. From the standpoint of self-reporting scales,
pain can be defined in terms of intensity, affect, quality, and location (Jensen
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and Karoly, 2010). Most research studies have opted to primarily measure
intensity and bothersomeness using the visual analog scale (VAS) or the dis-
crete version called the numeric rating scale (NRS). Average ratings of pain,
in terms of the VAS, fall in the range of 5.1–5.5 out of 10 (Ehde et al., 2000;
Ephraim et al., 2005). Ehde et al. found that when asked how bothersome the
pain is (scale of 0–10, 0 being not at all bothersome, 10 being as bothersome
as could be) 32% of respondents reported pain as being severely bothersome
(≥7) and only 10% rated the PLP as not bothersome at all (Ehde et al., 2000).
Likewise, Ephraim et al. found only 19% of respondents not to be bothered by
the PLP they experienced (Ephraim et al., 2005). Amputees tend to describe
PLP as knife-like (stabbing), sticking, burning, squeezing, etc. (Jensen et al.,
1983; Jensen et al., 1985; Montoya et al., 1997).
A final metric or description of PLP is needed to quantify frequency
and length-of-time of the pain. Efforts have been taken to define how often
amputees felt PLP, and how long the pain was present. Amputees suffering
from PLP experience the pain at different intervals; 31% report a frequency
less than 1 episode per month, 14% a few times a day, and 7% have constant
pain (Schley et al., 2008). Another study found 14%, 24%, and 24% for the
same time frames, respectively (Kooijman et al., 2000). Kooijman et al., in the
same work, found a fairly uniform distribution among frequencies of phantom
pain attacks from feeling PLP a few times per year, month, week, day and
constant pain, ranging from 14% to 24%. Kern et al. found of those experi-
encing PLP, 56.1% have pain lasting less than 5 h daily and many (27%) felt
pain constantly (Kern et al., 2012). Ephraim et al. reported frequency in terms
of never, sometimes, and always (20.1%, 58.7%, and 21.2%, respectively)
(Ephraim et al., 2005). Ehde et al. found 81% of amputees to experience
intermittent PLP, between once a week or less and four to six times per week
(Ehde et al., 2000). Among these studies the rates are different for frequency
of pain, as shown in Figure 1.2.
The median follow-up period for the study by Schley et al. was 3.2 years
while the median follow-up period for the study by Kooijman et al. was 19.1
years. Also, the events leading to amputation (i.e., the study population) were
slightly different among studies, where 98% of the Schley et al. data came
from traumatic cases (Schley et al., 2008), 78% from traumatic cases in the
study by Kooijman et al. (2000), and 50% for the study by Kern et al. (2012).
Conversely, frequency and duration of PLP have also been found to decrease
within 6 months after amputation (Jensen et al., 1985); this contradicts the
discrepancy in the constant pain rate between Schley et al. (7% at 3.2 years
after amputation) (Schley et al., 2008) and Kooijman et al. (24% at 19.1 years
after amputation) (Kooijman et al., 2000). It is not clear which findings are
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Figure 1.2 Various rates have been reported in literature for the frequency of PLP episodes.
Most respondents reported PLP as occurring at a frequency somewhere between never and
always. Several variables could explain discrepancies among studies, including epidemiology
and etiology of amputation, years since amputation, size of sample population, etc. The effect
of these factors on PLP presentation is not well understood.
more representative of the general amputee population. Ephraim et al. found
of amputees 10+ years postamputation; 74% were experiencing phantom
pain (Ephraim et al., 2005). The measure of length-of-time of pain has been
reported in several ways, which makes it difficult to compare among reports
in literature. PLP tends to flare episodically for seconds to minutes, but some
have reported pain lasting several hours to a day or even longer (Jensen et al.,
1985; Montoya et al., 1997; Ehde et al., 2000).
1.1.2.1 Triggers of PLP
Some have sought to understand the common comorbidities and triggers asso-
ciated with phantom pain. Those who indicate a depressed mood are more
likely to report severe pain and pain that is extremely bothersome (Ephraim
et al., 2005). Phantom pain comes in many forms with many triggers. Often
times PLP can flare during emotional distress, stump pressure, urination, cold
temperature, or while coughing (Jensen et al., 1983). Preamputation pain has
been recognized in several studies to be associated with phantom pain after
the amputation (Jensen et al., 1983; Jensen et al., 1985; Schley et al., 2008).
Many have suggested a correlation of PLP and RLP; however, Kooijman
et al. suggested that RLP acts as a trigger of PLP (Kooijman et al., 2000).
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This claim has not been substantiated by subsequent research. Giummarra
et al. suggest several categories of triggers, the most frequent of which
is “Movement and ‘behavioral schema’ triggers”; these include activities
such as scratching an itch, gesturing with the phantom, etc. (Giummarra
et al., 2011).
1.1.3 Residual Limb (stump) Pain (RLP)
A substantial number of amputees experience pain in their residual limb. As
with other descriptors of pain, the rates vary widely in literature. Rates of
stump pain span from 22% to 76% (Jensen et al., 1983; Smith et al., 1999;
Kooijman et al., 2000; Ephraim et al., 2005; Schley et al., 2008; Bekrater-
Bodmann et al., 2015). More recent surveys support rates on the higher side
(61–67.7%) (Ephraim et al., 2005; Schley et al., 2008; Bekrater-Bodmann
et al., 2015). Ehde et al. reported that, in response to asking which pain is the
worst, the highest rated site (33%) was the residual limb, over phantom limb,
back, and others (Ehde et al., 2000). RLP was also found in another study to
be more impairing than PLP or back pain (Marshall et al., 2002). Only 4–13%
of amputees experiencing RLP think of it as not bothersome at all (Ehde et al.,
2000; Ephraim et al., 2005). On average, the intensity of the RLP falls in the
moderate pain range at 5.4 on a 0–10 scale and is commonly described as
aching or burning (Ehde et al., 2000). This is supported by Ephraim et al.,
who found that for the individuals experiencing RLP, the pain was almost
uniformly spread among mild, moderate, and severe (41.8%, 28.3%, and
29.9%, respectively), with mild being slightly more prevalent (Ephraim et al.,
2005). Similar to PLP, RLP tends to present itself in episodes and can last
seconds, minutes, hours, or longer (Ehde et al., 2000). RLP does not tend
to diminish with time after amputation (Ephraim et al., 2005). Looking for
the possible cause behind the pain is an elusive question. O’Reilly et al.
propose the pain is a result of neuromata (O’Reilly et al., 2013, 2016), which
are sensitive bundles of nerve endings that result from inability to reconnect
with the target tissue (Fried et al., 1991). Taken together, the high rate of
prevalence and the impact on the quality of life highlight the degree to which
RLP is a debilitating problem that needs to be addressed. A clear path to
treating the issue of RLP is to look at treatment methods for NP. Neuromata
are often associated with this type of pain, since inherently neuromata are a
result of damage to the peripheral nervous system (PNS).
Amputees, often times, cannot distinguish between PLP and RLP (Hill,
1999; Flor, 2002). Generally, this confusion arises when pain is felt in the
1.1 Epidemiology and Etiology of Phenomena and Sequelae Associated 15
vicinity of the amputation site, where the phantom and residual limbs meet.
RLP and PLP tend to correlate, especially in intensity (Ehde et al., 2000).
Schley et al. found that 86% of amputees experiencing phantom pain also
experienced stump pain (Schley et al., 2008).
1.1.4 Neuropathic Pain (NP)
NP plays a role in phantom phenomena (Buonocore, 2015). Casale et al.
suggest that there is a significant link between neuromata and PLP (Casale
et al., 2009). Neuromata make the surrounding area more sensitive to stimuli
(mechanical, chemical, electrical), which explains correlations of pain and
various triggers (e.g., touch, mood, stress, etc.) (Casale et al., 2009). Many
of the descriptors of PLP and RLP reflect what would be expected of NP,
i.e., burning, stabbing, etc., which leads one to conclude that PLP and RLP
are forms of NP, and may link to the development of neuromata in the
stump. Neuromata are the most common cause of pain in one study (O’Reilly
et al., 2016). However, not all neuromata result in pain. For example, the
same study found 159 neuromata in the sample population, but only 91
(57%) were painful in response to transducer pressure (O’Reilly et al., 2013).
Another study supports this finding with similar rate of pain occurrence at
67% (O’Reilly et al., 2016). Furthermore, neuroma excision is not always
successful. In a small case study, neuroma excision relieved pain in only two
of the six patients (Nikolajsen et al., 2010). On the other hand, retrospective
studies of neuromata removal found surgery to be a very successful method
for relinquishing pain (Ducic et al., 2008; Sehirlioglu et al., 2009). Neverthe-
less, even though the links among neuromata, PLP and RLP are uncertain,
it does not rule out that PLP and RLP arise from NP origins. Nikolajsen
et al. found a link of PLP to N-methyl D-aspartate (NMDA) receptors through
treatment with ketamine and concluded that PLP and RLP have mechanisms
linked to both peripheral and central systems (Nikolajsen et al., 1996).
NMDA is an excitatory neurotransmitter which interacts with NMDA
receptors. NMDA receptors are known to be associated with neural plasticity,
having a role in long-term potentiation and long-term synaptic depression.
They are also involved in sensory transmission; A-delta and C fibers use
NMDA receptors among others in transmitting painful stimuli up nociceptive
pathways at synapses in the Rexed laminae of the dorsal horn (Bleakman
et al., 2006). Furthermore, having these roles gives way to one of the cur-
rent, proposed mechanisms for NP, which points to NMDA receptors as
a culprit for injury-induced central sensitization leading to secondary pain
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presentations such as allodynia and hyperalgesia (Bleakman et al., 2006;
Collins et al., 2010). For this reason, as discussed later, NMDA receptors are
a popular target for medicinal treatment approaches to alleviate NP (Collins
et al., 2010).
Whereas, PLP is pain in the phantom and RLP is pain in the stump,
linking the two to NP offers an explanation that neither form of pain would
exist without injury to the PNS. This also assumes that RLP and PLP are
not generated through traditional means of activating nociceptor pathways.
Although, this theory does not explain all observed conditions of phantom
pain, e.g., people who are congenitally limb-deficient. As many as 20% of
these individuals experience phantom limbs at some level (either sensation or
pain), even though there is no injury, per se (Melzack et al., 1997).
1.1.5 Secondary Effects of PAP
It is not just the rate of amputations and the severity of the pain that makes
this problem relevant, but also the impact of PAP on an individual’s everyday
life. The multifaceted attack of PAP through various mediums, such as
PLP, RLP, and other forms, interferes with daily activities (Marshall et al.,
2002). Amputation and PAP negatively affect the self-perceived quality of
life through fatigue and diminished mood (Trevelyan et al., 2016). This leads
to high rates of depression among amputees (as high as 41%) presenting a
vicious cycle, as there are substantial links among depression, level of pain,
and bothersomeness of pain for PLP and RLP (Cansever et al., 2003; Ephraim
et al., 2005). Depression secondary to amputation could be remediated by
educating the population on the risks of amputation and providing mental
health services (Darnall et al., 2005).
1.2 The Proposed Loci and Mechanisms of PLP
1.2.1 Neurologic Locus of PLP
The root cause of PLP is not clear as effects of amputation appear in each
level of the nervous system, indicating multiple compounding sources of pain.
Evidence suggests that PLP is the result of a multifaceted, combined system
response from cortical, peripheral, segmental, and even psychological origins
(Flor et al., 2006). Most propositions of mechanisms discuss cause and effect
on the level of the CNS or PNS. Because of the many proposed mechanisms,
further partitioning is necessary. Therefore, mechanisms are discussed below
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according to the relevant neurologic locus: peripheral, spinal, supraspinal,
and cortical (Flor et al., 2006; Hsu and Cohen, 2013).
1.2.2 Predominant Mechanisms of the Peripheral
Neurologic Locus
The Tinel sign (also “tingling” sign) was originally proposed to identify
regions of peripheral nerve regeneration, specifically regarding cases of nerve
injury (Davis and Chung, 2004). Similarly, one can use the Tinel sign on an
amputee to locate nerve injuries that cause sensations or pain in the stump
or phantom (referred sensation or RS). Commonly, the location that causes
sensation or pain is at the site of a severed nerve, which has morphed into
a neuroma. These neuromata (known as terminal neuromata) are typically
formed within 1–12 months after nerve transection (Boutin et al., 1998), but
start to form within hours (Fried et al., 1991). A study in rats found that
ectopic discharges from injured peripheral nerves have a role in initiating NP,
but do not have a significant role in the maintenance of NP (Sun et al., 2005).
The onset of ectopic discharges is correlated with the onset of allodynia
(pain from a stimulus that would normally be nonpainful) shortly after nerve
transection, indicating these are responses to or results of injury (Sun et al.,
2005). However, in animal studies ectopic discharges diminished over time,
while tactile allodynia was maintained (Sun et al., 2005; Flor et al., 2006).
These circumstances in the periphery seem to demonstrate two effects of
nerve transection, but do not identify the source or mechanism of pain.
For example, neuromata have been found to be sensitive to mechanical and
chemical stimuli (Fried et al., 1991; Flor et al., 2006), so much so that PLP
can be heightened from tapping (Nystrom and Hagbarth, 1981). However, a
study on two amputees found that PLP persisted even after blocking PLP
associated neuromata with lidocaine (Nystrom and Hagbarth, 1981). This
causes further suspicion that PLP and other phantom phenomena are not
caused by peripheral mechanisms; rather, they are merely accentuated by
peripheral factors.
1.2.3 Predominant Mechanisms of the Spinal
Neurologic Locus
Deafferentation of the dorsal horn is thought to be linked to PAP, specifically
through central sensitization, which is the increased activity of the dorsal
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horn afferent targets due to decreased suppression from the brainstem (Iacono
et al., 1987; Hsu and Cohen, 2013).
Deafferentation could be a result of amputation, or it could be another
type of injury such as brachial plexus injury. Jensen et al. proposed that
pain may be induced from atrophy of deafferented dorsal horn neurons and
changes to receptive fields in the spinal cord (Jensen et al., 1983).
Spinal reorganization has also been recognized in functionally inactive
regions and is reversible if the relevant nerves regenerate (Devor and Wall,
1981; Hsu and Cohen, 2013). It has also been manipulated through operant
conditioning of spinal reflexes (a well-known mechanism for learning).
Thompson and Wolpaw reviewed several studies that took advantage of the
operant conditioning paradigm to alter reflexes (Thompson and Wolpaw,
2014). Because of the integration of sensory information in the spinal cord
(especially connections involved in gating through suppressive inhibitory
interneurons), spinal mechanisms are important to consider (Teixeira et al.,
2015).
1.2.4 Predominant Mechanisms of the Supraspinal
Neurologic Locus
Florence and Kaas found in animal studies that cortical reorganization was
linked to reinnervation and sprouting afferents subcortically in the brainstem
and thalamus (Florence and Kaas, 1995). Some have linked amputation to
significant changes to the cuneate nucleus in the brainstem, which typi-
cally projects to the thalamus and transmits afferent sensory information,
especially from the hand (Florence and Kaas, 1995; Wu and Kaas, 2002).
Xu and Wall found changes in the cuneate nucleus to occur within minutes
to hours after injury in primates (Xu and Wall, 1997). Further evidence
of supraspinal reorganization was demonstrated in adult squirrel monkeys
(Churchill et al., 2001). Churchill et al. found that somatotopic reorganization
of the thalamus and brainstem was of a similar extent to what is reported for
the cortex (Churchill et al., 2001).
1.2.5 Predominant Mechanisms of the Cortical
Neurologic Locus
A traditional theory, as proposed by Ramachandran et al., is that cortical reor-
ganization is the primary mechanism of PLP, which is typically discussed in
terms of plasticity of the primary somatosensory cortex (S1) (Ramachandran
et al., 1992, Flor et al., 2000). Directly following amputation, the mapping of
1.2 The Proposed Loci and Mechanisms of PLP 19
S1, i.e., Penfield’s Homunculus, no longer matches the anatomical structure.
Changes occur in the sensory and motor cortices adapting to both the altered
anatomy and the loss of sensory input (Flor et al., 2000). Specifically, the
plasticity of the cortex allows neighboring regions of the somatosensory
homunculus to take over the region that previously mapped to the, now deaf-
ferented, limb (Ramachandran et al., 1992). However, this mechanism also
has missing links when looking at clinical experiences. A case study of two
amputees found that some experience RS in the phantom hand while touching
the ipsi- or contra-lateral foot (Grüsser et al., 2004). Another study found
RSs in the upper leg and genitals that mapped to the phantom in upper limb
amputees (Giummarra et al., 2011). Flor et al. found significant differences
in activity among amputees experiencing phantom pain compared to those
not experiencing PLP in regions such as SI, the secondary somatosensory
cortex (S2), and the posterior parietal cortex (PPC) (Flor et al., 2000). Other
cortical changes have also been evaluated, such as unmasking of preexisting
synapses of neighboring cortical regions, e.g., of SI, and of preexisting
transcommissural connections, e.g., for coordinated movements of multiple
limbs (Giummarra et al., 2007). The latter is of particular interest because it
may explain cortical reorganization ipsi-lateral to the amputation as seen by
(Schwenkreis et al. 2003; Garry et al., 2005).
1.2.5.1 Referred sensation and related mechanisms
While all phantom sensations are in a sense “referred,” the definitions of
PLS and RS are slightly different. PLSs are generally understood to be
any sensation felt in the phantom limb, whereas RSs are perceived feel-
ings in a body part when another body part is being stimulated (such as
the residual limb or the face). RS is a common occurrence in amputees
(Ramachandran et al., 1992; Flor et al., 2000). While it is possible to feel
RSs without nerve injury by stimulating proximal regions of a peripheral
nerve as demonstrated by Forst et al. (2015), RSs typically are amplified in
amputees (i.e., more regions of the body such as the face and ear map to the
phantom limb). Similar to amputation, substantial RSs have been noted in
individuals with type I complex regional pain syndrome (CRPS) (McCabe
et al., 2003), spinal cord injury (Moore et al., 2000; Soler et al., 2010), and
other nerve-related ailments. As with other aspects of phantom phenomena
there is debate on the mechanism of RSs. This phenomenon is thought to
originate from mechanisms that are separate from other phantom phenomena,
as they are non-neuropathic in nature (Buonocore, 2015). Flor et al. found
correlation of RSs to increased activity of the PPC (Flor et al., 2000),
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while Ramachandran et al. supported reorganization of S1 to be the primary
mechanism (Ramachandran et al., 1992). Stimulation of the remaining nerve
in the residual limb has also elicited RSs; Dhillon et al. achieved this through
stimulation with implanted electrodes (Dhillon et al., 2004). Similarly, Forst
et al. were able to evoke RSs through surface electrical stimulation in healthy
subjects by placing surface electrodes over the ulnar and median nerves (Forst
et al., 2015).
The mapping of RSs requires the analysis of three primary locations:
(1) the area being stimulated, (2) the area being referred, and (3) the cortical
location of somatosensory processing. Several questionnaires call for a sub-
ject to locate the areas of pain (Melzack, 1975), but because nonpainful
sensation are generally not bothersome (Smith et al., 1999), the location and
mapping of RSs have not been addressed except cortically. This is a useful
measure to determine changes in the presentation of pain. RSs can be evoked
by touch; the Tinel sign is a simple method for identifying these regions
(Trotter and Davies, 1909; Davis and Chung, 2004).
Several interesting phenomena, which likely have different mechanisms,
are considered RSs. For example, the RSs evoked by touching the face of an
amputee (as done by Ramachandran et al.) likely has a mechanism primarily
in the cortex (Ramachandran et al., 1992; Flor et al., 2000). However, an
RS evoked from stimulation of the proximal region of a peripheral nerve (as
done by Dhillon et al.) likely can be explained by peripheral and/or spinal
mechanisms (Dhillon et al., 2004; Forst et al., 2015).
1.2.6 Psychological Aspects of Pain
Emotional and psychological states have a large role in interfering with
amputees’ lives (Shukla et al., 1982; Kashani et al., 1983; Cansever et al.,
2003). The initiative on methods, measurement and pain assessment in clini-
cal trials (IMMPACT) recommends testing effects on emotional functioning
when conducting pain-related clinical trials (Dworkin et al., 2008). Since
amputees have exhibited differences from the general population in this
respect, it is reasonable to assume that it also plays a role in the experience
of PLP and other postamputation phenomena. In general, PLP is not a
symptom of psychological distress (Katz, 1992). Katz and Melzack reported
that depression and anxiety were not predictors of PLP (Katz and Melzack,
1990). This is further supported by Darnall et al. who found extremely
bothersome RLP or PLP lead to increased odds of depressed symptoms, but
depressed symptoms do not necessarily indicate bothersome RLP or PLP.
They concluded that one of the highest risk factors for depressive symptoms
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is PAP (Darnall et al., 2005). Both Hill and Katz cautioned researchers on
the assumptions related to depression and PLP saying claims of psycholog-
ical explanations of pain are unsubstantiated and study populations may be
inherently biased (Katz, 1992; Hill, 1999). Along the same lines, some have
suggested that the causal relationship between pain and mood is only unidi-
rectional, i.e., negative mood states are a result of pain, but pain is not a result
of negative mood (Blågestad et al., 2016). Even though the relationship of
PAP and depression is still under investigation, the relationship of depression
and amputation seems to be quite clear. In addition to depressive symptoms,
evidence of anxiety, insomnia, and other psychological ailments are prevalent
(Shukla et al., 1982). This demonstrates a need for mental health services
among the amputee population.
1.3 “Phantom” Pain in Nonamputees – A Complicated
Issue
The traditional definition of PLP refers to pain in a limb that is not present.
However, there are also instances of sensation and pain in a limb that has
lost connection to the CNS (deafferentation), from brachial plexus avulsion
(BPA) or intraspinal injury, for example. These scenarios have been dubbed as
“phantom” because the individual does not experience pain or even sensation
through typical nociceptive and sensory pathways, because they are no longer
connected. In this regard “phantom” sensations have been found in individ-
uals who have brachial plexus injuries (Sweet, 1975; Son and Ha, 2015;
Tsao et al., 2016). In addition to the similar descriptions of pain, after BPA
individuals experience RSs in the deafferented limb from touching the ipsi-
lateral face (Tsao et al., 2016). Brachial plexus injuries also lead to cortical
reorganization (Qiu et al., 2014). Most often pain is described as tingling, pins
and needles, burning, sharp, or paroxysmal (Parry, 1980), which is reason to
believe BPA causes NP (Teixeira et al., 2015). The underlying mechanisms
of pain as a result of BPA are not well defined. In comparing symptoms, one
must consider that brachial plexus injuries are often incomplete, meaning the
limb remains partially sensate because it is still partially neurologically intact.
If individuals with BPA or intraspinal injury experience PLP, the phantom
pain and phantom sensations convolute with trace sensations from the limb.
Furthermore, the presence of the limb further complicates discriminating
phenomena as phantom or not. While the pain presents in a similar fashion
to that of pain as a result of amputation, the presence of the limb makes it
difficult to know if the mechanisms are the same.
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1.4 Theories of Why PLP Presents
In the study of phenomena associated with amputation, an important thought
to consider is that a single mechanism will likely not explain all phenomena.
This idea was proposed by Sherman et al. in their evaluation of the
mechanism of PLP, which concludes that different presentations of pain
should be treated differently clinically, but does not suggest how (Sherman
et al., 1989). Several theories have been proposed over the years to explain
PAP and phantom phenomena. Ronald Melzack and Patrick Wall have had
many contributions to this list and evolution of theories including the Gate
theory of pain, the Neuromatrix theory, and others, which are discussed
further.
1.4.1 Gate Theory
Gate theory is a prominent pain theory developed in the 1960s (Melzack and
Wall, 1965). The concept in its most basic form can be summarized as a
complex multi-input, multilayered system, where inputs at various layers can
relay “off” or “on” signals, which cascade to determine whether or not pain
is perceived (Melzack and Wall, 1965; Mendell, 2014). More specifically,
Gate theory suggests that portions of the dorsal horns, such as the substantia
gelatinosa, and the brain are active contributors to the system, which excite,
suppress, and modulate signals to downstream targets (Melzack, 1999). Wall
reinforced the theory after a few years discussing new findings in the field
and how they relate to the previously proposed theory (Wall, 1978). In
development of the theory there were many unknowns as to how the theory
was implemented physiologically. In returning to the topic Wall proposed that
descending control involves the periaqueductal grey matter and nucleus raphe
magnus (Wall, 1978).
The theory was proposed ahead of its time, pushing the field for-
ward to better understand mechanisms of pain (Mendell, 2014). Since its
introduction, Gate theory has evolved over several decades to account for
new findings (Wall, 1978; Mendell, 2014). It provided the framework for
future theories of mechanisms that incorporate the CNS and an individual’s
unique life experiences (Hill, 1999; Melzack, 1999). Melzack proposed a
new theory as a derivative from Gate theory called the Neuromatrix the-
ory, which emphasizes a sense of self in the perception of pain (Melzack,
1999).
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1.4.2 Neuromatrix Theory
The Neuromatrix theory relies on the concept of a network of neurons that
defines a genetically determined feeling of self (Melzack, 1990, 1992). The
neuromatrix is thought to extend beyond the somatosensory areas of the
cortex to the limbic and thalamocortical systems (Giummarra et al., 2007).
Melzack proposed the neuromatrix could be molded by sensory input and is
comprised of “thalamocortical and limbic loops,” which cyclically process
and synthesize input and output patterns. These patterns are what Melzack
deemed the neurosignature, an individual’s pattern of synaptic connections
impressed on the neuromatrix (Melzack, 1990). An altered neurosignature,
due to amputation, for example, would result in the experience of a phantom
limb through sensations and possibly pain (Flor, 2002). The Neuromatrix the-
ory considers sensory input and transmission on a “level of equal importance”
as hormonal mechanisms of stress, meaning pain does not exist solely in a
space of neural mechanisms, but also has psychological factors (Melzack,
1990). The diffuse nature of the theory, i.e., pain (or even phantom sensation)
being the output of a large, complex psychophysical system, makes it difficult
to isolate and test clinically (Hill, 1999; Flor, 2002; Giummarra et al., 2007).
Furthermore and even more perplexing, the theory does not offer an explana-
tion for why some amputees experience phantom pain or phantom sensation
and others do not (Flor, 2002). Giummarra et al. offer examples of seven
phantom limb-related experiences that are not explained by the Neuromatrix
theory and concludes that Neuromatrix theory may provide explanations of
PLP, but not PLS (Giummarra et al., 2007). While Neuromatrix theory is
intriguing and will likely spark discovery in the current age of pain research
(like Gate theory did in the 1960s), it lacks some explanation for phantom
phenomena.
1.4.3 Maladaptive Cortical Plasticity
The idea of maladaptive cortical plasticity is that the sensorimotor cortex reor-
ganizes in a way that causes pain post deafferentation. Whereas, it is clear that
the cortex reorganizes postamputation, the extent of the relationship between
reorganization and pain is unclear (Flor et al., 2006). Evidence supporting this
theory compared hand and lip movements among upper limb amputees and
healthy controls, where amputees experiencing PLP showed reorganization of
the mouth and hand region of S1 and the primary motor cortex (M1) (Lotze
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et al., 2001). In a study of brain-machine interfaces with patients experiencing
phantom pain, Yanagisawa et al. found that attempting to merge and amplify
neural signaling to cortical representation of the phantom actually increased
pain (Yanagisawa et al., 2016).
1.4.4 Pain Memory
The pain memory hypothesis supposes that phantom pain mimics
preamputation pain because of implicit pain “memories” established in the
somatosensory system (Flor, 2002; Flor et al., 2006). The hypothesis relies on
plasticity of the somatosensory cortex due to nociception (Flor et al., 2006).
In a small study involving capsaicin injection, sensitivity of SI to nociception
has been measured, improving validity of the hypothesis (Sörös et al., 2001).
Further support for the hypothesis is that phantom pain commonly embodies
pain that was experienced preamputation (Katz and Melzack, 1990), and sev-
eral studies have found correlations between preamputation pain and phantom
pain (Jensen et al., 1983; Nikolajsen et al., 1997). However, this theory does
not account for the amputees who experience PLP but do not experience pain
preamputation. Furthermore, some amputees feel pain due to the phantom
limb being in an unnatural or biologically impossible orientation, which does
not support this hypothesis.
1.4.5 Sensory Confusion
The hypothesis of sensory confusion assumes that pain is a result of
ramping due to broken feedback mechanisms. While feedback loops exists
subcortically, evidence also points to involvement of frontal and parietal brain
areas in the “incongruence of motor intention and sensory feedback” (Harris,
1999; Flor et al., 2006). Similar to Gate theory, this hypothesis relies on
closed-loop control of peripheral and central mechanisms, which modulate
sensorimotor information during movement. Harris compares this effect to
the feeling of nausea when senses do not agree on body position or balance
(Harris, 1999).
1.5 Measuring PLP
Pain has both behavioral and physical properties and can be largely
subjective. Intensity, affect, quality, and location are the primary experiential
dimensions of pain (Jensen and Karoly, 2010). Pain intensity refers to the
extent of the pain and can be subjective based on historical experience of the
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individual reporting the pain. Pain affect refers to the “emotional arousal or
changes in action readiness caused by the sensory experience of pain,” as so
eloquently put by Jensen and Karoly (Jensen and Karoly, 2010). In essence,
pain intensity refers to the extent of pain while pain affect refers to the
emotional experience related to pain or the extent to which the individual is
bothered by the pain. Pain quality refers to the descriptors of pain with respect
to sensation, such as tingling, burning, sharpness, etc. and also includes
the time-related aspects of pain, such as frequency, length-of-time of pain,
etc. Pain location defines the area pain is perceived. Each of these four
dimensions of pain is important to measure when studying the effectiveness
of treatments and therapies for PLP. However, the measurement of PLP is
a complicated issue. When measuring pain in a research setting (clinical or
animal), there are additional considerations, such as the effects of habituation
and sensitization (Johnson, 2016). Because of these barriers, pain-researchers
utilize multiple measures and consider behavioral presentations of discomfort
in analysis (Huskisson, 1974). Across studies of proposed therapy methods,
various pain measures and scales have been utilized; in regards to PLP, studies
tend to describe the degree of pain and the extent the pain interferes with
the individual’s life through various psychophysical measurement modalities
(Hill, 1999). This variety of methods makes comparisons of results difficult.
1.5.1 Psychophysical Measures of Pain
In order to understand the effects of a given therapy modality, one must
measure the various aspects of pain. Several validated measures are available
to do this. The instruments used in the present study for effect determination
are the VAS, neuropathic pain symptom inventory (NPSI), profile of mood
states-short form (POMS-SF) and are discussed further.
1.5.1.1 Self-report questionnaire
While self-report questionnaires are an obvious way to gather information
and understand the pain being perceived, the subject-to-subject (intersubject)
variation cannot be predicted. For example, Dar et al. found, in a small
study of injured veterans, that severely injured individuals have a higher
pain tolerance and higher pain threshold than lightly injured individuals (Dar
et al., 1995). In a study of thermal pain thresholds, Wasner et al. explored
preconditioning as a means of testing sources of intersubject variations;
however, in terms of pain thresholds, the study found no difference in subjects
who were preconditioned and subjects who were not preconditioned (Wasner
and Brock, 2008). This is a relevant finding because of the concern for scale
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recalibration presenting a potential source of variability in self-report data.
The proposition of scale recalibration is an issue that is not addressed in the
realm of PLP. However, in other research areas, this has not been validated as
a source of variation. Lacey et al. found no evidence of scale recalibration in
individuals suffering from chronic illness (specifically with regards to quality
of life ratings) (Lacey et al., 2008). Nevertheless, studies typically rely on
validated instruments and assessments to characterize pain and understand
the effects of a given treatment for a population.
1.5.1.2 The visual analog scale (VAS)
Psychophysical measures involve those that describe an individual’s
perception. A commonly used instrument is the VAS. With respect to pain
intensity, an individual experiencing pain ranks the pain somewhere between
“no pain” and the “pain as bad as it could be” by marking a line spanning
between the two extremes (commonly separated by 10-cm). The individual’s
severity of pain can be enumerated by measuring the length from 0 (no pain)
to the marking (Huskisson, 1974). The primary measure of most studies
describing the prevalence of PLP is typically some version of pain intensity;
most often this is done with the VAS (Hill, 1999). The VAS and the discrete
version, NRS, can be used for any measure in which there are two extremes.
The VAS has been used to understand other aspects of phantom phenomena,
such as intensity of PLS (Sherman and Sherman, 1983), and it can be useful
in describing the effect of a treatment or therapy. In fact, it is used frequently
outside of the realm of PLP (Huskisson, 1974). When describing the intensity
of phantom pain, the VAS is often used along with the interpretation or
adaptation into mild, moderate, and severe pain. Jensen et al. attempted to
standardize these descriptors to pain ranges, 1–4, 5–6, and 7–10, respectively,
by considering factors such as pain interference and impact on quality of life
(Jensen et al., 2001).
1.5.1.3 The neuropathic pain symptom inventory (NPSI)
The idea of using a VAS or NRS has been adopted and adapted to quantify
other unmeasureables because of its dependability (Huskisson, 1974). The
NPSI utilizes several NRSs to quantify the qualities of NP (Bouhassira
et al., 2004). Ultimately, the responses are combined to form subscores,
which represent different aspects of NP, i.e., burning, pressing, paroxysmal,
evoked, and paresthesia (or dysesthesia), and overall NP. In the case of NPSI,
paresthesia/dysesthesia are defined by the same subscore, which is related
to feeling pins and needles and feeling tingling (Bouhassira et al., 2004).
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The usefulness of the NPSI is that it not only demonstrates the presence
of NP, but also the presentation of the pain. Having this capability offers
the opportunity to study the effects of treatment on subtypes of NP as well
as the effects on overall NP. Mackey et al. proposed extracting information
on NP from the short-form McGill pain questionnaire (SF-MPQ; discussed
further in subsection\ref{opm}); this method takes advantage of an existing
questionnaire, but it is not as specific as other measures, such as NPSI
(Mackey et al., 2012). Other measures specifically related to NP exist, such as
the neuropathic pain scale (NPS) (Galer and Jensen, 1997), the neuropathic
pain questionnaire (NPQ) (Krause and Backonja, 2003), the “neuropathic
pain four questions” (DN4) (Bouhassira et al., 2005), the Leeds assessment
of neuropathic symptoms and signs (LANSS) (Bennett, 2001), among others;
however, these alternative instruments are either not strongly validated, not
detailed enough, or are designed to differentiate non-NP from NP and not to
assess NP (Bouhassira et al., 2004). The NPSI has been validated in several
languages among various populations (Bouhassira et al., 2004; Sommer,
2011; Matsubayashi et al., 2015). A German study found NPSI test-retest
reliability to be suboptimal (Sommer, 2011), compared to the original study
(Bouhassira et al., 2004). Although, in the German study the time lag was
24 h (compared to 3 h in the original study (Bouhassira et al., 2004)). While
this is a notable finding, it does not change the validation of the instrument as
it is reasonable to expect changes in the presentation of pain in a 24 h period;
temporal variation is a known characteristic of NP (Gilron et al., 2006).
1.5.1.4 The profile of mood states-short form (POMS-SF)
In traumatic lower limb amputees, the prevalence of depression was 41.6%
(Cansever et al., 2003). In a broader population base of various etiologies,
significant depressive symptoms were seen in 28.7% (Darnall et al., 2005)
(compared to 4.9% point prevalence) and 17.1% life-time prevalence in the
general population (Blazer et al., 1994).
Ephraim et al. aptly noted the correlation of depression and the presence
of PLP, where increased pain intensity corresponded to heightened depressive
symptoms (Ephraim et al., 2005). The finding suggests that there is a need
to continuously monitor and swiftly treat depression in amputees (Ephraim
et al., 2005). In a more general sense, mood correlates to the intensity and
perception of pain greatly (Blågestad et al., 2016). Some attempts have been
made to treat pain using the class of drugs called antidepressants and through
psychological treatments of pain Gilron et al., 2006; Alviar et al., 2016;
however, these have been ineffective (Eccleston et al., 2015). Mood does not
28 An Introduction to Phantom Limb Pain
act as an effective target for treatment. However, it may act as an indicator of
positive or negative effect because of its correlation to pain.
The POMS-SF is comprised of 37 descriptors of mood. Each descriptor
is ranked by the study subject on a five-point scale (1 = “Not at all,”
5 = “Extremely”) and is incorporated into a subscale, which can be used
to characterize the individual’s mood. The subscales are depression, vigor,
confusion, tension, anger, and fatigue. Whereas depression has been shown
to positively correlate with pain, other mood descriptors could provide more
insight on the relationship of PLP and psychological state.
1.5.1.5 The brief pain inventory-interference scale (BPI-IS)
The brief pain inventory (BPI) has been adapted into a more succinct
questionnaire as the BPI-short form (BPI-SF), which is a validated instrument
for pain interference (Tan et al., 2004; Osborne et al., 2006; Raichle et al.,
2006). The final series of questions is known as the BPI-IS. Questions are
nonspecific to phantom pain and describe how pain has interfered with daily
living over the past 24 h. The seven-question interference scale utilizes
11-item NRSs to describe pain’s interference with general activity, mood,
walking ability, normal work, relationships with other people, sleep, and
enjoyment of life. The NRSs span from 0 (“Does not interfere”) to 10
(“Completely interferes”).
1.5.1.6 Problems with measuring PLP and other phantom
phenomena
One factor not addressed by Jensen et al. when describing the standardization
of the VAS with respect to PLP is the associated anchors of the VAS (Jensen
et al., 2001). Anchors are defined as the descriptions of the minimum and
maximum scores. Jensen et al. used a scale of 0–10 with anchors of “0 = no
pain” and “10 = pain as bad as it could be” (Jensen et al., 2001). A prime
example of this inconsistency in research related to PLP can be found in
reports of the intensity of pain. In Table 1.1, several examples demonstrate
how intensities are reported among various authors. The outcome of not
utilizing a standard instrument for measuring pain intensity is data that are
not directly comparable. While it may be possible to normalize the various
scales back to the standard scale proposed by Jensen et al., correlations have
not been proposed among the various scales.
Furthermore, interpretation of changing VAS scores is nontrivial. Jensen
et al. suggest that a change in pain intensity from “7 to a 4 might be considered
more beneficial and more clinically relevant than a reduction from a 4 to a 1,
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Table 1.1 Different investigators use VAS pain scales that quantify pain intensities using
different anchors, making it difficult to compare the measures between studies
Reference Pain Scale Anchors
Sherman and Sherman (1983) 0–100 Anchors not described
Montoya et al. (1997) 0–10 No pain / Unbearable pain
Smith et al. (1999) 0–100 Extremely mild / Extremely intense
Ehde et al. (2000) 0–10 No pain / Pain as bad as it could be
Marshall et al. (2002) 0–10 No pain / Pain as bad as it could be
Ephraim et al. (2005) 1–10 Mild pain / Extremely intense pain
Schley et al. (2008) 0–100 Anchors not described
at least in terms of the impact of the treatment on function and quality of
life” (Jensen et al., 2001). This conclusion suggests that both the change in
pain intensity as well as the baseline or reference pain intensity are important
factors to keep track of in establishing effective treatments and therapies.
1.5.2 Other Proposed Self-report Measures of PLP
Because of the lack of standardization, several questionnaires and instruments
have been developed or adapted for measuring PLP. Hill notes in a literature
review of PLP, the MPQ and SF-MPQ have been used in several studies
(Hill, 1999). The MPQ and its variants have significantly contributed to the
understanding of pain (in general) and PLP, and it acts as a primary instrument
in many pain studies (Katz and Melzack, 2010).
Alternate measures of depression include the Center for Epidemiolog-
ical Studies-depression questionnaire (CES-D) (Ephraim et al., 2005). The
chronic pain grade (CPG) (Von Korff et al., 1992; Ehde et al., 2000; Marshall
et al., 2002) distributes an individual’s pain into one of four grades based on
intensity and disability associated with pain. Grade I is the least intense and
least disabling, while Grade IV is the most intense and most disabling (Von
Korff et al., 1992). Flor et al. and Montoya et al. used a 122-item phantom-
and-stump phenomena interview as a primary instrument (Flor et al., 1995;
Ehde et al., 2000). The interview is a compilation of several standard
instruments to separately analyze stump and phantom sensations and pain,
including a modified version of the MPQ, several VASs to describe average
pain severity and intensity of nonpainful sensations, descriptors of sensations,
along with several open-ended questions (Ehde et al., 2000). Montoya et al.
also utilized the West Haven-Yale multidimensional pain inventory (MPI) to
evaluate the severity and interference of stump and phantom pain (Ehde et al.,
2000). Smith et al. (1999) used the prosthesis evaluation questionnaire (PEQ;
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developed by Legro et al. (1998)). The PEQ highlights intensity, frequency,
and bothersomeness of phantom, stump, and back pain as well as phantom
sensations (Smith et al., 1999). Further evidence of lack of standardization
is that study designs have opted to utilize self-designed questionnaires such
as the Groningen questionnaire problems after arm amputation (GQPAA) by
Kooijman et al. (2000).
1.5.3 Measuring Cortical Reorganization
Cortical plasticity or cortical reorganization is a popular topic in the study
of postamputation phenomena. This is mainly because of the desire to
understand the underlying mechanisms. While plasticity is not unique to
the cortex (Florence and Kaas, 1995), it gets particular attention because
of the relationship of the somatosensory mapping and observations of RSs
in the facial region (Ramachandran et al., 1992). From the perspective of
characterization, studies have investigated the differences in cortical activity
among amputees and healthy controls. Lotze et al. studied the locus of
activation for hand and lip movements using functional magnetic resonance
imaging (fMRI), comparing amputees with PLP (n = 7), amputees without
PLP (n = 7) and healthy controls (n = 7) (Lotze et al., 2001). Reorganization
of the hand and lip areas in M1 and S1 was recognized in patients with PLP
but not others. Many studies have also investigated the cortical differences
between the activities utilizing the affected limb versus the individual’s
healthy limbs. This paradigm attempts to have an individual serve as his
or her own control. Measurement of changes to the cortex can be done
through several modalities. Blood oxygen level dependent (BOLD) fMRI
is used most often because of the ability to relate activation to particular
cortical structures. Most studies that use event-related BOLD fMRI to look
at cortical reorganization focus on S1 and M1 (Flor et al., 1995; Lotze et al.,
2001). Other instruments include electroencephalogram (EEG) coupled with
some type of somatosensory evoked potential (SEP) in the periphery, such as
tactile evoked potential (TEP) or laser evoked potential (LEP) (Flor et al.,
2000; Zhao et al., 2016). Coupling both EEG and MRI, Flor et al. used
EEG to record cortical activation during RSs elicited by TEP, and used
the activation map to overlay an anatomical image captured via magnetic
resonance imaging (Flor et al., 2000).
Some disadvantages should be considered when using BOLD fMRI to
study cortical differences. The main disadvantage is the length of time
required for measurement. BOLD fMRI contrast relies on the hemodynamic
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response function (HRF), which is an increase in oxygenated blood (specifi-
cally oxyhemoglobin) compared to a resting state. The underlying assumption
is that the increase in blood in a particular region is a causal, time-delayed
effect of increased neuronal activity. These details reveal a reason behind the
intensive time requirements of fMRI, as stimuli do not elicit instantaneous
responses. Beyond the time dynamics of the biological system, the larger
contributors to lengthy experimentation paradigms are issues of signal-to-
noise ratio (SNR). To alleviate the poor SNR, fMRI paradigms typically
utilize signal averaging, thus longer measurement times. Analysis of fMRI
results involves an understanding of both estimation efficiency (ability to
estimate the HRF) and detection power (ability to detect activation) as
described by (Liu and Frank 2004; Liu, 2004). Furthermore, a recent study
attempting to validate fMRI statistical analysis methods found high rates of
false positives (Eklund et al., 2016).
1.5.4 Pros and Cons of Different Measurement Approaches
If relating back to the four primary dimensions of pain (intensity, affect,
quality, and location), various instruments have positive aspects and points
of weakness. For this reason, several research studies have implemented
multiple instruments. Depending on the study design this could have different
effects on self-report data. Thorough questionnaires and interviews (such as
the MPQ or the phantom-and-stump phenomena interview) allow for detailed
description of the pain, but take substantial time and concentration for the
study participant. This could cause frustration and bias if the participant is
enrolled in a study of temporal effects of treatment and having to complete
a questionnaire multiple times, for example. Substantial effort should be
taken to consider the length of time a study participant spends responding
to questionnaires and the number of times a study participant responds to
a particular questionnaire. On the other hand, there are disadvantages of
being too brief (Jensen and Karoly, 2010). Brevity is just one consideration
in the list of primary trade-offs, where targets should be set to reduce the
required contact time between the health care provider (HCP) and patient,
while maximizing the collection of relevant pain characterization data.
1.6 Current Treatment/Pain Management Methods
The proposition of treating PLP has been under study for decades. In 1980,
Sherman et al. reported on 68 different possible methods (Sherman et al.,
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1980; Sherman, 1980). To this day, a concise method for treatment has not
been identified. Flor suggested more than 30 commonly used treatments for
PLP in 2002, only a small fraction of which have shown any success in
randomized controlled trials (RCTs) (Flor, 2002). Ideally, treatment methods
of PAP and phantom limb phenomena would be developed from a mech-
anistic approach, i.e., the mechanism of pain would be utilized to address
and reverse the pain. Since the mechanisms are not well understood, ther-
apies tend to treat the symptoms, leading to a high number of available
treatments, low rates of success, and high rates of dissatisfaction among
patients (Sherman et al., 1980; Vernadakis et al., 2003). Current treatments
of PAP can be broken down into medicinal and nonmedicinal methods.
Medicinal treatments of pain utilize various methods of application: topical,
oral, and local injection. A wide variety of nonmedicinal treatments have
been explored, taking advantage of mechanical and electrical sensitivity
of PAP. Other methods have used traditional pain management techniques,
while some have ventured into the psychological treatment of pain. All-in-all
treatment of any form of PAP has been largely unsuccessful.
1.6.1 Current Standard of Care
In 1983, a study found that only 17% of amputees were offered treatment for
PLP even though 61% reported experiencing PLP (Sherman and Sherman,
1983). Several authors have noted a variety of responses from physicians
to those suffering from PLP such as, “it is in your head” or PLP is “psy-
chogenic” (Flor, 2002; Sherman et al., 1984; Mortimer et al., 2004; Sherman
et al., 1987). Conversely, while the limb may no longer be present, the pain
and sensations seem real. Another study in 1997 found nearly one-third of
amputees who discussed PLP with their doctor were told no treatment was
available (Wartan et al., 1987). Kern et al. attempted to study the success
rates of relevant treatment methods by surveying amputees. Seventy-one
percent (N = 537) of the amputees suffering from PLP had never received
or sought after treatment; 19% felt their doctors were incompetent on the
topic (Kern et al., 2012). Of those who did receive treatment for phantom
pain, the treatment with the highest success rate was opioids via oral or
IV administration at 67%. The second highest treatment method was opioid
injection via intrathecal pump at 58%. Neither of these treat the root problem
but only temporarily mask the pain (Kern et al., 2012). Whereas the medical
and scientific communities are more accepting of the reality of PLP, the
current standard of care is still up for debate. A focus group of health
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professionals found that information given to patients experiencing PLS and
PLP is grossly inconsistent, indicating a necessity for a standard of care to be
developed (Mortimer et al., 2004).
1.6.2 Medicinal Treatments
Medicinal treatments are among the most successful at alleviating PLP.
Opioids/Opiates have shown a success rate as high as 67.4% (Kern et al.,
2012), in particular morphine via injection and oral administration has shown
successful reduction of but not elimination of PLP and RLP in a randomized
controlled trial (Wu et al., 2002, 2008; Alviar et al., 2016). However, long-
term analgesic efficacy has not been verified (Kern et al., 2012; Alviar
et al., 2016). Anticonvulsants have also shown moderate success (52%) (Kern
et al., 2012). Gabapentin is a commonly used anticonvulsant, which has
had controversial results in RCTs. Bone et al. showed reduction of PLP in
comparison to a placebo but no significant change in secondary measures,
such as depression, mood, or sleep interference (Bone et al., 2002). Con-
versely, a separate RCT showed no significant difference between gabapentin
and placebo groups (Smith et al., 2005). Some side effects were noted;
however, these were not significantly different from the control groups (Bone
et al., 2002; Smith et al., 2005).
Alviar et al. reviewed three NMDA receptor antagonists as possibili-
ties: memantine, dextromethorphan, and ketamine (Alviar et al., 2016). The
review identified only ketamine (Eichenberger et al., 2008) and dextromethor-
phan (Ben Abraham et al., 2003) to provide pain relief from this class
of pharmacologic interventions (Alviar et al., 2016); however, both studies
were underpowered (Alviar et al., 2016) and treatment with ketamine had
substantial side effects, including dizziness, light hallucinations, and hearing
impairment (Eichenberger et al., 2008). NMDA receptor antagonists have
shown moderate success at relieving pain. The unsuccessful cases may be
related to the mode of administration; each memantine trial reviewed utilized
oral administration while other studies of this intervention method were
successful with injection (Alviar et al., 2016).
Various other options have been explored and proposed for treatment
including antidepressants, calcitonins, and local anesthetics (Alviar et al.,
2016). In patient surveys, antidepressants have shown to be ineffective. Only
36.4% noted this method as effective (Kern et al., 2012). This ineffectiveness
was supported in a RCT of amitriptyline that failed to show positive results
(Robinson et al., 2004; Alviar et al., 2016). Furthermore, amitriptyline had
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a significant adverse effect of dry mouth over the placebo (Robinson et al.,
2004). Local anesthesia was largely ineffective according to patient surveys
(21.6% success) (Kern et al., 2012); RCTs of intravenous infusion with
Lidocaine have shown successful treatment of RLP but not of PLP (Wu et al.,
2002).
1.6.3 Nonmedicinal Treatments
Several nonpharmacological approaches have been proposed and tested as
possible treatments for PLP, such as proper stump management, electrical
stimulation, and mental imagery. Treatments vary significantly in regards to
stimulus modality, psychological demand, and efficacy. Many therapies are
proposed in case studies and uncontrolled trials, but either do not reach the
stage of conducting a RCT or are not successful in a RCT, which makes
identifying potential effective treatments in literature difficult (Halbert et al.,
2002). Some of the more prominent methods are discussed further.
1.6.3.1 Nerve and stump management
Several methods have been proposed to thwart PAP related to neuromata; a
universal method has not been accepted (Ducic et al., 2008; Vernadakis et al.,
2003). Proper care of the stump and preventative measures in surgery are
crucial to mediate pain. Painful neuromata are common among amputees;
nearly 30% undergo surgery after amputation with the hopes of relieving
neuroma-related pain (Kern et al., 2012). Often they form from improper
surgical technique during the original amputation (Vernadakis et al., 2003).
Studies have shown that simply excising the neuroma and applying traction to
the nerve (encouraging the nerve to retreat into the stump) is not a successful
procedure, only demonstrating successful results 33% of the time (Tupper and
Booth, 1976). Over the years several techniques have emerged to ameliorate
this painful phenomenon (Vernadakis et al., 2003). A recent review of neu-
romata treatment and prevention found nearly 200 techniques, supporting
the perfect solution has not yet been found (Vernadakis et al., 2003). Some
techniques have proven successful and appear notable; excision with silicone
capping (83% success (Swanson et al., 1977)) or centrocentral anastomosis
(94–95% success (Kon and Bloem, 1987; Barberá and Albert-Pampló, 1993))
are prime examples (Vernadakis et al., 2003). On the other hand, techniques
such as these also present unnecessary risks to the patient. Silicone capping
involves the introduction of a foreign body, which risks immunological
response and inflammation in the stump (Ducic et al., 2008). Centrocentral
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anastomosis lengthens the time of surgery due to the meticulous nature of
microsurgery, which means more opportunities for infection (Ducic et al.,
2008).
One of the most notable techniques is nerve transposition (Vernadakis
et al., 2003). Mackinnon et al. demonstrated the capability of minimizing
neuroma formation in an animal model (Mackinnon et al., 1985). Rerout-
ing the transected nerve into adjacent muscle without tension, resulted
in significantly smaller neuromata compared to control groups in primate
models (Mackinnon et al., 1985). Mackinnon and Dellon revisited the tech-
nique emphasizing the importance of separating the nerve ending from the
scar tissue (Mackinnon and Dellon, 1987). This study found different success
rate depending on a patient’s previous experience ranging from 56% to 100%
for good or excellent results (Mackinnon and Dellon, 1987). The nerve
transposition technique had good or excellent results in 81% of cases (42
patients).
Another method that has had some success is targeted muscle
reinnervation (TMR) (Souza et al., 2014). This is the act of intentionally
ligating the original innervation of a nearby muscle to direct alternative
peripheral nerves to the muscle. Generally, TMR utilizes a muscle that is
no longer providing functional advantages to the patient with the hopes of
the muscle acting as a target for the nerve. The long-term goal for these
patients is that they could intuitively move their phantom, which would cause
muscle activity in the targeted muscle; then, this muscle activation could be
recorded, e.g., via EMG, to manipulate an active prosthetic. Conveniently,
this method serves a dual purpose by also preventing the formation of neu-
romata. In a retrospective study 6 months after surgery, the method appears
to be successful (Souza et al., 2014). All patients in this study reporting pain
reported reduced or eliminated pain, and just under 90% were able to operate
a TMR-controlled prosthesis.
Peripheral nerve surgery, such as TMR, is a treatment option for manag-
ing pain related to neuromata that has shown success in several studies, and
is an excellent example of advancement in the field (Vernadakis et al., 2003);
however, the degree of functionality provided by this method is often not nec-
essary for lower extremity amputees. Rather than transferring the transected
afferent nerve fibers to an alternative muscle or region, some have suggested
merely tying the sensory nerves to nearby muscle away from areas forming
scar tissue. If done during the amputation surgery, it could prevent formation
and excision of the neuroma postamputation, thus lowering overall patient
risk through reduction of procedures and procedural time (Ducic et al., 2008).
36 An Introduction to Phantom Limb Pain
This procedure, proposed by Ducic et al. as an outpatient operation has
had great success in a retrospective study of 21 neuroma excisions; patients
reported an the average preoperative pain of 8.04 that decreased to 1.07 on
the VAS (ranging 0–10) (Ducic et al., 2008). Furthermore, 85% reported
improved quality of life. The key to this technique involved suturing the
nerve-ending (after neuroma excision) to the nearby muscle. Some have
proposed applying light traction to the nerve is sufficient, but an important
detail to many of the techniques is to keep the nerve tension free (Vernadakis
et al., 2003).
1.6.3.2 Electrical stimulation
Electrical stimulation of the residual limb, especially transcutaneous elec-
trical nerve stimulation (TENS) or functional electrical stimulation (FES),
has had success in case studies and small trials. However, as is the case
with other therapy methods, the effectiveness of TENS has not been shown
with a RCT (Johnson et al., 2015). Other forms of electrical stimulation
have shown promise as well. Peripheral nerve stimulation showed significant
improvement in regards to pain and quality of life, but the study lacked a
placebo and had a small number of participants (Rauck et al., 2014). Others
have attempted applying TENS to areas other than the residual limb, such as
the contralateral limb (Tilak et al., 2016) and the ears (Katz and Melzack,
1991). Both of these methods showed a positive effect in small, short-term
trials, but neither was compared to placebo groups. Sensory discrimination
training using TENS has shown positive results (reduction in PLP and effect
in cortical reorganization) in a small comparative study of 10 amputees (Flor
et al., 2001). This method involved the application of random, nonmeaning-
ful stimulation patterns of varying frequency, intensity, and location. Trial
subjects were instructed to identify different patterns with the hypothesis that
distraction from the pain actually reduces the pain (Flor et al., 2001). Success
indicates there is a positive relationship among discrimination ability, cortical
reorganization, and decreased PLP; although, the long-term effects of this
method were not reported in (Flor et al., 2001).
1.6.3.2.1 Considerations for FES of peripheral nerves
Studying the effect in cats, Agnew et al. found that 8 h of high-rate, high-
amplitude electrical stimulation resulted in irreversible damage of sciatic
nerve axons (Agnew et al., 1999). In an earlier paper (McCreery et al.,
1997), this effect was referred to as stimulation-induced depression of neu-
ronal excitability (SIDNE). SIDNE, which according to the authors differs
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from long-term depression (LTD) because it does not involve a change in
efficacy of the synapses and does not worsen day-to-day, can occur in the
CNS if axons are subjected to “prolonged, high-frequency microstimulation”
(McCreery et al., 1997). McCreery et al. stimulated the posteroventral
cochlear nucleus (PVCN) for 7 h per day to find that with high enough
intensity SIDNE could be induced, but was still reversible. The speculated
mechanism attributed the effect to the entry of calcium into the neurons
activating second messengers and several downstream pathways.
Lu et al. studied the effects of electrical stimulation on peripheral nerve
regeneration in Sprague-Dawley rats (Lu et al., 2008). Methods involved
transecting the right sciatic nerve, separating the nerve endings by 10-mm,
and surrounding the nerve endings by a silicone rubber chamber. Stimulation
was applied for 15 min every other day at 1 mA (1, 2, 20, 200 Hz depending
on group). Results included histological samples as well as tests of nerve
conductivity that showed the 2-Hz stimulation group to have the most mature
structure. Lu et al. concluded that in regards to peripheral nerve regeneration,
stimulation (depending on frequency) can have a positive or negative effect.
Note, control group had 100% success in regenerating a nerve cable spanning
the 10-mm gap; however, the conclusion was that the nerves generated under
2-Hz stimulation were healthiest (Lu et al., 2008). Cogan et al. suggest many
culprits when it comes to the cause of tissue damage and that macroelectrodes
and microelectrodes have different challenges when it comes to preventing
tissue damage (especially charge density and charge per phase), but they did
not address continuous stimulation (Cogan et al., 2016). Patel and Butera
used stimulation frequency of up to 70 kHz to block nerves, but did not report
on the possible effects of continuously stimulating at these high frequencies
(Patel and Butera, 2015). Prodanov et al. (2003) reviewed FES in 2003
and pointed to two other articles by McCreery et al., which also discussed
the negative effects of continuous electrical stimulation (McCreery et al.,
1992, 1995). The 1995 McCreery paper indicates that low-frequency stim-
ulation does not lead to early axonal degeneration, independent of stimulus
amplitude.
1.6.3.3 Imagery
Mental imagery coupled with various techniques, such as muscle relaxation
(Brunelli et al., 2015) or virtual visual feedback (Ramachandran and Rogers-
Ramachandran, 1996; Mercier and Sirigu, 2009), present enlightening results
that may reveal psychological aspects of PLP. Ipsi-lateral cortical reorga-
nization could be a target for mental imagery, especially when utilizing
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coordinated bimanual movements through visual feedback (Schwenkreis
et al., 2003; Garry et al., 2005). Mental imagery and muscle relaxation
showed a significant reduction in PLP, PLS, and pain interference compared
to a positive control group (Brunelli et al., 2015). The positive control group
maintained the same physical therapy schedule as the test group, while the
test group exercised mental imagery, in addition to the physical therapy. The
success of this trial demonstrates an advantage of coupling physical stimulus
with psychological exercise. Graded motor imagery (GMI) utilizes gradual
training in three strategies: (1) implicit motor imagery, (2) explicit motor
imagery, and (3) mirror visual feedback (Priganc and Stralka, 2011). Implicit
motor imagery training involves laterality recognition or identification of
images representing left limbs versus right limbs; explicit motor imagery
practices movement of the phantom limb, or focusing on consciously manip-
ulating the phantom; and, mirror visual feedback exercises the movement
of the phantom while the patient utilizes visual feedback. Typically, the
visual feedback involves placing the contralateral limb in front of the mirror,
the amputated limb behind the mirror, and simultaneously moving both the
contralateral and phantom limbs. Bowering et al. reviewed studies, including
work on PLP by Moseley (2006), using this multipronged approach and
found it to successfully treat chronic pain (Bowering et al., 2013). While
the method has been proposed to treat PLP and PAP, the effects have not
been thoroughly evaluated in this context (Limakatso et al., 2016). Some have
compared the effects of mental imagery through virtual visual feedback (also
known as mirror therapy) to that of TENS when applied to the nonamputated
limb (Tilak et al., 2016). Both groups showed reduction in pain over a 4-
day treatment phase, but neither group performed significantly better than the
other.
This type of mental imagery could be considered a form of conditioning,
where participants actively and consciously reinforce imagined movement
with feedback (e.g., visual or tactile).
Imagery is supported by Macuga and Frey (2012), who found that
imagery, i.e., actively simulating movements, stimulates more brain regions
than passive observation. Studies on operant conditioning have shown to
alter CNS organization in the spinal cord, specifically through retraining
of spinal-cord-mediated reflexes (Thompson and Wolpaw, 2014). Thus, in
these circumstances psychological treatment has physiological implications.
Psychological treatments have had positive results for the treatment of NP
in a few, small studies; however, treatment recommendations for NP have
moved toward a multimodal approach incorporating psychological treatment
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with pharmacological or nonpharmacological methods (Turk et al., 2010).
This serves as a possible opportunity that has not yet been thoroughly
explored in the realm of PAP, through the combination of psychological and
nonpharmacological treatment.
No single treatment method seems to be a superior method for alleviating
PLP. This may be due to the nature of nonmechanism-based therapy devel-
opment, treating symptoms rather than the root cause. In order to develop
successful therapies, we should first seek to understand the primary mech-
anisms driving PLP in the background (Hsu and Cohen, 2013). We should
also seek to understand the effects of various methods by reporting results in
a consistent way. Several studies and the measured effects have been reported
and reviewed; the unfortunate reality is that many of the therapy methods are
difficult to compare in terms of effect because there is not a standard metric
for PLP.
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Lütkenhöner, B., Bürkle, H. and Henningsen, H. (2001). Functional
reorganization of the human primary somatosensory cortex after acute
pain demonstrated by magnetoencephalography, Neurosci. Lett., vol.
298, no. 3, pp. 195–198.
50 An Introduction to Phantom Limb Pain
Schley, M. T., Wilms, P., Toepfner, S., Schaller, H.-P., Schmelz, M., Konrad,
C. J. and Birbaumer, N. (2008). Painful and nonpainful phantom and
stump sensations in acute traumatic amputees, J. Trauma, vol. 65, no. 4,
pp. 858–864.
Schwenkreis, P., Pleger, B., Cornelius, B., Weyen, U., Dertwinkel, R., Zenz,
M., Malin, J. P. and Tegenthoff, M. (2003). Reorganization in the ipsi-
lateral motor cortex of patients with lower limb amputation, Neurosci.
Lett., vol. 349, no. 3, pp. 187–190.
Sehirlioglu, A., Ozturk, C., Yazicioglu, K., Tugcu, I., Yilmaz, B. and Gok-
tepe, A. S. (2009). Painful neuroma requiring surgical excision after
lower limb amputation caused by landmine explosions, Int. Orthop., vol.
33, no. 2, pp. 533–536.
Sherman, R. A. and Sherman, C. J. (1983). Prevalence and characteristics of
chronic phantom limb pain among American veterans. Results of a trial
survey, Am. J. Phys. Med., vol. 62, no. 5, pp. 227–238.
Sherman, R. A. (1980). Published treatments of phantom limb pain, Am. J.
Phys. Med., vol. 59, no. 5, pp. 232–244.
Sherman, R. A., Sherman, C. J. and Parker, L. (1984). Chronic phantom and
stump pain among American veterans: Results of a survey, Pain, vol. 18,
no. 1, pp. 83–95.
Sherman, R. A., Sherman, C. J. and Bruno, G. M. (1987). Psychological fac-
tors influencing chronic phantom limb pain: An analysis of the literature,
Pain, vol. 28, no. 3, pp. 285–295.
Sherman, R. A., Arena, J. G., Sherman, C. J. and Ernst, J. L. (1989). The
mystery of phantom pain: Growing evidence for psychophysiological
mechanisms, Biofeedback Self-Regul., vol. 14, no. 4, pp. 267–280.
Sherman, R. A., Sherman, C. J. and Gall, N. G. (1980). A survey of current
phantom limb pain treatment in the United States, Pain, vol. 8, no. 1, pp.
85–99.
Shore, S. E., Roberts, L. E. and Langguth, B. (2016). Maladaptive plasticity
in tinnitus–Triggers, mechanisms and treatment, Nat. Rev. Neurol., vol.
12, no. 3, pp. 150–160.
Shukla, G. D., Sahu, S. C., Tripathi, R. P. and Gupta, D. K. (1982). A psy-
chiatric study of amputees, Br. J. Psychiatry J. Ment. Sci., vol. 141, pp.
50–53.
Smith, D. G., Ehde, D. M., Hanley, M. A., Campbell, K. M., Jensen, M.
P., Hoffman, A. J., Awan, A. B., Czerniecki, J. M. and Robinson, L.
R. (2005). Efficacy of gabapentin in treating chronic phantom limb and
residual limb pain, J. Rehabil. Res. Dev., vol. 42, no. 5, pp. 645–654.
References 51
Smith, D. G., Ehde, D. M., Legro, M. W., Reiber, G. E., del Aguila, M. and
Boone, D. A. (1999). Phantom limb, residual limb, and back pain after
lower extremity amputations, Clin. Orthop., no. 361, pp. 29–38.
Soler, M. D., Kumru, H., Vidal, J., Pelayo, R., Tormos, J. M., Fregni, F.,
Navarro, X. and Pascual-Leone, A. (2010). Referred sensations and
neuropathic pain following spinal cord injury, Pain, vol. 150, no. 1, pp.
192–198.
Sommer, C., Richter, H., Rogausch, J. P., Frettlöh, J., Lungenhausen, M.
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2.1 Physiology of Pain
Pain is a physiological experience, designed to alert us from potential dam-
ages to our body, so it has a clear protective role. Pain is defined by the IASP
(International Association for the Study of Pain) as an unpleasant sensory
and emotional experience associated with actual or potential tissue damage,
or described in terms of such damage. When the pain circuits are correctly
working they aware us from external (abnormal heating, pinch stimuli, etc.)
or internal stimuli (cardiac ischemia) that would potentially hurt the tissues.
Ideally, the sensation we perceive should be unpleasant enough, so it cannot
be ignored, and the sensation should continue as long as the stimulus is
present. Different types of “normal” pain can be distinguished depending on
their origin and characteristics: acute (or pricking), chronic (or burning), and
continuous or visceral.
2.1.1 Nociceptors and Nociceptive Fibers
There are two main types of nerve fibers conveying pain information: C fibers
and Aδ fibers (Table 2.1). In both cases, the stimuli may come from the skin,
muscle, and joint tissues or certain visceral structures. They do not present
a clear ending receptor structure and are commonly identified as free nerve
endings.
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Table 2.1 Classification of the primary afferent axons in the peripheral nervous system
Fiber Myelin Diameter (µm) Velocity (m/s) Function
Aα Yes 13–20 80–120 Proprioceptors of skeletal muscle
Aβ Yes 6–12 35–75 Touch, mechanoreceptors, proprioceptors
Aδ Yes 1–5 5–30 Pain, mechanical and thermal receptors
C No 0.2–1.5 0.5–2 Pain, warm thermoreceptors
Aδ fibers are thinly myelinated, so they can conduct a fast pain signal, at
5–30 m/s. In this case, Aδ nociceptive fibers convey nociceptive information
as well as information coming from intense mechanical or thermal stimula-
tion. This fast pain has been reported as the first pain, the initial sharp painful
sensation just after the contact with the noxious stimuli.
C fibers are related with a slow pain, since these unmyelinated fibers
conduct impulses at less than 2 m/s, normally evoked by thermal, mechanical,
and chemical stimuli. Most of them act as polymodal nociceptors, although
a proportion seems to be sensitive only to mechanical or thermal stimuli. This
slow pain is also called second pain, and evokes a more diffuse and longer
lasting painful sensation than the pain evoked by the Aδ fibers.
The unmyelinated C nociceptive afferents can be divided into two major
subpopulations, the peptidergic and the nonpeptidergic. The peptidergic noci-
ceptors express substance P (SP) and calcitonin gene-related peptide (CGRP),
and the nonpeptidergic ones possess fluoride-resistant acid phosphatase
(FRAP) activity, bind the lectin IB4 and express purinergic P2X3 receptors.
These two populations differ in neurotrophic support in the adult. In fact,
during development, both populations require nerve growth factor (NGF) for
survival, but shortly after birth only the peptidergic continue to respond to
NGF, whereas the nonpeptidergic population starts to respond instead to glial
cell line-derived neurotrophic factor (GDNF). Accordingly, the peptidergic
population expresses the NGF high-affinity receptor trkA, whereas the non-
peptidergic expresses GDNF receptors. Although the distinction between two
populations of primary sensory fibers, peptidergic and nonpeptidergic, seems
attractive, it is not completely accurate as a small proportion of peptidergic
sensory fibers (those that colocalize CGRP and somatostatin (SOM)) do not
respond to NGF in the adult and bind the lectin IB4. In the spinal cord,
sensory fibers that express SP and CGRP terminate mostly in laminae I, outer
II, and V; those that colocalize CGRP and SOM terminate in laminae I and II,
and those that contain FRAP, bind the lectin IB4 or express the purinergic
P2X3 receptor terminate mostly in the inner lamina II.
The peripheral terminal of the nociceptor, embedded in the tissue,
is where the noxious stimuli are detected and transduced into electrical
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impulses. This leads to the train of events that allows for the conscious
sensation of pain. The sensory specificity of nociceptors is established by the
high threshold to particular types of stimuli. Only when the high threshold
has been reached by either chemical, thermal, or mechanical events are the
nociceptors activated.
The transduction of the nociceptive information starts in the periphery,
where a stimulus is able to activate the nociceptor endings, by stretching or
bending the nociceptor surface or by activating ion channels present in its
membrane. At the site of injury some algogenous substances are released,
such as proteases, bradykinin, ATP, and potassium ions. Due to the variety
of stimuli that can elicit nociceptive signaling (thermal, mechanical, and
chemical stimuli), different specific receptors have been described. Both
Aδ and C fibers present transient receptor potential (TRP) receptors, which
resemble voltage gated ion channels, presenting six transmembrane domains
and a central pore which allows an influx of sodium and calcium that initiates
the generation of action potentials. One subtype of these channels is the
vanilloid receptor (TRPV1), that responds to capsaicin but is also activated
by acidification of the extracellular medium, by heat (thermal threshold
>43◦C) and by anandamide, an endogenous cannabinoid. Other channels of
the TRP family activated by temperature increase are TRPV3 and TRPV4,
with thresholds of 33◦C and 25◦C, respectively. There are also nociceptors
activated by intense cold, below 15◦C, that causes painful sensations with
a burning or stabbing component. The TRPA1 channel is activated both by
temperatures below 18◦C and by irritant compounds.
Other channels present in nociceptive terminals are those of the degenerin
family (Deg/ENaC), which are epithelial sodium channels activated by
mechanical forces. Some of these channels also respond to decrease in the
pH of the extracellular medium and are therefore called acid sensing channels
(ASICs). Also important as stimulus transducer channels are those belonging
to a diverse family of channels for potassium ions (K2P channels). These
channels are open at rest, and are closed by the stimulus, causing depolar-
ization of the fiber. Their activity can be modified by mechanical, thermal
stimuli, intracellular and extracellular pH changes, and hypoxia.
2.1.2 Nociceptive Spinal Cord Circuits
The different subpopulations of primary afferent fibers convey nociceptive
information through parallel spinal pathways. At every stage of the pain path-
way – from sensory nerve to spinal cord, from spinal cord to brainstem and
from brainstem to the forebrain – information signaling injury is subdivided
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Figure 2.1 Representation of the three main types of nociceptive fibers, their markers and
the laminae of the dorsal horn where they mainly project central terminals.
or shared between these parallel systems. Molecular dissection has begun to
reveal distinct functions for these separate pathways and their contribution to
the final behavioral outcome.
Nociceptive neurons have their body in the dorsal root ganglia, where they
can be divided in three main populations (Figure 2.1): (i) mid-size neurons
with Aδ axons, that express CGRP, and TRPV2 receptors, (ii) small neu-
rons with unmyelinated C axons, expressing neuropeptides (SP, CGRP) and
TRPV1 receptors, and (iii) small neurons nonpeptidergic, with C axons, that
express receptors TRPV1 and P2X. It has been suggested that the C peptider-
gic pathway would be particularly important in conveying inflammatory pain,
whereas the nonpeptidergic pathway would play a role in neuropathic pain.
Peptidergic primary afferents connect with the pathway that derives
largely from lamina I neurons of the dorsal horn expressing the NK1 receptor,
and terminates within the thalamus, the parabrachial area, and the periaque-
ductal grey matter (PAG). These latter areas in turn project on brain areas such
as the hypothalamus and amygdala that modulate the affective dimensions of
pain and control autonomic activity. The lamina I pathway is mainly involved
in signaling the intensity of pain, therefore these second-order neurons are
capable of reliably detecting and transmitting precise quantitative information
about noxious pressure and noxious heat to higher centers. Of interest, the
selective destruction of lamina I results in loss of the increased sensitivity
to stimulation that follows inflammation or manipulation of the peripheral
nerve.
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On the other hand, the IB4 binding subpopulation of nonpeptidergic C
fibers contact with neurons in inner lamina II of the spinal cord. These
interneurons in turn contact projection neurons of lamina V, and many of
these send axons to fourth-order neurons in the amygdala, hypothalamus,
bed nucleus of the stria terminalis and globus pallidus. Interneurons in
this lamina also show increase in protein kinase Cgamma (PKCγ) follow-
ing inflammation which results in mechanical hypersensitivity. However,
these interneurons predominantly receive inputs from myelinated, rather
than unmyelinated, primary afferent terminals. In contrast, calbindin posi-
tive interneurons of lamina IIi are located postsynaptic to the IB4-positive
subpopulation of nonpeptidergic C fibers, but not to myelinated afferents.
Type A nociceptive fibers send collateral branches to contact with the
wide dynamic range (WDR) neurons or nociceptive neurons type 2, located
mainly in lamina V. Taken together, these observations illustrate the very
complex connectivity of primary afferents with the interneurons of the dorsal
horn of the spinal cord.
2.1.3 Nociceptive Ascending Pathways
The nociceptive information arriving from the periphery travels along the
peripheral axonal branch of primary nociceptive neurons, whose soma are
located in the dorsal root ganglia, and the central axon entering into the spinal
cord by the dorsal roots. After the dorsal root entry, they travel within the
zone of Lissauer, in which axons move up or down a pair of segments before
entering the gray matter of the dorsal horn, in a region called substantia gelati-
nosa. Central nociceptive terminals contact to second-order neurons mainly
placed in laminae I and II (pure nociceptive), and V (mixed nociceptive and
mecanosensory, WDR). Sensory fibers that are peptidergic terminate mostly
in laminae I and outer II, and a few in lamina V; those that are nonpeptidergic
terminate mostly in the inner lamina II. The main neurotransmitter involved
in these first relay is glutamate, but also substance P, acting as cotransmitter in
peptidergic nociceptors, is important to experience moderate to intense pain.
From the second-order neuron the thermal and nociceptive information
crosses the midline and ascends to the brain in the spinothalamic tract,
part of the anterolateral system. This decussation occurs at the spinal level
and in two or three segments all the fibers are in the contralateral side.
The ascending axons travel through the medulla, the pons and the midbrain
without synapsing, until reaching the thalamus. From here, the information
is conveyed to the primary somatosensory cortex (Figure 2.2). This route
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Figure 2.2 Schematic of the ascending pathways of somatic sensations. Low threshold
mechanoreceptive afferents follow the dorsal column system, that decussates at the medulla,
whereas thermal and pain afferents constitute the anterolateral system, crossed at segmental
cord levels.
is followed in order to transmit the gross information of pain, the essential
information for the brain to note stimuli that threaten the integrity of the body.
Axons from the second-order spinal neurons make relays on different
structures in order to mediate different aspects of the sensory and behavioral
response to pain. One of these aspects is the sensory discrimination of pain,
in terms of location, intensity, duration, and quality. The main responsible of
this discrimination is the thalamus, in particular the ventral posterior lateral
(VPL) nucleus, and its projections to the primary somatosensory cortex
(SI). Another important aspect is the affective or motivational, more related
with the emotion that pain provokes in the individual who is suffering it
(unpleasant feeling, fear, anxiety, and secondary autonomic reactions). In this
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case, the information travels by the spinoreticular and spinomesencephalic
tracts, reaching several structures, such as the reticular formation, the superior
colliculus, PAG, hypothalamus, and amygdala. In addition, another group
of neurons constituting the anterior spinothalamic tract, reach the midline
thalamic nuclei, that will connect with the anterior cingulate cortex and the
insular cortex.
Apart from the anterolateral system, another fraction of information
entering from the periphery travels along the dorsal columns, which will
provide a more qualitative information of the stimulus that is reaching the
nociceptive signaling system. This route is used essentially by mechanore-
ceptive afferents, which provide information about touch, vibration, and
proprioception, and is known as the dorsal column-medial lemniscus system.
This information travels directly by the central axons of primary sensory
neurons in the dorsal columns ipsilateral to the site of entrance until the dorsal
column nuclei in the medulla, where it decussates to reach the thalamus in the
contralateral side and later on the cortex. This system also participates in the
discriminative aspects of pain.
2.1.4 Descending Control of Pain
Once the nociceptive information arrives to the higher level centers, it is
integrated in order to elicit a complex physiological response in front of
the noxious stimuli, and also modulated in order to reduce the intensity
of the painful sensation. The main mechanisms for pain modulation conform
the descending pathway (Figure 2.3). One of the most important regions is
the PAG in the midbrain, but there are other regions in the brainstem also
involved in this process: parabrachial nucleus, medullary reticular formation,
locus coeruleus, and raphe nuclei. These centers use noradrenaline, sero-
tonin, dopamine, histamine, and acetylcholine to exert both excitatory and
inhibitory effects on different sets of neurons in the dorsal horn. Then, they
can act on synaptic terminals of nociceptive afferents, interneurons (excita-
tory and inhibitory), synaptic terminals of other descending pathways, and
projection neurons. These contacts do not only act inhibiting the transmission
of nociceptive information but also modulating it, as well as controlling the
balance between excitation and inhibition in the spinal cord.
The main action of the PAG is to modulate nociceptive signaling in
the dorsal horn by releasing endogenous opioids (encephalin, endorphins,
and dinorphins) on the dendrites of nociceptive neurons and WDR neurons,
causing hyperpolarization, thus inhibiting, of the second-order neurons. They
62 Neurobiology of Pain
Figure 2.3 Ascending (left side) and descending (right side) pain pathways.
also release glycine on the terminals of primary afferents (A and C fibers),
inducing presynaptic inhibition that reduces the release of neurotransmitters
on the second-order neurons. Finally, the secretion of glutamate from the PAG
excites the GABAergic interneurons in lamina II of the dorsal horn. This
promotes the release of GABA on the second-order neurons, hyperpolarizing
and therefore inhibiting them.
The PAG also causes depolarization of serotoninergic neurons in the
raphe magnocellular nucleus (RMN), which project to second-order neurons
in the dorsal horn via the raphespinal tract. The binding of serotonin to
receptors 5-HT1 and 5-HT2 induces an increase in the conductance of potas-
sium and therefore the hyperpolarization of the second-order nociceptive
neurons. It also interacts with 5-HT3 receptors in the dendrites of GABAergic
interneurons in lamina II, inducing the release of GABA and the inhibition of
second-order neurons. Something similar happens when PAG neurons secrete
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glutamate on the locus coeruleus neurons. Once depolarized, these neurons
release noradrenaline, which causes hyperpolarization of the nociceptive
second-order neurons by binding to α-adrenergic receptors.
Local circuits within the dorsal horn also play a role in modulating the
nociceptive system. One of these systems was proposed by Melzack and Wall
(1965), and called the “gate theory of pain,” which actually is included under
the afferent regulatory system of pain. This theory says that the activation
of mechanoreceptors (large A fibers) can act on local interneurons to inhibit
the transmission of information from C fibers to the dorsal horn projection
neurons. This would explain how a mechanical stimulus such as scratching
can temporarily give relief from pain in the same area.
Similarly, it has also been described a mechanism by which pain can
inhibit pain. This phenomenon is called “diffuse noxious inhibitory control”
(DNIC), or heterotopic noxious conditioning stimulation (HCNS) (Sprenger
et al., 2011), and implies a spinal-medullary-spinal pathway. DNIC systems
permit that a spinal neuron can be inhibited by a nociceptive stimulation
applied in another part of the body (outside its receptive field), thus inhibit-
ing the pain sensation after the application of a remote pain stimulation.
WDR neurons and trigeminal nociceptive neurons play a key role in this
phenomenon, which is regulated by serotoninergic pathways, and probably
by opioids. DNIC effects are usually contralateral and extrasegmental, and
highly dependent on the intensity of the stimulus. DNIC mechanisms may
reflect alterations in the function of central descending inhibitory systems
that could be potentially involved in chronic pain. In fact, research based
on the use of DNIC has shown dysfunctions in this system in chronic pain
conditions, such as fibromyalgia or irritable bowel syndrome (van Wijk and
Veldhuijzen, 2010).
Other elements are also involved in pain regulation, such as the endoge-
nous opioids. Several brainstem regions, most of them conforming the
descending system of pain control, are susceptible to the action of these
molecules, provoking an important analgesic effect. Endogenous opioids
are classified in three groups, called enkephalins, endorphins, and dynor-
phins, which present different distribution along the nociceptive system.
Enkephalins, for example, can be released by local neurons on the dorsal
horn, then impeding the release of neurotransmitters from the terminals onto
the projection neurons, and therefore diminishing their level of activity. This
local circuit can also be the target of other descending inhibitory projec-
tions, therefore constituting a powerful control mechanism of the amount
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of nociceptive information able to reach superior centers. Endorphins are
released in pain states within some brain regions, but they can also provide
tonic analgesic effect in the dorsal horn. Dynorphins have been described
to increase after neural injuries, and are related to the development of ther-
mal hyperalgesia by acting on the NMDA receptors and driving to spinal
sensitization (Ossipov et al., 2000).
2.2 Neurobiology of Neuropathic Pain
Neuropathic pain is defined as that pain provoked by a lesion or a dysfunction
in the nervous system. Although sharing features with other kind of pain
(inflammatory or cancer pain), neuropathic pain presents some particular
characteristics. Nociceptive and inflammatory pain can be both symptoms of
peripheral tissue injury, and present a clear defensive, beneficial component,
whereas neuropathic pain is a symptom of neurological disease or injury,
either affecting the peripheral or the central nervous system (Cervero, 2009),
and instead of a defensive component it is considered as a maladaptive
response.
Neuropathic pain states are characterized by an almost complete lack
of correlation between the intensity of peripheral noxious stimuli and of
pain sensation, and are produced by neurological lesions that cause abnor-
mal impulse activity generated in nerve sprouts, neuromas, or dorsal root
ganglion cells, ephaptic coupling between adjacent nerve fibers and abnor-
mal responses of peripheral nociceptors and CNS neurons. Neuropathic
pain syndromes produce pain sensations well outside the range of the
sensations produced by the normal nociceptive system, even after serious
peripheral injury or inflammation (Cervero, 2009). Neuropathic pain may
include spontaneous, or stimulus-independent pain that has been described as
shooting, burning, lancinating, prickling, and electrical. Evoked, or stimulus-
dependent, neuropathic pain includes allodynia, defined by the IASP as “pain
due to a stimulus which does not normally provoke pain.” These stimuli
may be nonnoxious heat, light touch, or even a puff of cool air. Moreover,
mechanical allodynia may be static, as evoked by light touch, or dynamic,
as evoked by a light brush of the skin. Hyperalgesia is identified when a
stimulus that normally produces nociceptive responses produces exaggerated
responses.
Epidemiological studies on the prevalence of neuropathic pain indicate
a high incidence of about 5% of the general population (Bouhassira et al.,
2008; Dieleman et al., 2008). Associated risk factors include gender, age, and
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Figure 2.4 Schematic representation of the main peripheral mechanisms involved in the
generation of neuropathic pain after a peripheral nerve injury.
anatomical site of the injury. Emotional and cognitive factors influence how
patients react to chronic pain (Haythornthwaite et al., 2003), but it is much
less certain if these factors contribute to the risk of developing pain.
The different forms through which neuropathic pain manifests suggest
that different mechanisms are likely to mediate the different features of the
condition. Features that appear most often related to neuropathic pain include
tingling or numbness, pain evoked by heat or cold, and sensation of heat or a
burning-like quality.
2.2.1 Mechanisms of Neuropathic Pain
Five key processes are considered in the neurobiological approach to the
mechanisms of pain and hyperalgesia following a peripheral nerve injury
(Figure 2.4): (1) the process of nociceptor activation and sensitization,
responsible for the initial signaling of injury and the peripheral changes in
the nociceptive system induced by a noxious stimulus; (2) the process of
central amplification of nociceptive signals, known as central sensitization,
generated by synaptic strengthening of connections between CNS neurons
and responsible for the enhanced excitability that accompanies persistent pain
states; (3) the process whereby activity in low-threshold sensory receptors
from undamaged peripheral areas can access the nociceptive system and
evoke pain sensations and hyperalgesic states (e.g., touch-evoked pain, tactile
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allodynia); (4) the loss of endogenous inhibition produced at spinal level
paired with changes in descending inhibitory pathways; and (5) neuroplastic
changes at subcortical and cortical levels (Navarro et al., 2007).
2.2.2 Nerve Injury-induced Changes in Transduction
Peripheral nerve injury leads to a redistribution of transducers in the wrong
place within a neuron, and this event carries two consequences: the emer-
gence of mechanical sensitivity at sites that are normally mechanically
insensitive and mechanical allodynia. Even mechanical stimuli associated
with physiological functions, such as movement of tissue associated with
blood flow, may also stimulate these transducers.
Normal pain sensations are normally elicited by activity in unmyelinated
(C) and thinly myelinated (Aδ) primary afferent neurons. These nociceptors
are usually silent in the absence of stimulation, and respond best to stimuli
that are potentially noxious. In neuropathic pain disease, after a peripheral
nerve lesion, axotomized neurons become abnormally sensitive and develop
pathological spontaneous activity generated at any anatomical level proximal
to the lesion. These pathological changes are underpinned by dramatic molec-
ular and cellular changes at the primary afferent nociceptor that are triggered
by the nerve lesion.
A long time ago, spontaneous ectopic activity was demonstrated in
awakened human amputees with phantom limb pain, by microneurographic
single-fiber recordings from afferent fibers projecting into the neuroma, as
well as barrages of action potential firing. After a nerve injury there is an
increase in membrane excitability. Spontaneous discharges in DRG neurons
have been recorded from cells of both intact and injured nerves. There are
phenotypic changes in injured neurons but also in uninjured ones, driven by
cytokines and growth factors released by denervated Schwann cells.
An embryonic channel, Nav1.3, is upregulated in damaged peripheral
nerves, and this is thought to promote ectopic spontaneous activity in primary
afferent neurons. Also, genes for the voltage-gated sodium channels Nav1.8
and Nav1.9 are expressed selectively in nociceptive primary afferent neurons.
These fibers acquire a unique sodium-channel expression profile after nerve
injury, with upregulation of Nav1.3 and downregulation of Nav1.7, Nav1.8,
and Nav1.9. Changes of these channels are responsible for the lowering of
the action-potential threshold and consequent hyperexcitability, playing an
important role in the genesis of neuropathic pain (Omana-Zapata et al., 1997).
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Entrance of calcium ions into the nerve endings regulates growth-related
proteins and can participate also in the increased excitability of the injured
neurons. In vitro, N and L-type calcium channels have been found to con-
tribute to CGRP release from injured nerves. Blockade of N-, T-, and P-type
calcium channels reduces neuropathic pain.
Related to thermal stimuli, normal body temperature can elicit sponta-
neous activity of primary afferents as a result of a change in the activation
threshold of the noxious heat-sensitive TRPV1 channel. Damage to periph-
eral nerves provokes upregulation of TRPV1 that are located predominantly
on uninjured C fibers and A fibers. These changes might contribute to the
development of C-nociceptor sensitization and the associated symptom of
heat hyperalgesia.
In transduction for mechanical stimuli, ASICs seem to be involved in
static mechanical hyperalgesia. Nerve lesion fibers developing adrenergic
sensitivity. It is known that in amputees, the perineuronal administration of
norepinephrine induced intense pain. Neuroma after injury has both afferent
C fibers and efferent post-ganglionic sympathetic C fibers which release
noradrenaline and adrenaline. With high sympathetic activity there is a raised
sensitivity of the regenerating sprouts toward the detection of nociceptive
substances, such as bradykinin, serotonin, histamine, and capsaicin evoking
depolarization and ectopic firing. Afferent excitability can also be increased
by the combination of a downregulation of inhibitor transducers, such as
opioid receptors, and the upregulation of excitatory transducers, such as the
ATP receptor P2X3.
After Wallerian degeneration, products such as nerve growth factor
(NGF) are released in the vicinity of spared fibers triggering the release of
tumor-necrosis factor-α (TNF-α), channels and receptors expression (sodium
channels, TRPV1 receptors, adrenoceptors. . . ) thereby altering also the prop-
erties of uninjured afferents (Wu et al., 2002). Research is more focused
now on the variety of changes that might occur in uninjured axons, as these
neurons are still connected with their peripheral organs and could have a
pivotal role in the generation of neuropathic pain.
2.2.3 Central Sensitization
Neuropathic pain may arise either as a result of peripheral sensitization of
intact afferents or due to central sensitization. Central sensitization has been
defined as “a prolonged but reversible increase in the excitability and synaptic
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efficacy of neurons in central nociceptive pathways.” The enhanced synap-
tic transmission is manifested by long-term potentiation (LTP) following a
short train of stimulation of C fibers. The transition of LTP between spinal
interneurons involves glutamate and neurokinin 1 receptors.
The function of nociceptive pathways is increased due to high membrane
excitability, synaptic efficacy, and reduced central inhibition. The net effect
of central sensitization is to recruit previously subthreshold synaptic inputs to
nociceptive neurons, generating an increased or augmented action potential
output: a state of facilitation, potentiation, augmentation, or amplification
(Latremoliere and Woolf, 2009). It is manifested as allodynia (touch-evoked
pain), enhanced temporal summation (escalating pain in response to a con-
stant stimulus), hyperalgesia (exaggerated pain experience to a standardized
noxious stimulus), and secondary hyperalgesia (pain and hypersensitivity
beyond the dermatome of the nerve injury).
Primary nociceptive neurons release glutamate, SP, CGRP, and ATP
as neurotransmitters and neuromodulators. After injury, hyperexcitability is
established with greater release of neurotransmitters in the spinal cord. They
interact with NMDA, AMPA, mGluR, NK1R, and P2X receptors causing
depolarization of nociceptive second-order neurons and scattering throughout
the spinothalamic pathway.
Peripheral nerve injury leads to an increase in the general excitability of
wide dynamic range neurons in the dorsal horn with multiple synaptic inputs
from nociceptive and non-nociceptive system. This central sensitization is
initiated and maintained by activity in pathologically sensitized C fibers.
After peripheral nerve injury there are presynaptic functional changes that
increase synaptic strength: the synthesis of transmitters and neuromodulators
and more calcium. Aβ touch fibers express increased levels of neuropeptides,
such as CGRP and SP, and enhance activity of excitatory amino acid
transmission via NMDA receptors.
Healthy nerve terminals uptake NGF and other growth factors from their
target cells and transmit them by axonal transport to the DRG neurons. After
nerve transection, this growth factors supply is interrupted, so that gene tran-
scription and protein synthesis are altered. At the level of transcription control
in the DRG neurons, the c-jun gene can be inducted 1 day after axotomy. It is
well known that c-Jun expression in the DRG neurons after nerve transection
is associated with changes in neuropeptide levels: SP and CGRP decrease;
galanin and NO synthase (NOS) increase dramatically during weeks fol-
lowing axotomy. The induction of c-jun of axotomized neurons has been
closely related with inhibitory transynaptic neuron death or apoptosis by NGF
starvation.
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The increased release and production of NOS at the intraspinal presy-
naptic terminal may facilitate afferent synaptic transmission to the dorsal
horn neurons contributing to spinal neuronal sensitization and hyperalgesia.
Repetitive noxious stimulation leads to the increased activity of NMDA and
AMPA receptors, which produce an influx of extracellular Ca2+ and activa-
tion of PKC in dorsal horn neurons. The increased intracellular Ca2+ induces
the expression of c-fos. Fos protein is involved in the transcriptional control
of genes that encode a variety of neuropeptides, including enkephalin and
dynorphin. Enkephalin typically produces antinociceptive effects. Dynorphin
has direct excitatory effects on spinal projection neurons and may also pro-
duce inhibition via a negative feedback mechanism on dynorphin-containing
neurons. The net effect of these changes may have complex modulations in
the development of central plasticity.
Postsynaptically, second-order dorsal horn neurons also abnormally
express Nav1.3 after peripheral nerve injury. Physiologically, dorsal horn
neurons receive a strong inhibitory control by GABA releasing interneurons
that are lost by apoptosis after partial peripheral nerve injury, thus favoring
central sensitization. Other postsynaptic changes involve phosphorylation
of NMDA subunits and increased receptor density due to trafficking and
enhanced synthesis of ion channels and scaffold proteins. These changes
underlying central sensitization occur in the dorsal horn, amygdala, anterior
cingulate gyrus, and prefrontal cortex.
Continuous and sustained afferent inputs, due to hyperactivity of the
damaged nociceptive fibers, into the spinal cord cause a state of spinal
sensitization. This is related to the demonstrated phenomenon of wind-up,
in which noxious stimuli applied to the skin also enhance the excitability
of dorsal horn units, producing exaggerated responses to subsequent stimuli
(Mendell and Walsh, 1965). Another mechanism of intraspinal disinhibi-
tion following peripheral nerve injury involves a trans-synaptic reduction
in the expression of the potassium-chloride cotransporter KCC2 in lamina
I neurons, which disrupts anion homeostasis in these neurons (Mòdol et al.,
2014). The effect is that GABA release from normally inhibitory interneu-
rons and now exerts an excitatory action increasing central sensitization.
Dorsal horn neurons receive a powerful facilitatory but mostly inhibitory
descending modulating control from supraspinal brainstem centers. A loss of
function in descending inhibitory serotonergic and noradrenergic pathways
contributes to central sensitization and pain chronification. Peripheral nerve
injury activates spinal cord glia and causes these cells to enhance pain by
releasing proinflammatory cytokines and glutamate producing also central
sensitization.
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2.2.4 Low-threshold Aβ Fiber-mediated Pain
Neuropathic pain involves a profound switch in sensitivity such that low-
threshold Aβ fibers, which normally signal innocuous sensations, may begin
after neural lesions to produce pain sensation (Witting et al., 2006). A
number of changes either independently or combined can promote Aβ
fiber-mediated pain: central sensitization, disinhibition, and central afferent
terminal sprouting.
Differential block induced by compression of the radial nerve in patients
with nerve injury or exposed to experimental pain clearly demonstrated that
pain induced by light brushing was mediated through Aβ fibers, whereas ther-
mal pain was mediated through unmyelinated C fibers. Intrathecal morphine
reversed nerve injury-induced thermal, but not tactile, hypersensitivity.
After peripheral nerve injury the most spontaneously active fibers are Aβ
and Aδ fibers (>80%), whereas C fibers represent a small (0–30%) portion of
the active population. This hypersensitivity includes areas outside the injured
nerve territories and occurs largely in the absence of peripheral sensitization.
It is typically associated with a loss of C fiber peripheral terminals and
disappears when conduction in large myelinated fibers is blocked. After
nerve injury polysynaptic and monosynaptic Aβ fiber inputs in the most
superficial laminae I and II of the dorsal horn are increased. These laminae
normally receive only input from Aδ and C fibers. After an injury, this clear
organization can be lost, as some Aβ fibers arriving to lamina III–IV can
produce aberrant sprouting and reach outer laminae. This may imply that
some innocuous, tactile information will be processed abnormally in a noci-
ceptive territory, constituting a potential mechanism for allodynia (Costigan
and Woolf, 2000).
2.2.5 Changes in Endogenous Inhibitory Pathways,
Disinhibition, and Plasticity
After nerve injury there is loss of pre- and postsynaptic inhibition in the spinal
cord. This can occur because of death of inhibitory interneurons caused by
the excitotoxicity of the lesion, reduction in the release of inhibitory neu-
rotransmitters from surviving interneurons, and reduction in the expression
of inhibitory transmitter receptors. In nociceptive lamina I neurons, the trans-
membrane gradient for chloride ions changes. GABA receptors no longer lead
to hyperpolarization, instead depolarization is induced, provoking excitation
and spontaneous activity (Keller et al., 2007). Independently, there is loss of
GABAergic interneurons by apoptosis compromising the dorsal inhibition.
2.2 Neurobiology of Neuropathic Pain 71
After GABAergic or glycinergic blockade or removal, tactile allodynia is
induced and synaptic currents from Aβ fibers to nociceptive lamina I neurons
increase.
The tonic noradrenergic inhibition that acts on α2-adrenoceptors appears
to be suspended after lesion thus, the net effect of descending adrenergic input
goes paradoxically, from inhibition to facilitation. Other descending pathway
in the modulation of the nociceptive input are the µ opioid receptors, which
reduce their expression together with less sensitivity of dorsal horn neurons
to its agonists after nerve injury.
Activated microglia synthesize and release prostaglandins, chemokines,
NOS, and cytokines (TNFα, IL1, IL6. . . ) acting as chemical mediators to
amplify the microglial reactivity favoring the elevation of these molecules in
the dorsal horn. Reactive microglial cells are also responsible for the release
of cathepsine-S protease that causes the proteolysis of a transmembrane
glycoprotein called fractalkine (CX3CL1) which interacts with its receptor
(CX3XR1) located in the reactive microglial cell membrane, maintaining its
reactivity and therefore contributing to the preservation of neuropathic pain.
Microglia can also provoke neuronal death by producing ROS, proapoptotic
cytokines and by a diminished glutamate uptake. Astrocytes also become
activated after peripheral nerve injury with a slower onset and more prolonged
time course than microglia, but also playing a role in the maintenance of
neuropathic pain hypersensitivity.
The energy depletion in the injured neurons decreases the intracellular
ATP concentration and consequent KATP channels activation. The activation
causes potassium ions outflow leading to hyperpolarization, less excitability,
and reduction in the release of neurotransmitters. However, KATP expression
is decreased after peripheral nerve lesion of myelinated Aδ nociceptive fibers
enhancing hyperexcitability.
In the thalamus, there is an upregulation of nicotinic and cannabinoid
receptors after peripheral nerve injury, suggesting that supraspinal recep-
tors in the thalamus may contribute to the modulation of neuropathic pain
responses. On the other hand, µ-opioid receptor mediated G-protein activity
is reduced producing desensitization in receptors from this region. Also,
NKCC1 and KCC2 dysregulation in the spinothalamic pathway is produced
after sciatic nerve section, suggesting that neuropathic pain is maintained by
reducing inhibitory inputs not only in the spinal cord but also at thalamus and
cortex (Mòdol et al., 2014).
In summary, multiple and different mechanisms operate after nerve injury
to increase excitability and reduce inhibition in the central pain pathway.
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Apart from the loss of descending inhibition, another feature contributing
to the hyperexcitablity in the pain pathway after injury is disinhibition.
Silent circuits and synapses in normal conditions can become activated after
peripheral nerve injuries. The disinhibition can be produced by a shift in
the properties of inhibitory receptors, for example, the loss of inhibitory
function in GABA receptors, in relation with a shift in the function of chloride
transporters NKCC1 and KCC2 (Mòdol et al., 2014).
Neural plasticity occurring after neuronal lesions is also detectable in
reflex circuits, which are usually used as an indirect measure of central
hyperexcitability. Electrophysiological changes caused by the lesion and
following plastic reorganization can produce the appearance of hyperreflexia
and an increase in wind-up responses that can eventually lead to spasticity
and neuropathic pain (Valero-Cabré and Navarro, 2010; Redondo-Castro
et al., 2010).
2.2.6 Changes in Subcortical and Cortical Regions
Some groups of brainstem neurons are related with nociceptive modulation,
forming the called “brainstem pain modulating system.” It includes the mid-
line PAG-RVM system, the more lateral and caudal dorsal reticular nucleus
(DRt) and caudal ventrolateral medulla (cVLM). The descending projec-
tion of RVM includes the nucleus raphe magnus and the adjacent reticular
formation. Serotonin and noradrenaline are the main neurotransmitters in
these descending pathways. The predominant source of serotonergic input to
the spinal cord arises from the nucleus raphe magnus. Serotonin causes hyper-
polarization of afferent nociceptive fiber terminals and dorsal horn projection
and it produces excitation in spinal GABAergic interneurons. Noradrenaline
causes hyperpolarization of projection neurons and over terminals of primary
afferent fibers inducing excitation of dorsal horn inhibitory interneurons.
There are two types of neurons in the PAG-RVM system: “ON” cells facilitate
and “OFF” cells inhibit pain transmission (Fields et al., 2000).
Neuropathic pain induces hyperexcitation of specific nociceptive and
WDR neurons in the spinal cord causing a potentiation of the “ON” neurons
response and a decrease of the “OFF” neurons. The preferential activation
of “ON” cells located in RVM causes hyperalgesia, whereas hypoalgesia is
achieved by the activation of RVM “OFF” cells. A sensitization of “ON”
RVM neurons is also induced by overexpression of NMDA/AMPA, Trk-B,
and NK1 receptors, whereas µ opioid receptor expression decreases. Under
these circumstances, “ON” RVM neurons do not respond to inhibitory signals
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from PAG, whereas they are highly stimulated by ascending inputs that
release glutamate, SP, and dynorphin over thalamic and brainstem neurons.
PAG neurons are also sensitized due to overexpression of several receptors
including NMDA/AMPA and SP/NK1 but also overexpression of gluta-
mate and BDNF. These PAG-BDNF-positive neurons project their axons
over the “ON” RVM neurons, enhancing their depolarization via Trk-B and
NMDA/AMPA receptors.
Furthermore, “OFF” RVM neurons mainly express NMDA/AMPA and
TRPV1 receptors. After neuropathic and/or inflammatory painful insults,
there are molecular changes in “OFF” RVM neurons such as an overexpres-
sion of GABA-A and kappa opioid receptors provoking hyperpolarization and
reduction of their antinociceptive effect on spinal cord dorsal horn neurons.
The increase of microglial and astroglial reactivity in RVM also contributes to
the misbalance of the normally inhibitory descending pathways, by releasing
several mediators that facilitate the excitation of “ON” RVM neurons and
their excitatory effect on dorsal horn neurons (Wei et al., 2008).
A simple cutaneous nerve anesthetic blockade causes fast and reversible
reorganization of dorsal column nuclei and thalamus. In primates, imme-
diately after section of ulnar and median nerves there is a change in hand
representation mapping in their brainstem cuneate nucleus, maintained over
several days. Reorganization in cortex and thalamus territories is delayed
a few weeks to months, depending on the growth of new connections and
the expansion of thalamic receptive fields that tend to be larger than in
somatosensory cortex. Cortical and subcortical reorganization and plasticity
depend on the abnormal projections from peripheral and spinal levels.
Peripheral nerve injuries result in loss of evoked activity by deafferenta-
tion in the corresponding cortical map. Then, plastic changes occur resulting
in reduction of the cortical area representing the denervated part of the body,
in favor of expansion of adjacent representations from intact sources with
hardly discernible somatotopy. The brain plasticity is not very accurate per se,
as it was demonstrated in several cases of nerve section and repair in humans
where sensory mislocalizations persist for many years due to misdirected
reinnervation. The reorganization has different time courses depending on
the severity of the lesion. After experimental sensory deafferentation of one
finger in a human patient, the expansion of cortical representations of intact
fingers is very fast and is recovered in minutes when the sensory blockade
is stopped. On the other hand, amputees suffer a slower brain plasticity
process for a few weeks to become permanent with reduction of affected area
and expansion of adjacent cortical regions. The basis of phantom sensations
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secondary to limb amputation seems to include reorganization phenomena at
the cortical and subcortical levels. Furthermore, a sensory map corresponding
to the different portions of the missing limb can be traced in the stump or in
the face of some amputee subjects (Ramachandran and Hirstein, 1998).
The first changes in the brain produced by a peripheral nerve injury
involve changes in synaptic efficacy, including increased excitatory neu-
rotransmitter release, increased density of postsynaptic receptors, changes
in membrane conductance, or removal of inhibitory projection resulting in
unmasking of inactive synaptic connections at cortical and subcortical levels.
Loss of GABAergic inhibition is the main cause of the short-term plastic
changes in the cortex. In the same way that occurs in the spinal cord,
there is an upregulation of Nav1.3 in the third-order nociceptive neurons
in the thalamus resulting in hyperexcitability and expanded receptive fields.
In situations of chronic deafferentation, structural mechanisms like LTP or
LTD phenomena, sprouting for the formation of de novo connections and
synaptogenesis can be reduced by NMDA receptor antagonist administration
at the beginning of the plastic process.
At subcortical levels, transneuronal atrophy associated with retraction of
axons and compensatory axonal sprouting seems to play a significant influ-
ence on the reorganization of somatotopic maps in the brain cortex. Plastic
reorganization after nerve injuries has been related with structural changes
in dendritic arborization within the cortex. Brain reorganization processes
in adult subjects seem to occur primarily through changes in the strength
and efficacy of existing synapses, rather than implicate active remodeling of
connections.
In summary, neuropathic pain triggers plastic changes in the descending
pain modulatory pathway: “ON” cell activation and “OFF” cell inactivation
from the PAG-RVM system, to increase pain facilitation in the spinal cord.
In addition, reorganization of ascending projections takes place sequen-
tially from the dorsal horn to the brainstem, the thalamus and finally the
somatosensory cortex.
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Transversal intrafascicular multichannel electrodes (TIMEs) have been
developed using state-of-the-art micromachining technologies. This chapter
presents the different designs of the implantable thin film electrode array,
cable and connector development, and the assembling of components into
implantable devices. As a last step towards translational research and human
clinical trials, implantable devices have been fabricated under a quality
management system to meet the essential requirements of active implantable
medical device regulations.
3.1 Introduction
Research on interfaces to the nervous system is driven by application needs
and knowledge about the performance, effects, and side effects of existing
devices. Knowledge from material sciences and “novel” manufacturing tech-
nologies that go beyond the integration level and degree of miniaturization of
precision mechanics propose regularly new approaches to obtain better spatial
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resolution with less foreign body reaction and more and more recording or
stimulation channels. Promises have been made in many cases but only few
devices have been transferred into chronical applications and even fewer in
humans in clinical practice.
Based on our expertise in microsystems engineering and promising
results published about the performance of longitudinal interfascicular
electrodes made with means of precision mechanics as well as microma-
chined ones, we started the endeavor to develop a new type of intrafascicular
electrode that should deliver good levels of special selectivity on a fascic-
ular or even subfascicular level. Investigations should not only include the
technical development but also target a first-in-man clinical trial. Therefore,
designs had to be developed for small and large animal models to prove that
selective stimulation of peripheral nerves with little crosstalk at low stimu-
lation thresholds is feasible. From the engineering side, system integration
with cables and connectors to stimulators and percutaneous wires for human
clinical trials had to be developed. Devices had to be implanted and prove
biocompatibility and functionality for up to 30 days as legally defined period
for a first-in-man study. Nevertheless, questions on long-term functionality
were investigated with the objective to come to much longer stability of
implanted microsystems. In the course of the developments, several designs
were made for small and large nerves to finally come to a version for our
human subject. This last design of TIME probes had to be manufactured
under quality management requirements and regulations to fulfill “essential
requirements” according to medical device laws in Europe. This chapter is a
journey through the different steps of TIME developments and will not only
deliver the final results but show how iterative research work helps to improve
device functionality and performance when only little pre-existent knowledge
is available.
3.2 Design and Development of TIME Devices
Previous experience of other research groups in interfaces to the peripheral
nervous system showed well that invasiveness and selectivity have to be well
balanced with respect to the envisioned medical application. The goal of
treating phantom limb pain after amputation trauma of a hand by implanting
electrodes for electrical stimulation of sensory feedback required coverage of
the whole arm nerve(s) with selectivity on the (sub-)fascicular level. While
cuff electrodes deliver good selectivity to superficial fibers and longitudinal
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intrafascicular electrodes (LIFE) are superior with local selectivity but lack
cross-sectional coverage, we propose the transversal intrafascicular multi-
channel electrode (TIME) to get both nerve cross-sectional coverage and local
selectivity in one device (Figure 3.1) (Boretius 2009).
Good experience of implanting thin-polymer-based electrodes longitudi-
nally in the nerve (tfLIFE) brought us the idea to try out a modified design
to have similar foreign body reaction and selectivity of the adjacent fascicles
and to cover the whole cross section of the nerve by transversal implantation.
This idea led to the first basic electrode design of a transversal intrafascic-
ular multichannel electrode which is still similar to the tfLIFEs. An electrode
arrangement comprising three active stimulation sites plus an indifferent and
a ground electrode was designed on a substrate that subsequently becomes
kinked within the center line and gets inserted into the peripheral nerve. This
kinking allows to have electrode sites on both sides of the implant without
sophisticated (non-standard) micromachining technologies that quite often
leads to low yield and prevents medium-scale manufacturing of devices (in
our case tens to hundreds) with a comparable quality at early stages when
technology and manufacturing readiness level are still low. In addition to
the transversal implantation procedure, it was hypothesized that a corrugated
substrate allows better adaptation to the different fascicles and thus lower
stimulation thresholds, less crosstalk, and higher selectivity. The engineering
challenge was the development of a post-micromachining technology to
achieve a corrugation of polymer substrates with integrated electrode sites
(see below).
An estimation of the forces at the material–tissue interface due to
lateral displacement of the implant has been calculated with the envi-
sioned geometrical design parameters and the Young’s modulus of the
substrate material (polyimide, UBE U-Varnish-S) that had been determined
as E = 7 GPa in another study (Rubehn 2010). We assumed the interconnect-
electrode structure as a rectangular beam with a one side restraint and a
connector side and neglected the thin platinum metallization in the first
approximation. The beam had a thickness of h = 11 µm, a width of
b = 580 µm, and a length of w = 3400 µm:
Iz =
bh3
12
= 6.43 · 10−20m4 (3.1)
Iy =
b3h
12
= 1.79 · 10−16m4 (3.2)
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The given geometry leads to moments of inertia in the direction of the
structure Iz and the structure orthogonal to it Iy.
The application of a point load on one side leads to a displacement:
w(x) =
F
6EI
·
(
x3 − 3lx2
)
(3.3)
w(x = l) =
l3
3
F
EI
(3.4)
A displacement of 10 µm inserted into the beam equation (Equation 3.3)
at the end of the structure at x = l (Equation 3.4) leads to a force of
F = 0.343 µN in the normal direction and a force of F = 956 µN in
the orthogonal direction with a relationship of the moments of inertia of
Iy: Iz = 2783.
Since the first proof-of-concept studies in vivo were scheduled with rat
animal models, the design was adapted to the anatomy of the rat sciatic
nerve which has a diameter of approximately 1.2 mm. The electrodes were
designed with a final pitch after corrugation of 300 µm (400 µm before),
thus ensuring a proper positioning and contacting of the three fascicles
within the rat sciatic nerve. The electrode sites had an effective diameter of
60 µm (80 µm metallization) and the electrode tracks had a width of 50 µm
(Figure 3.2).
The design of this first version of a TIME device had an overall width
of 580 µm, a thickness of approximately 12 µm, and a length from center
to interconnection pads of 3.4 cm. The fins in the device center are used for
positioning purposes within the moldform and will be cut after corrugation
(for corrugation see section below).
Metallization had been performed by sputter depositing of platinum and
lift-off structuring technique, so far. Limited charge injection capacity and
foreign body reactions around the implant limited the performance of the first
thin-film LIFE (tfLIFE) in a human to 10 days. To enhance the performance
of the device, that is, decreasing the impedance and cut-off frequency (as
well as increasing the charge injection capacity), different coatings for the
electrode sites were investigated. Details of process and coating technology
are given in detail in the following sections.
3.2.1 Process Technology to Manufacture TIMEs
The electrode manufacturing was conducted in a class 1000 cleanroom using
state-of-the-art micromachining processes (Figure 3.3).
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Figure 3.2 Design of the first version of a TIME. Red color indicates metallization and blue
color indicates polyimide borders. All dimensions are presented in millimeters.
Figure 3.3 Schematic view of the micromachining process to manufacture TIME devices
(see text for details).
First, a 5.5-µm-thick layer of polyimide (U-Varnish-S, UBE Industries,
Tokyo, Japan) was spin coated onto a silicon wafer that was solely taken for
handling purposes (Figure 3.3a). A layer of lift-off resist was deposited and
patterned by photolithography using a mask aligner (MA/BA6, Carl Zeiss
AG, Jena, Germany). Next to an oxygen flash of 30 seconds that enhances the
adhesion of metal to polymer, a 300-nm-thick layer of platinum was deposited
by sputtering technique (Leybold Univex 500, Leybold GmbH, Germany)
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(Figure 3.3b). Next to an oxygen flash of 30 s that enhances the adhesion of
metal to polymer, a 300-nm-thick layer of platinum is deposited via sputtering
technique (Figure 3.3b) (Leybold Univex 500, Leybold GmbH, Germany).
Following the lift-off process, which removes any excess metal, this step
is repeated but SIROF (800 nm in thickness) is used as metal rather than
platinum (Figure 3.3c). This step is optional and has been omitted in the first
fabrication rounds for simplicity reasons. Again a lift-off process is necessary
to remove metal residues, before the structured metal is exposed to oxygen
plasma (30 s) and coated with a second layer of polyimide (Figure 3.3d).
To open the electrode sites, interconnection pads and perimeters, a photo
resist (AZ 9260, MicroChemicals GmbH, Ulm, Germany) is spin coated
and patterned via photolithography serving as etching mask (Figure 3.3e).
A reactive ion etching (RIE) process is then used to open the electrode sites
and interconnection pads, and to etch the device perimeters down to the sup-
porting wafer. At the end of the process, the single device can mechanically
be peeled off the wafer (Figure 3.3f).
3.2.2 Coating of Electrode Sites
In both, recording and electrical stimulation, small platinum electrodes need
to be coated to improve electrode properties with respect to low impedance
and high charge injection capacity (Stieglitz 2004). Platinum black and
Pt-gray were the first candidates of choice due to their known character-
istics and simplicity in deposition. Both coating techniques implement an
electrochemical deposition step by applying an electrical voltage on the elec-
trodes with square-shaped voltages of different magnitudes. The materials
in the electrolyte (basically platinum chloride acid) determined therefore
the resulting coating. Electrolytes were synthesized for platinum gray and
black according to the literature. The electrolyte for platinum gray consisted
of 0.5 g platinum chloride (PtCl4), 0.3 g sodium dihydrogen phosphate
(NaH2PO4), and 6.03 g disodium hydrogen phosphate (Na2HPO4) dissolved
in 100 ml of deionized water according to Method 1 of the US patent
number 2007/0089994A1 (Zhou 2005). The electrolyte to electroplate Pt-
black (Schuettler 2005) was made by dissolving 5 g hexa-chloroplatinic acid
(H2PtCl6) in 357 ml ultrapure water and by adding 71.4 mg lead(II)-nitrate
(Pb(NO3)2) (Chemicals: Merck KGaA, Darmstadt, Germany). Different
TIME samples were immersed into the corresponding electrolyte. A three-
electrode setup with the sample as working electrode, a large surface platinum
counter electrode, and a Ag/AgCl electrode with 3 M KCl as reference
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were used. The working electrode was balanced with a negative square wave
voltage of −0.25 V for 10 s for Pt black and −0.525 V for 30 s for Pt-gray
deposition, respectively. Later in the development phase, sputtered iridium
oxide (SIROF) has been used as electrode coating.
3.2.3 Electrochemical Characterization In Vitro
Electrochemical characterization of the electrodes has been performed to
assess the transfer functions during recording and stimulation and compare
the different coating processes. The electrochemical impedance of the elec-
trodes was characterized using a gain-phase analyzer with a potentiostat
(Solartron 1260 & 1287, Solartron Analytical, Farnborough, Hampshire, UK)
in combination with the software ZPlot (version 2.8 by Scribner Associates
Inc., Southern Pines, NC, USA) within a three electrode setup using a
platinum counter electrode and a Ag/AgCl reference electrode (3 M KCl) in
0.9% NaCl solution. Impedance spectra have been taken between 10 Hz and
700 kHz applying a sine wave of 10 mV. Eight electrode sites (n = 8) were
measured per electrode material and coating. Mean and standard deviation
were calculated. Lumped parameter equivalent circuit models were fitted
with ZView (version 2.8 by Scribner Associates Inc., Southern Pines, NC,
USA) using a simple model with the Helmholtz-capacitance in parallel to
a Faraday resistance and the access resistance in series. The rationale to
take an electrical rather than an electrochemical equivalent circuit was an
opportunity to match electronic circuits if recording over the electrodes is
intended.
Johnson’s voltage noise (Liu 2008) (Equation 3.5) was calculated via the
real part of the interface impedance at body temperature (T = 311 K) with
the Boltzmann’s constant (k = 1.38 ∗ 10−23 J/K) in the frequency range
between 300 and 1500 Hz that has been envisioned to be adequate to record
either neural single unit or mass activity. The final value was calculated taking
the real part of the recorded impedance at a certain frequency (Equation 3.6)
and multiplying it with the related frequency “slice” (∆f = 1 Hz). From these
1200 slices per electrode site, the Johnson’s voltage noise was derived for a
single electrode site within the defined frequency range:
V =
√
4kT · Re {Z} ·∆f (3.5)
Re {Z} = |Z| · cos θ (3.6)
Noise has been calculated for platinum, platinum gray, and platinum black.
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The stability of the platinum coatings, that is, the adhesion of the coating
on the substrate metal, has been evaluated. Therefore, the TIME devices were
placed into an ultrasonic bath (Emmi-6, 20W US, Schalltec GmbH, Walldorf,
Germany) filled with deionized water. They have been exposed to ultrasound
for 2, 4, and 10 min. Electrical impedance was measured before and after
treatment to investigate changes in the coatings. The electrode properties
during electrical stimulation have been investigated by determination of
the water window during cyclic voltammetry and succeeding application of
current pulses with typical envisioned stimulation parameters to determine
the polarization and capacity of the electrode site. Cyclic voltammetry has
been performed with the three electrode setup described above at a sweep
rate of 100 mV/s. A custom made voltage controlled current source was
used to apply biphasic, symmetric, rectangular, charge balanced, cathodic
first current pulses with an amplitude of 100 µA and a pulse width of 200 µs,
that is, 20 nC in 0.9% saline solution via block capacitors of 1 µF. A large
platinum electrode was taken as counter electrode. First, electrodes have been
treated with ultrasound for 2 minutes before applying current pulses. The
voltage over the electrodes and the electrolyte was recorded via an oscillo-
scope with a sampling frequency of 1 MHz (54622D, Agilent Technologies
GmbH, Böblingen, Germany). Data were transferred to a computer for offline
analysis afterwards.
The platinum electrodes as well as the platinum gray and black coating
showed the typical metal behavior with an access resistance of about 10 kΩ
and varying cut-off frequencies and impedances (Figure 3.4, Table 3.1, mean
values of n = 8) according to their surface roughness.
The fitting of the measurement data with the R||C-R model of the elec-
trodes resulted in the parameters of the Helmholtz-Capacity CH, the Faraday
resistance RF, and the access resistance RA as shown in Table 3.2.
Thermal (Johnson) noise has been calculated in the frequency range
between 300 and 1500 Hz to be (mean ± standard deviation) VPt = 72.5 ±
23.8 µV for platinum, VPt-black = 45.7 ± 13.0 µV for platinum black, and
VPt-gray = 52.3± 15.8 µV for platinum gray.
Stability of the electrode coatings has been investigated after ultra-
sound treatment for 2, 4, and 10 min by means of impedance spectroscopy
(Table 3.1). The impedance remained stable for the platinum metallization.
The impedance of both platinum gray and platinum black coatings increased
from 22 to 33 kΩ at 1 kHz for Pt-gray (i.e. 33%) and from 15 to 22 kΩ
at 1 kHz for Pt-black (i.e. 32%) after 2 min of ultrasound but stayed stable
during further ultrasound treatment.
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Figure 3.4 Impedance and phase angle of the TIME with platinum, platinum gray, and
platinum black as electrode material.
Table 3.1 Results of EIS measurements with different electrode-coating materials
Material |Z|in kΩ @ 1 kHz Phase Angle θ in ◦ Cut-off Frequency in Hz
Pt 81.8 −71.4 ∼10000
Pt-gray as deposited 20.2 −41.7 ∼1600
Pt-gray after 2 min US 32.5 −60.8 ∼2900
Pt-black as deposited 14.6 −36.7 ∼1100
Pt-black after 2 min US 19.7 −50.5 ∼2000
Note: Mean values of n = 8 electrodes.
Table 3.2 Lumped parameter equivalent circuit model of the electrodes fitted from
impedance measurement data
Material CH in nF RF in MΩ RA in kΩ
Pt 6.9 1.9 10.5
Pt-gray 15.3 1.5 11.1
Pt-black 24.4 1.7 10.8
The water window for all electrodes was determined to be between 1.1
and−0.8 V with respect to Ag/AgCl. Under stimulation conditions (100 µA,
200 µs), the recorded voltage over the electrodes was analyzed (Figure 3.5).
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Figure 3.5 Voltage response after current stimulation of the TIME with platinum, platinum
gray, and platinum black as electrode material.
Table 3.3 Voltages Vc and the derived capacitance of different materials during stimulation
Material Vc (V) C (nF) Cd(µF/cm2) Surface Factor, n
Pt 1.56 12 424 1
Pt-gray 1.1 18 636 1.5
Pt-black 0.8 25 883 2.1
The voltage drop VIR over the access resistance RA was found to be
about 560 mV in all experiments. Platinum had the largest polarization of
Vc = 1.56 V, followed by Pt-gray (Vc = 1.1 V) and Pt-black (Vc =
0.8 V). The value for platinum has been out of the reversible region. The
peak of this voltage ramp Vc, which is related to charging the Helmholtz
capacitance at the phase boundary, was used to calculate the charge injection
capacitance C = Qinj/Vc where Qinj is the charge injected into the phase
boundary (Table 3.3). The surface factor of the electrode coating related
to pure platinum has been calculated as the charge density Cd of a given
electrode divided by Cd of platinum. It indicates the enlargement factor of
the electrochemical active surface of different surface qualities (Table 3.3)
(Schuettler 2007, Franks 2005).
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The stimulus pulse parameters in the in vitro characterization (200 µs,
100 µA) have been derived from experiences with cuff electrodes. The charge
of 20 nC resulted in a charge density of about 708 µC/cm2 of geometric
electrode area. This is far beyond the electrochemical safe limits of polished
platinum (Veraart 2004, Shannon 1992). The used stimulation parameters in
the in vivo pilot studies (20 µs pulse width) stay within the most conservative
prediction of reversible charge injection capacity of 40 µC/cm2 (Donaldson
1986) for polished platinum if an amplitude of 500 µA is not exceeded,
that is, Qinj = 35.4 µC/cm
2. Up to an amplitude of 1000 µA, that is,
Qinj = 70.8 µC/cm
2, and 1500 µA, that is, Qinj = 106.2 µC/cm
2, inves-
tigations reported to be still in the electrochemical safe stimulation regime
with a reversible charge injection capacity of 50–100 µC/cm2 geometrical
(Robblee 1990) and 400–500 µC/cm2 “real” (electrochemical active) elec-
trode area (Brummer 1977). Integration of the electrodes into a completely
implantable stimulation system might afford a change of the pulse width from
small pulse width that results in minimum charge of the stimulation pulse
towards pulse width about the chronaxie of the stimulated nerve that results
in minimum energy per stimulation pulse to maximize life time of batteries
or minimize the need of inductive energy transmission. These parameters
together with reduced charge carrier mobility in vivo (Cogan 2007) will lead
to different reversible charge injection limits that have to be investigated in
chronic studies. The increase of the electrode impedance of platinum black
after explantation might indicate some instabilities in the layer. Modification
of the deposition technology to ensure denser material with better adhesion
(Marrese 1987) might be necessary, if platinum gray will come to its limits.
3.2.4 Assembling of Connectors and Design Optimization
for First Preclinical In Vivo Studies
For in vitro characterization and acute in vivo experiments, a fast and easy to
use interconnection is favorable. Therefore, a flip-lock zero insertion force
(ZIF) connector was chosen. The assembly contains only few and simple
steps (Figure 3.6). The interconnection pads are reinforced by an electrical
insulation tape, inserted into the ZIF which is closed afterwards. With this
technique, the whole assembly time can be reduced to just three steps, and
the SMD configuration of the ZIF connectors allows multiple forms of cable
connections, for example, soldering bare wires or a flat flex cable (FFC).
After first acute rat experiments, the need for a new electrode design
became obvious. The TIME-1 was bulky and, when folded, rectangular
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Figure 3.6 Assembling of TIME with a flip-lock ZIF connector. (a) Pad array on polyimide,
(b) reinforcement with tape, (c) insertion into ZIF connector, and (d) closing of connector
fixates substrate and reinforcement.
Figure 3.7 Folded TIME-1 with arrow-like tip.
in design which posed a serious problem during implantation procedure.
Beneath difficulties in insertion, tremendous nerve damage was induced
resulting in limping rats. Hence, a provisional solution was found in sharp-
ening the folded electrode tip in an arrow-like structure (Figure 3.7). This
improving implantation technique increased the success of implanting and
stimulating the rats’ sciatic nerve. Nevertheless, TIME-1 is far too wide
(580 µm) for the rats’ nerve and its straight arrangement of electrode sites
is suboptimal. Henceforth, TIME-2 will become smaller in width, have
a defined arrow shape with a tip-width of merely 100 µm, and have an
increased electrode count of 3 to 6 active sites.
In general, three different versions of the TIME-2 were designed
(Table 3.4): one for small animal models (rat, Figure 3.8a) and two layouts
for large animal models (pig, Figure 3.9). Design specifications were derived
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Different connectors available, MFI & ZIF 
MFI; connection to ceramic adapter 
ZIF; directly to plug
Two different lengths: 40 & 60 mm 
2 mm  1 mm  1 mm  
280 μm 
100 μm  
1.5 mm  
5.5 mm  
pitch 230 μm 
A
B
Figure 3.8 Schematic view of the TIME-2 device for small nerve models. (a) Substrate
design with arrow tip and 5 electrode sites per side. (b) Different connection pad designs. Left:
arrangement for MFI on ceramic substrate. Right: Arrangement for direct ZIF connection.
from anatomical studies in close cooperation with the corresponding partners
(AAU and UAB). ZIF and MicroFlex Interconnection (MFI) options for
assembly were realized for all versions of TIME-2 (Figure 3.8b).
TIME-1 electrodes were assembled using zero insertion force (ZIF)
connectors, because of the easiness in handling and the ability to connect
the devices post implantation (Figure 3.10). This technique ensures an easy
implantation procedure, since the electrodes’ handling is not hindered by
cables and the electrodes’ relative movement can be kept at a minimum.
This approach is adequate for the rat animal model since the length of the
integrated interconnects ensures that the cable–socket interface is outside of
the animal.
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Table 3.4 Specifications of TIME-2 devices
Large Nerve Large Nerve
Small Nerve (Version A) (Version B)
Interconnection ZIF and MFI MFI MFI
Length
(without interconnection)
40 and 60 mm 60 mm 60 mm
Width 280 µm 180/400 µm 260/480 µm
Width in mirror line 100 µm 100 µm 100 µm
Number of electrode sites 5 3 6
Electrode pitch 230 µm 1 mm 0.5 mm
Ø active sites 60 µm 60 µm 60 µm
GND dimensions 60× 400 µm 0.24 × 2.4 mm 0.24 × 2.4 mm
Distance from mirror line
to first electrode
2 mm 7 mm 7 mm
Distance from first to last
electrode
1 mm 2 mm 2.5 mm
Track width 15 µm 15 µm 15 µm
Track pitch 15 µm 15 µm 15 µm
Referred as TIME2-S-40/60-MFI/ZIF TIME2-L-A TIME2-L-B
But since the ZIF connectors are bulky and comparably heavy, a new
approach was undertaken to further decrease the weight and dimension of the
adapter from thin-film substrate to the actual wiring of the TIME-2 devices
for a large animal model (Figure 3.11). Here, longer cables are needed to
connect the electrode–cable assembly to standard plugs outside the animal.
Therefore, a ceramic adapter (alumina, Al2O3 ceramics) was introduced
which comprises Pt/Au conductive tracks and an insulating overglaze layer.
This adapter is manufactured through screen printing of thick films. The tech-
nology was already established at IMTEK during the electrode assembling
process and could be applied for this purpose. For the assembly of TIME-2
devices, Cooner wires (AS-632 by Cooner Wire Inc., Chatsworth, CA, USA)
were soldered to the 10- or 16-way pin connector for version TIME-2 A
or B, respectively. These Cooner wires were cut at a specified length of
approximately 25 cm and again soldered to the two ceramic adapters (one
for each side of the thin film substrate). Afterwards, the polyimide substrate
was assembled onto the ceramic adapters with the MicroFlex Interconnection
technique (Meyer 2001). The assembly was fixed with a tiny droplet of epoxy
glue. The adapters with the attached thin films were placed back to back and
fixed through a silicone tube. At last, residual openings become insulated with
silicone rubber (Figure 3.11).
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a)
7 mm 2 mm 3 mm
30 mm
1 mm pitch
- broadens from 180 to 400 μm
- used as insertion stop
2.4 x 0.24 mm GND
5 mm
1.4 mm
b)
7 mm
30 mm
2.5 mm
pitch 500 μm
broadens from 260 to 480 μm
2 mm
2.4 x 0.24 mm GND
5 mm
Figure 3.9 Schematic view of the TIME-2 devices for large nerve models. (a) Version A
with three active sites and (b) Version B with 6 active sites.
Figure 3.10 Photograph of a fully assembled TIME-1 electrode with ZIF connectors.
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Figure 3.11 Light micrographs of fully assembled TIME-2 devices. Left: TIME-2-B; right:
both versions of the TIME-2.
The devices were ready for in vitro and acute in vivo use and passed to
the partners’ laboratories for validation of simulation studies and acute in vivo
tests (see chapters below).
One of the main challenge in manufacturing devices for chronic implan-
tation lies within a well adherent encapsulation (Schuettler & Stieglitz 2013).
Since all polymers are permeable to water molecules, the main responsibility
of a non-hermetic encapsulation is to prevent condensation of water on the
surface of the device. If, for example, an air bubble is enclosed within the
encapsulant and the devices’ surface or conducting track, water will permeate
through the barrier and slowly fill the bubble. With time, the pure water
will dissolve ions out of the surface of the device and, thereby, change the
direction of the osmotic pressure towards the bubble itself. Consequently,
more water permeates to the bubble, more ions are dissolved, and the osmotic
pressure increases furthermore. Since the bubble has to expand, the encap-
sulant will be separated from the surface at some point, leaving an even
bigger crevice behind which again fills with water. Therefore, it is mandatory
to yield a clean and well adherent boundary between the devices’ surface
and the encapsulation. For this purpose, a cleaning and rinsing protocol
was established to ensure that all residues from soldering and handling are
removed prior to encapsulation.
After successful acute animal experiments, the TIME-2 was tested in
chronic animal experiments. Beneath the results from stimulation and record-
ing tests, it will show whether our protocols and precautionary measures of
cleaning and encapsulation were sufficient to sustain a working device in the
living body. As for the acute experiments, Cooner wires were cut and soldered
to the thick-film printed ceramic adapter as before. The other ends of the
94 The TIME Implantable Nerve Electrode
Figure 3.12 Cooner wires soldered to different plugs.
wires are soldered to two different connectors (Figure 3.12): one small, 12-
way socket plug which is made out of high temperature thermoplastics and
incorporates gold over nickel contacts, and 12 single pin contacts consisting
also of a gold–nickel compound. The motivation to use these connectors
was the need to implant the whole device including plugs, since rats quite
often try to remove any percutaneously placed connector, and the ability
to coat these plugs easily with silicone rubber. If a measurement would
be required, the plugs could be explanted and the encapsulation removed
using a scalpel. After the experiments, silicone caps can be reattached to the
connector and sealed with a few droplets of silicone glue which cures within
minutes. Subsequently, plugs can be buried again in tissue pockets until the
next measurement is due.
When assembling of plugs and ceramic adapters was finished, the com-
plete structure had to be thoroughly cleaned. To ensure an overall immaculate
surface, all steps afterwards are conducted in a class 10000 clean room. The
steps of the cleaning process included the following:
• Removal of flux residues from soldering with flux-remover (de-flux 160
by Servisol, Iffezheim, Germany)
• Removal of flux-remover residues by washing with isopropyl alcohol
(IPA)
• Removal of IPA residues by washing in deionized water
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Figure 3.13 Completely encapsulated TIME-2 electrode. Left: MicroFlex Interconnections
between thin-film and ceramics. Right: Overview of TIME, adapter, and wires.
• Removal of any other residues by slewing device five minutes in Leslie’s
Soup (Leslie’s Soup is named after a British researcher and consists of
the glass cleaner “Teepol-L” (0.5%), Na3PO4 (2.5%), and deionized
water (97%)).
• Removal of residues by rinsing with deionized water
• Washing in deionized water till the conductance value of DI water settles
again
• Drying on lint-free cloth at 60◦C in an oven for at least 3 hours
After transferring the cleaned structures into the clean room, the actual
thin-film electrodes were connected via MFI technique to the ceramic
adapters with the soldered wires. The two separated adapters are placed back
to back and glued via a droplet of silicone rubber. Following the curing period
which hardens the polymer, the ceramic adapters are encapsulated in medical
grade silicone (MED-1000 by PolyTec PT GmbH, Waldbronn, Germany).
Special attention is hereby dedicated to ensure a void-free film by apply-
ing first a more viscous solution of silicone (50% silicone and 50% n-heptane)
to encapsulate the small structures around the solder joints and MicroFlex
Interconnections. A curing step is followed by a second layer of encapsulation
(100% silicone) to encompass the complete adapter (Figure 3.13). The plugs
are processed in a similar manner later on, when the adapters are fully cured.
3.3 From Flat to Corrugated Intrafascicular Electrodes
In addition to the TIME’s ability to access deeper nerve fibers in the nerve
trunk, the corrugation of the TIME structure is expected to not only lead to
better selectivity and electrode–tissue contact but also stabilize the electrode
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structure by preventing device movement after implantation. Preliminary
studies on the corrugation of electrodes were conducted by Bossi et al.
(2007, 2009). Shape memory alloys (SMA) were added to the tf-LIFEs to
add micro-actuation in these studies. Concerning the corrugation dimensions,
they achieved amplitudes of around 10 µm (Bossi et al. 2007) and 20 µm
(Bossi et al. 2009), where half-wavelength was around 500 µm in both cases.
These corrugated LIFE structures, however, were not tested in vivo.
3.3.1 Design Considerations
The design guidelines and desired target specifications for corrugated TIMEs
included: (1) low power consumption during the implantation period with
respect to corrugation and actuation; (2) temperature increase should be kept
as low as possible considering thermal damage during the implantation period
when active corrugation is used; and (3) simple structure for easy fabrication
and good biocompatibility and long-term mechanical stability. Among the
well-known micro-actuation principles (Kovacs 1998), electrostatic and elec-
tromagnetic actuation principles are not suitable in our case because of their
high actuation voltage (or current). Thermal actuation principles, including
thermal bimorph and SMA, could possibly cause heat damage to surrounding
tissue. Piezoelectric actuation could be a good candidate because it has
a medium-range actuation voltage and no thermal issues. The multi-layer
structure of these actuators, however, together with the fact that they are made
from novel materials may cause long-term stability and toxicology problems.
Moreover, in all cases, the issue of power consumption cannot be avoided
and integration of actuators significantly changes the mechanical properties
of the implantable devices and thereby their structural biocompatibility. In
this context, we chose the ‘shaping of flat electrode through pre-actuation’
strategy instead of integrating actuators in the electrodes. For the pre-shaping
of electrodes, we tried three approaches: a precision machining approach,
a micromachining approach, and a hybrid of precision and micromachining
approach. The details and results of these approaches will be described in the
following sections. The pre-shaped electrodes are to be implanted in their
original corrugated shape. Therefore, no additional power consumption is
needed after implantation for corrugation. Thanks to the inherent flexibility
of the thin film polymer substrate, the pre-shaped electrode substrate can
be stretched to ‘mild-corrugated’ shape during the insertion period and then
return to its corrugated shape after insertion, minimizing cell damage during
the insertion period. The structure and materials used in these approaches
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Figure 3.14 Schematic view of the cross section of nerve trunk with corrugated electrode:
(a) in small animal model, which has 4 active sites; (b) in large animal mode, which has 6
active sites.
Table 3.5 Comparison of required corrugation dimensions and achieved ones by various
manufacturing technologies
Required for Achieved by
Parameters
Small
Animal
Large
Animal
SMA
(Bossi
et al.
2007,
2009)
Precision
Mechanics
Micro-
machining
Hybrid
Machining
Wavelength (λ) ≈400 µm 850 µm ∼ ≈1 mm 500 µm ∼ 300 µm ∼ 400 µm ∼
1000 µm 4000 µm 400 µm 1500 µm
Amplitude (h) >50 µm >100 µm 10 µm ∼ 90 µm ∼ ≈20 µm >50 µm
20 µm 700 µm
remain mainly the same as within the basic TIME, which means no additional
mechanical influence and cytotoxicity concerns. One possible drawback of
this approach is passivity of corrugation parameters (dimension of wave-
form). The dimension of corrugation, however, can be tested and optimized
during the animal test phase, and the results will be directly reflected in the
fabrication process.
To derive corrugation parameters (wavelength: λ, and amplitude: h), we
assumed four active sites in the small animal model (rat) and six active sites in
the large animal model (pig). Figure 3.14 shows a schematic cross-sectional
view of a nerve trunk with a corrugated TIME. Each red dot indicates an
electrode’s active site. The nerve diameter for the small animal model was
assumed to be 0.8 mm and that of the large animal was assumed to be
2.5–3.0 mm based on anatomical studies. Considering these parameters, the
required wavelength (λ) of corrugation was calculated as 400 µm for the
small animal model and 850–1000 µm for the large animal model. In terms
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of corrugation amplitude (h), we decided to fix the minimum requirement
as 50 µm in the small animal model and 100 µm in the large animal
model, according to our experiences (see Table 3.5). The detailed design
specification had to be determined from the chronic test phase.
It is noteworthy that we devoted ourselves to developing manufacturing
technologies, which can cover a wide range of dimensional spectra. While
we did not yet have the specific dimensional requirements before the animal
experiments started, some of the technical approaches developed had to be
adoptable to the final specific needs.
3.3.2 Precision Machining Approach
Similar to the thin-film cuff electrode manufacture, this approach can be
achieved through a temper process that comprises a moldform and the already
fabricated flat TIME substrate. Since the moldform is solely fabricated via
precision mechanics, variable dimensions can easily be obtained, yielding in
low cost and rapid prototyping (Boretius 2009).
Three moldforms were designed and fabricated through wire-cut elec-
trical discharge machining (EDM). The forms comprise a medical grade
steel mold (1.4541 by Goodfellow GmbH, Bad Nauheim, Germany) and an
aluminum housing.
Figure 3.15 Schematic view of the moldform’s design.
Source: Reprinted with permission from Boretius, T., Zimmermann, D., and Stieglitz, T. Development of
a corrugated polyimide-based electrode for intrafascicular use in peripheral nerves. IFMBE Proceedings
25/IX, Springer, Munich, Germany, pp. 32–35 (2009).
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Figure 3.16 Prototypes of corrugated electrodes using precision machining approach.
The three forms of different dimensions were fabricated in this first trial.
All comprise a sinusoidal form defined by a wavelength λ and an amplitude h
(Figure 3.15). The manufacturing of the test structure was performed using
standard TIME manufacturing processes (see above and Boretius 2010). The
test structures were mechanically peeled off the wafer using tweezers and
inserted into the mold. The mold was closed afterwards and fixed via screws.
The complete form was transferred into an oven (PEO-601, ATV Technologie
GmbH, Vaterstetten, Germany) and tempered in an inert nitrogen atmosphere
at 300◦C for 90 minutes. After the cooling period, the mold was opened again
and the corrugated electrode was retrieved.
Electrodes have been fabricated and successfully corrugated (Figure 3.16).
Contour accuracy and strength of shape of corrugated devices were obtained
optically and compared to the original moldforms’ dimensions. Amplitude
and wavelength were separately measured for tempered electrodes, yielding
the contour accuracy, and for devices stored for 2 weeks in saline solution
at 37, 60, and 85◦C, which gives the strength of shape. Regarding the
amplitude, between∼91% and∼51% of the moldforms’ dimension could be
transferred into the polyimide substrate after the temper process, whereas the
strength of shape decreased (∼3.3% to ∼24.8%) with the storage at different
temperatures. The transferred wavelength was more accurate with ∼98% to
90% for the small and large molds. In this case, only 0.3% to 9.4% strength
of shape was lost while stored at 85◦C for 2 weeks. After the temper process,
80% of the amplitude and 98.5% of the wavelength were transferred into the
substrate. The storage time decreased the wavelength of about 4.6% and the
amplitude of about 13.4% further (Boretius 2009).
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It is important to note that corrugation within the small mold, which
was designed for small animal usage, yielded a rather trapezoidal structure
instead of a sinusoidal one. Since this trapezoidal form has an extreme
high strength of shape, it is nearly impossible to “decorrugate” the substrate
during implantation and handling. Hence, it can be concluded that substantial
nerve damage would be introduced using this small mold to corrugate TIME
electrodes. Larger molds yielded smoother corrugations, and the sinusoidal
form was also implemented within the substrates. Although the dimensions
of corrugation would fit large nerve models, this approach was neglected
because of the observation of microcracks within the platinum layer due to
mechanical stress (thermal expansion) of moldform and polyimide substrate.
To overcome these limitations, a comb like mold was designed in which the
polyimide substrate comes to rest in mid-air, and thus, no mechanical stress
can take effect (see Section 4.3 in Chapter 4).
3.3.3 Micromachining Approach
In the previous precision mechanics approach, the achieved amplitude val-
ues were satisfactory. The smallest wavelength, however, which is limited
by the precision of EDM process, was marginal, especially for small ani-
mal application. For the smaller wavelength, we have applied a thin-film
micromachining process. Here the dimensions of corrugation are defined
by lithography technique. Thus, the smallest feature size can be downsized
dramatically compared to precision mechanics. General thin-film microma-
chining technique, however, has difficulty in achieving out-of-plane three-
dimensional structure, like corrugated electrodes. To tackle this problem, we
used deformation induced by unevenly distributed residual stress.
Residual stress layers were incorporated into the flexible substrate of the
TIMEs (Figure 3.17). In contrast to the basic TIME, high residual stress lay-
ers (red color in Figure 3.17a) are placed on top and bottom side of electrodes.
Regardless of compressive or tensile residual stress, the residual stress layer
induces bending of substrate layer under (or over) it, because the position of
residual stress layer is far from the geometrical center (i.e., the neutral fiber)
of the substrate layer. We simplified the structure (Figure 3.17b) without
difficulty making the substrate instead of the stress layers asymmetric. The
resulting radius of curvature, R, can be derived from the beam bending
theory as:
R =
Est
2
s
6tfσf
(3.7)
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Figure 3.17 Schematic drawing of electrode to be corrugated using residual stress. (a) Cross-
sectional view of electrode structure. High residual stress layer (red layer) is placed on both
side; (b) Simplified model of structure in (a) (top) and its deformed shape (bottom). Residual
stress layer is placed in the middle and the substrate layer is placed on either top side or bottom
side of the residual stress layer repeatedly.
where Es denotes Young’s modulus of substrate, ts and tf are thick-
ness of substrate and residual stress layer, respectively, and σf is the
residual stress in the residual stress layer. From the geometrical relation
(Figure 3.17b, bottom), the wavelength, λ, and amplitude, h, can be calcu-
lated as:
θ = D/R
λ = 2× (2R sin θ/2 + L cos θ/2) (3.8)
h = (R−R cos θ/2) + L/2 sin θ/2
where D and L are denoted in Figure 3.16b.
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Table 3.6 Design parameters and expected results of the corrugation induced by residual
stress
Design Parameters (Denoted in Figure 3.17b) Expected Results
Device Type D L Wavelength, λ Amplitude, h
Type 1 150 µm 150 µm ≈400 µm ≈100 µm
Type 2 150 µm 75 µm ≈325 µm ≈68 µm
Type 3 200 µm 200 µm ≈355 µm ≈157 µm
Type 4 200 µm 100 µm ≈319 µm ≈108 µm
We designed four different kinds of test structure depending on various
D and L values. The designed dimensions and expected wavelength and
amplitude are listed in Table 3.6. The residual stress was assumed as 1 GPa,
and the other parameters, for example, thickness of substrate layer, came from
basic TIME design.
Silicon nitride (SiNx) was the material of choice as a high residual stress
layer. Silicon nitride can tolerate high residual stresses in thin layers. It is
also known that silicon nitride is a biocompatible material (Neumann 2004;
Kue 1999). However, potential materials for a residual stress layer are not
limited to SiNx. If it has high residual stress and its fabrication process is
compatible with that of basic TIME, any material such as metal or polymer
can also be applied. The manufacturing process was carried out in a class
1000 clean room. The manufacturing process (Figure 3.18) started with spin
coating of a thin polyimide layer (<2 µm) (Figure 3.18a). The first silicon
nitride layer was deposited using plasma-enhanced chemical vapor deposition
(PECVD) and patterned photolithographically (Figure 3.18b). The structural
polyimide layer (≈3 µm) was coated (Figure 3.18c) and followed by second
silicon nitride deposition and patterning (Figure 3.18d). Finally, a polyimide
covering layer was coated (Figure 3.18e), and the perimeter was etched via
reactive ion etching (RIE).
After the release from the wafer, the test devices were deformed and
corrugated as expected (Figure 3.19). Corrugation parameters were measured
to be smaller than the estimated values. Especially the amplitude seemed not
exceeding several tens of micrometers. The reason for this discrepancy could
be due to the fact that: (1) the residual stress in silicon nitride was not as high
as expected; (2) the residual stress in silicon nitride was relaxed due to the
high process temperature (350◦C) in the following polyimide curing process;
(3) residual stress in the silicon nitride layer was compensated by opposite
residual stress in polyimide layer.
More detailed modeling and measurements would be able to better
understand shape fidelity, stress development, and release.
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Figure 3.18 Thin-film micromachining process for corrugated electrode.
Figure 3.19 Photograph of the corrugation test structure fabricated by micromachining
technique.
3.3.4 Precision Mechanics and Micromachining Hybrid
Approach
The third approach was a trade-off between the first two approaches. In the
precision mechanics approach, high aspect ratio (large amplitude) was pos-
sible compared to micromachining. The wavelength, however, was limited
by the EDM process compared to the micromachining process. In the hybrid
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approach, we were pursuing fabrication of the moldform using a microma-
chining technique, and the corrugation of the electrode would have been
achieved by temper processing like in precision mechanics. The moldform
is to be fabricated by photolithographical patterning of thick-film photoresist
(SU-8) and copper (Cu) electroplating, which should overcome the limits of
precision mechanics in defining corrugation patterns. Furthermore, a comb-
like structure will be implemented to resolve mechanical stress issues as seen
in the closed moldform version. Here, the polyimide substrate is inserted into
the comb mold and gets fixed at the outer perimeters (ribbon and bight), while
the actual part to be corrugated rests in mid-air within the comb. Thus, all
designated amplitudes and wavelengths should be feasible without the impact
of mechanical stresses or additional manufacturing steps.
3.3.5 Final Decision on Corrugation Processes for Various
Nerve Diameters
Three different approaches to corrugate flexible electrode substrates were
developed and evaluated in total (Table 3.5). In the first approach, a mold-
form was made by precision mechanics and the electrode was corrugated
using temper process in the moldform. This approach worked for ‘large-
scale’ corrugation, that is, wavelengths of about 1 mm (minimum value was
500 µm) with different possible amplitudes. This technique, however, did
not meet the requirements for dimensions needed within TIME electrodes
for small animal models. Second, a micromachining approach was utilized
which uses different residual film stresses to corrugate the electrode. A silicon
nitride (SiNx) polyimide stack was produced with defined dimensions to
yield the desired amplitude and wavelength of corrugation. The achieved
wavelengths were about 300 µm, which would fit the small nerve model.
The amplitudes, however, were limited as merely tenths of microns, which
was found to be too small, since fascicle distributions within nerves are to be
expected in the hundreds of microns. Third, a hybrid approach of precision
and micromachining has been designed using an electroplated comb-like
moldform by patterning a SU-8 layer, followed by copper electroplating.
This technique is expected to overcome the limits of precision mechanics in
defining the mold and corrugation pattern and, thus, should yield in a trade-off
between the first two corrugation techniques.
All techniques described above are developed to cover different ranges
of corrugation dimensions (wavelength and amplitude) but no one would fit
all nerve dimensions. The micromachining approach is intended for the small
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animal model and the other two for the large animal model. Each of them
showed feasibility to each application area. However, we found many techni-
cal difficulties in developing corrugated electrode for small animal model.
Developing corrugated electrodes for small nerve models would demand
completely different approaches that would be cost and time-consuming and
would not be transferrable to larger nerves. It is important to mention that
all techniques described above are feasible for use within large nerve models
in preclinical trials in large animals and clinical trials in humans which is in
accordance with the ultimate goal of the TIME project. Results from simula-
tion experiments indicated no significant difference in stimulation threshold
decrease when using corrugated electrodes in comparison to flat ones. Since
the goal of the project was to investigate a treatment of phantom limb pain
and not a comprehensive design study on micromachining techniques, we
eventually decided not to spend more time on the development of corrugation
strategies but on a flat design and its assembly with cables to be able to
stimulate large nerves on a fascicular level.
3.4 From First Prototypes to Chronically Implantable
Devices
When manufacturing chronic implants, many different considerations have to
be taken into account like the overall design, encapsulation, choice of mate-
rials, cleaning protocols, and handling. While many of these aspects were
already considered in building up chronic electrodes for small animal models
(Section 4.2), great efforts were invested to develop alternative connectors
and cables for a large animal model. Suitable connectors should be placed
protectively under the skin so the animal can move freely and is not able
to root or bite the electrode system out by itself. However, the connector
must also be readily accessible for recording and stimulation experiments
without the need of time-consuming surgeries. Therefore, a percutaneously
placed connector was chosen for chronic pig experiments, which exits the
skin in the neck and is fixed to the skin via a custom build metal housing
that is sutured in place. This concept of percutaneous cables is identical to
the envisioned human implantation in which the cable passes the skin and the
connector is outside the body. On the same end, cable and wires have to be
built in a way so they can give the possible highest degree of flexibility and
stretchability. Since the cable is rooted through the animal and will mediate
any movement to the electrodes’ and connectors’ placement, it is mandatory
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to include means of stress and strain relief. Henceforth, the developmental
outcome will be depicted in detail within the next sections. Additionally,
the TIME-3 electrode is introduced, and the improvements in comparison
to TIME-2 devices are explained.
Because chronic implants in rats did not show reactions with respect to
residues after cleansing (i.e., they have been cleaned in a proper and adequate
manner) or degrading/detaching encapsulations, the protocols for cleaning
and rinsing during manufacture and encapsulation techniques were main-
tained as described above. Additionally, the complete assembled electrode
is purged with alcohol (70% ethanol) within a cleanroom environment and
disinfected within an implant washing machine (Miele, Germany) as a last
step before it is dried again and double-bagged in sterilizable pouches. Steam
sterilization itself is carried out at the institutions of the partners performing
large animal experiments.
3.4.1 Design Changes Towards TIME-3
After the initial acute experiments in small and large animal models (rats
and pigs) as well as in chronic implantations (rats), first drawbacks became
obvious within the TIME-2 design. Since the polyimide ribbon was com-
pletely straight in design with cables orthogonal to the peripheral nerve, the
implanted device had degrees of freedom in all three directions and, thus,
could move in relation to the surrounding tissue, which implies the danger of
deranging the location of the active sites and/or inducing nerve damage. Addi-
tionally, TIME-2 electrodes incorporated no structures for fixation, which
promoted the aforementioned problem even further. Although stimulation
could be successfully administered within these initial animal models, the
maximal capacity of injectable charge was restricted to small values due to
the use of platinum. Values of charge injection capacities of platinum were
measured to approximately 75 µC/cm2, which is in accordance with the
values found in literature (Craggs 1986). With respect to the area of one active
site (Ø80 µm), this yields in only 4 nC of injectable charge. According to
human trials with thin-film LIFE electrodes (Rossini 2010), this is definitely
insufficient for the stimulation of human nerves over a period of 4 weeks.
Dhillon and Horch reported that values of 5 nC only after 2 weeks were
necessary to elicit sensations in human amputees and values up to 60 nC
were used in trials to detect the limits of non-painful stimulation with their
LIFE electrodes (Dhillon 2005).
To overcome these problems, a new design of TIME-3 electrodes was
developed in collaboration with all partners participating in preclinical and
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Figure 3.20 Schematic side view of a TIME-3 electrode. Fixation flaps have been integrated;
90◦ angle between intraneural linear array and interconnection lines reduces movement
opportunities after implantation. Units in mm.
clinical trials. To minimize movement and improve fixation, a 90◦ bend was
introduced to the electrode that separates the ribbon and the actual implanted
lip (area of active sites and arrow shape; see Figure 3.20). For fixation, three
vias (i.e. holes) were incorporated into the device. To increase the visibil-
ity of these vias during implantation, a shiny platinum ring encompasses
the fixation structure. With these modifications, the electrode can now be
implanted in a true transversal way and the ribbon can be routed distally from
the implantation site in parallel to the nerve surface where it can be fixed
to the surrounding tissue (epineurium). For strain relief, the cable is routed
a few centimeters more in the distal direction before turning 180◦ to the
targeted area of connector placement (in the neck of the animal). To increase
the maximal charge injection capacity, sputtered iridium oxide films (SIROF)
were incorporated as active site metallization. SIROF benefits from its high
intrinsic porosity that increases the electrochemical active surface area (not
the geometrical area) and faradaic charge transfer mechanisms (Cogan 2008).
Therefore, a superior charge injection capacity is achieved in comparison to
platinum. The values were again measured to approximately 2.3 mC/cm2,
which yields in more than 100 nC of injectable charge for an electrode with a
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diameter of 80 µm. So even with common safety margins (75% of maximal
charge injection), sufficient charge capacities should be available for chronic
pig experiments and human trials.
3.4.2 Development of Helical Multistrand Cables
Within the very first acute studies in rats, insulated copper wires were used as
cable strands because of their easy handling and soldering (see Figure 3.21
top). But due to the fact that copper wires are toxic in the case of a first
failure and tend to corrode, there is no mean to use them within implants
that should last days or even months in vivo. Therefore, Cooner wires were
used as standard wires in all the following experiments (see Figure 3.21
bottom). Their properties are well known, since they are also commonly
used as leads within pacemakers for years. Cooner wires consist of 10–40
stainless steel strands (15 within AS632 wires) that are braided into a single
wire and are insulated with fluorinated ethylene propylene (FEP). The overall
diameter of one such wire is approximately 120 µm. Although they meet
all the requirements mandatory for chronic implanted wires, there are still
Figure 3.21 Comparison of different cable assemblies. Top: 12 helical copper wires in
silicone tube; center: 12 helical MP35N wires in silicone tube; and bottom: 12 bundled Cooner
wires type AS632.
Source: Reprinted with permission from Stieglitz, T., Schuettler, M., Rubehn, B., Boretius, T., Badia,
J., Navarro, X. Evaluation of polyimide as substrate material for electrodes to interface the peripheral
nervous system. Proceedings of the IEEE-EMBS Conference on Neural Engineering, April 27–May 1,
2011, Cancun, Mexico, 2011, pp. 529–533. Copyright 2011 IEEE.
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drawbacks to be considered. First, 120 µm in diameter is still bulky when
more than about 6 wires have to be used. Second, when placed into an
additional silicone tube for further protection (and to avoid the incorporation
of tissue into the wire bundle), the cable gets quite stiff which prevents easy
routing throughout the body. And third, given that the wires are already
braided, there is no possibility to incorporate structures for strain relief, which
is mandatory in peripheral nerve implants.
Hence, a third alternative was necessary that encompasses all properties
and requirements. MP35N was therefore the material of choice, because of
its comparable properties to Cooner wires and its established use in clinical
applications like the electrode cables of the cardiac pacemaker. MP35N is
a nickel–cobalt base alloy that has a unique combination of properties like
ultra-high strength, toughness, ductility, and outstanding corrosion resistance.
One strand is insulated with polyesterimide (PEI) and has an overall diameter
of merely 75 µm (Polyfil AG, Zug, Switzerland), which makes it suitable
for multi-stranded wires. To add strain relief to these wires, a custom build
machine was acquired (Figure 3.22 left) that is able to helically wind up to 18
single strands in parallel with a defined pitch between the single packages of
strands (see Figure 3.21 center). Afterwards, a swelled silicone tube (swelling
agent is n-heptane) is slipped over the helix and arbor and is allowed to shrink
again to its original size. Since the arbors’ thickness (plus wire diameters) is
specifically chosen to match the inner diameter of the silicone tube, a tight
and uniform helix is created and the arbor can be removed safely (Figure 3.22
right). This spring-like structure in the silicone tube makes the cable handy
and easily routable. Furthermore, the silicone tubing is commercially avail-
able in medical grades and can incorporate X-ray contrast strips which makes
the cable more visible in follow-up examinations as well as plates with serial
Figure 3.22 Left: Custom build cable winder with attached arbor and 16 single wires on
spindles. Right: Arbor with helix of 16 MP35N wires and silicone tubing. Excess material is
cut after the arbor is removed.
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numbers. The feature of strain relief was investigated per tensile test, and the
results proved that the helical cable could be elongated to about 150% of its
initial length without any loss of electrical contact. Further tests according to
pacemaker standards were successfully carried out to test the cables flexibility
to bending and lifetime (see Section 4.5 on lifetime testing).
The wires have to be attached to the actual thin-film electrode. Since
direct soldering of wire to thin film is not reliable, a ceramic adapter is used
to mediate the connection. These adapters are manufactured in two steps:
(1) a patterned layer of conductive PtAu paste is screen printed onto a small
ceramic plate (2 inch) and fired within an oven at 1000◦C, and (2) to insulate
the single tracks, a patterned overglaze layer of glass composite is screen
printed onto the ceramic and first layer. This overglaze layer insulates the
complete adapter, despite specific solder and microflex spots, to which the
wires and electrode are attached in a later step. After firing the overglaze
layer at 750◦C, the ceramic adapters are separated from the plate by a laser
and are ready to use. Attachment of MP35N wires to the ceramic is done by
soldering using a SnAgCu solder, because of its lead-free formula.
3.4.3 Connector Development
Within the initial studies, a classical epoxy-based connector was used because
of its simplicity to use, low cost, and sufficient stability in acute experiments
(see Figure 3.23 left, upper row). In chronic implants, however, the complete
cable including connector has to be implanted subcutaneously (into a tissue
pocket) to provide the animal with an adequate freedom to move. Addition-
ally, animals tend to gnaw and/or shrub at transcutaneously placed connectors
until this “foreign object” comes off, which will dislocate or even destroy the
implanted device. Therefore, a new kind of connector was developed that uses
simple stainless steel metal rings as electrical contacts (see Figure 3.23 left,
lower row and right). These metal rings are placed onto a silicone tubing
through a reducer chipper and are contacted via wire welding. The main
properties of the rings are corrosion resistance, easy cleaning (body fluids,
remains of tissue, etc.), and MRI compatibility. For further reinforcement of
the connectors, the silicone tube is filled up with silicone rubber in region
of the metal rings. Electrical contact is achieved through a custom build
guiding structure made out of PMMA in which the metal ring contacts are
inserted (see Figure 3.23 right). This guiding structure including cable is then
plugged into an epoxy-based connector that incorporates protruding pins,
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Figure 3.23 Left: Comparison between classic epoxy-based connector and metal rings.
Right: Completely assembled TIME-3 electrode for chronic implants including a connector.
which ultimately establish the electrical connection with the metal rings. This
system is easy to handle, is easy to clean after experiments (rinse with water
or light solvents), and can be adapted to all kinds of pole configurations.
In the first chronic animal experiments with pigs, a lot of connectors
with the metal rings have gone lost due to scrubbing of the animal on the
ground and to the wall. Therefore, miniaturization and protection of the
connector were necessary. Rings were replaced by smaller connectors which
are commercially available and standard in neuroscience but unfortunately
not available in medical grade quality.
The chosen connector is a commercially available Omnetics nanoplastic
circular (NPC) connector with 16 poles (Figure 3.24, left). Its dimensions
are 4.6 mm in diameter with a length of 5.6 mm. Cables are easily attached
to the connector by soldering, and protection is provided via encapsulation
with silicone rubber. Furthermore, a tag with the specific serial number of the
electrode is implemented within the silicone tubing just before the Omnetics
connector (Figures 3.24 and 3.25). The counterpart is also an Omnetics
nanoplastic circular connector, but the male version, which has protruding
pins that make contact to the electrodes’ connector. A “nose” within both
connectors defines the angle of insertion and ascertains correct alignment.
The external cable, which is soldered to this counterpart and is running to
the stimulator, can be terminated with all kinds of connectors by soldering or
welding techniques. Depending on the stimulator in use, this external cable
can easily be produced and distributed.
In addition, a custom build metal housing was developed by the partners
who performed the pig experiments. It gets sutured to the skin and can hold
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Figure 3.24 Left: Omnetics nano connector assembled to 12 strand helical cable. Middle:
Metal housing holding two Omnetics connectors sutured to the skin. Right: Closed metal
housing after experiments.
Figure 3.25 An assembled TIME-3 electrode for chronic pig models. Note that the cable
length is shortened within this picture.
up to three TIME-3 electrodes in parallel (Figure 3.24 middle). When no
experiment takes place, the housing can be sealed with a metal cap to avoid
dirt and fluid intrusion (Figure 3.24 right). This cap will not be necessary in
human clinical trials since humans can be advised not to pull on the cables
that pass their skin. Human implantations with percutaneous cables have been
successfully performed in the last years in Europe (Rossini 2010) as well as
in the USA (Dhillon 2005).
3.4 From First Prototypes to Chronically Implantable Devices 113
3.4.4 Final Assembly of the TIME-3 Implants
The final TIME-3 design for the large animal model of the pig has been
adapted to the pig nerve and implantation site geometry with respect to
electrode pitch and cable length (Figure 3.25, Table 3.7).
Electrodes were assembled with cables and connectors, cleaned as
described above, packaged in sterile bags, and sent to the partners to get
sterilized before implantation in their respective environment. Serial numbers
close to the connectors allow identification of electrodes even after being
implanted.
Table 3.7 Specifications of assembled TIME-3 electrodes for chronic implants in pigs
Value Comment
Electrode
Type TIME-3 Design details in Figure 3.20
Ø active site 80 µm
Number of active sites 6/12 Per side/overall
Pitch of active sites 440 µm Covering 2.4 mm depth from the
nerve surface
Indifferent electrode Yes One per side
Reference electrode Yes GND; one per side
Coating SIROF All active sites
Cable
Length 65 cm
Diameter 2.6 mm Outer diameter
Strands 12 Helical
Strand material MP35N With PEI insulation
Tubing Silicone Without contrast strip
Connector
Type Omnetics NCP Nanoplastic circular connector
Number of contacts 16 Only 12 are used for pigs
Ø connector 4.6 mm
Length of Omnetics connector 5.6 mm
Cleaning and Packaging
Rinsing 70% ethanol Complete device in cleanroom
Drying ∼10 min In cleanroom
Disinfection Miele disinfector G7735 Certified program
Packaging Sterile pouches Double bagged
114 The TIME Implantable Nerve Electrode
3.5 Life-time Estimation of TIMEs for Human Clinical Trials
Bringing new developments from preclinical trials on animal models into a
first-in-human clinical trial requires verification that the components as well
as the whole implant stay intact and functional over the predicted life time.
In a first-in-human clinical trial, 30 days implantation time are scheduled
from European laws as longest time to prove safety of the device. Therefore,
evaluations have to take place to investigate and assess the stability of the
different materials and components as well as the whole implant. In the case
of the TIME-3H (H stands for human application), we had to assess the
stability of the polyimide substrate, the stability of the electrode material
with respect to stimulation pulses, and the wire-based cable with respect
to stretching and bending. All tests were performed in vitro in physiologic
saline solution to mimic the implantation environment. Details on the final
TIME-3H design and process technology can be found in Section 3.6.
3.5.1 Lifetime Estimation of Polyimide
Although older literature (Campbell 1998, Murray 2004) reported data
regarding the degradation of polyimide under high temperature and exposed
to humidity, little is known about the long-term behavior of polyimide in
body tissue. Our group performed long-term investigation of the mechanical
properties of polyimide to evaluate its lifetime (Rubehn 2010). After storing
the material in phosphate-buffered saline (PBS) at 37◦C, the mechanical
properties were examined with tensile test and weighing test. For accelerated
ageing, the specimens were also stored at elevated temperature (60◦C and
85◦C) and also tested, even though 80◦C are too high for polyimide to follow
the Arrhenius approach for lifetime testing.
For the tensile test, polyimide specimens were designed according to
ASTM D882-02 (ASTM 2002) but the dimensions were scaled down. The
same kind of polyimide (U-Varnish-S, UBE) and curing process which are
used in TIME-3H electrode fabrication was chosen. The Young’s modulus of
the polyimide film showed stable behavior over 18 months stored at 37◦C
(Figure 3.25, green line), while the moduli changed in samples stored at
elevated temperatures (Figure 3.26, blue and red line). Other mechanical
properties such as stress at break, strain at break, stress at 10% strain, and
fracture energy are not changed significantly during the same time period.
To observe material degradation, gravimetric analysis was carried out.
A standard polyimide foil (Upilex25S, UBE) was purchased from the man-
ufacturer. Upilex25S is the trade name of a foil made of the precursor resin
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Figure 3.26 Young’s modulus’ change of polyimides (U-Varnish-S, UBE) stored in PBS at
different temperatures.
Source: Reprinted from Rubehn, B., and Stieglitz, T. In vitro evaluating of the long-term stability of
polyimide as a material for neural implants, Biomaterials, 31(13): 3449–3458, 2010, with permission
from Elsevier.
U-Varnish-S. The mass of polyimide film stored in PBS at 37◦C (Figure 3.27,
triangles) did not change during 16 months.
Based on these long-term results of polyimide stored in PBS, we predicted
that the lifetime of polyimide is much longer than 30 days which is the
planned human trial period.
3.5.2 Stability of Iridium Oxide as Stimulation Electrode Material
Sputtered iridium oxide (IrOx) was chosen as electrode coating since its
reversible charge injection capacity is much higher than the one of platinum
(Cogan 2008). The lifetime of IrOx, the conductive coating on the TIME-
3H electrode, was estimated by pulse tests. Pulse testing was carried out
with a custom made 12-channel pulse tester (Schuettler 2008), composed of
improved Howland current pumps and circuits to subtract the voltage drop
over the access resistance. Applied pulses were rectangular, biphasic, and
charge balanced in nature with a pulse width of 200 µs/phase and a repetition
frequency of 200 Hz. The test was carried out in PBS at room temperature.
A large area stainless steel electrode served as counter electrode. Injected
charge was chosen to and held constant at 20 nC/phase, and the voltage across
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Figure 3.27 The development of the mass of polyimide films (Upilex25S, UBE) stored in
PBS at different temperatures.
Source: Reprinted from Rubehn, B., and Stieglitz, T. In vitro evaluating of the long-term stability of
polyimide as a material for neural implants, Biomaterials, 31(13): 3449–3458, 2010, with permission
from Elsevier.
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Figure 3.28 Voltage across the phase boundary (upper) and injected current pulse (lower)
during the pulse test of IrOx.
the phase boundary was monitored over the timeframe of 250 million pulses
(Figure 3.28). A slight decrease of the voltage across phase boundary (Vc)
was observed during the 250 M injected pulses. Vc was measured as 646 ±
21 mV, 619±17 mV, and 576±24 mV for pristine IrOx, after 120 M pulses
and after 250 M pulses, respectively. The safety limits of charge injection,
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which are determined by the material’s water window, were not exceeded
during all pulse tests.
In addition, impedance spectra were measured to quantify possible alter-
ations during the pulse test in the IrOx coating (Figure 3.29). After the
250 M pulses, no significant change in the impedance spectra was observed,
confirming that the coating is still stable.
If we consider that the absolute maximum number of pulse which will be
used in the human trial is 162 M pulses (500 Hz repetition rate, 2 times of
90 min duration per day, and 30 days), these results after the 250 M pulses
confirm that this IrOx coating is safe for the scheduled human trial.
3.5.3 Mechanical Stability of Helically Wound Cables
Helically wound cables connect the polyimide-based thin-film electrode via
an adapter with the extracorporal stimulation equipment in the human clinical
trial in a percutaneous way. These cables were made out of a helix of 16 par-
allel conductors (MP35N; Ø 90 µm) inside a silicone tubing. Since silicone
rubbers are merely ion barriers, water would penetrate this encapsulation
and might induce failure mechanisms. Therefore, the hollow tube carrying
the helix is filled up with another silicone adhesive in a way that no air
is entrapped within the tubing. To maintain flexibility, the shore hardness
(type A) of the filler matches that of the tubing. In order to characterize
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Figure 3.29 Impedance spectra of IrOx coating before pulse test, after 175 M pulses and
250 M pulses.
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Figure 3.30 Picture of test assembly to characterize fabricated cables according to ISO
45502.
the lifetime of such a cable, a custom made testing machine was built
(Figure 3.30) in accordance with the pacemaker standards (ISO 45502).
As described by the standard, the cable has to be bent by a specific
bending radius, has to be inserted in the setup with a distinct load force, and
has to withstand at least 47,000 cycles. Pneumatic cylinders moved a trolley
of six parallel spindles, which define the bending radius (1 cm). The cables
were inserted into the setup with a load force of 1 N, measured by a force
meter. A sinusoidal signal with a frequency of 100 Hz and an amplitude of
1 V was applied to one conductor within each cable and used to measure
impedance over the complete timeframe of the test. The trolley was moved
inside a bath of saline solution (0.9% NaCl) to simulate the body environment
and, in analogy, the water uptake of silicone rubber. Tests were carried out
over 75,000 cycles, whereas no single cable or wire broke. Impedance values
of the wires were constant over the complete timeframe of the test and varied
only about ±2% from their initial value.
To further characterize the electrical properties of the cables, impedance
values and coupling capacities per centimeter cable length were measured,
and the coupling capacities were modeled between two adjacent conductors
(Figure 3.31). While the coupling capacities to ground (C1G and C2G) can
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Figure 3.31 Model of coupling capacities between two adjacent conductors.
Table 3.8 Properties of helically wound cables
Property TIME-3H Cable
Conductor material MP35N
Material of isolation Polyesterimide, silicone rubber hose
Outer diameter of the cable 1.80 mm
Max. usable length 105 cm
Number of conductors 16
Outer diameter of the conductor 90 µm
Resistance of the conductor 3.02 Ω cm−1
Capacitive coupling to neighboring conductor ∼2.6 pF cm−1
be neglected within implantable cables, the “direct” coupling capacity (C12)
of one conductor to the other is of importance during stimulation as well as
during recording. Whenever a signal is applied to conductor 1, a current will
inevitably start to flow, generating an electrical field around conductor 1. This
electrical field will induce a current in conductor 2 and, dependent on cable
impedance and load resistor R, an electrical noise potential can be measured
(VN) in wire 2. In stimulation mode, this noise potential could, in a worst-
case, induce a stimulation pulse within an active electrode site next to the
targeted active site and, hence, decrease selectivity. In recording, the general
noise level is increased and, again as worst-case scenario, targeted neural
activity could be lost. Hence, a small coupling capacity is preferable between
the two conductors.
The TIME-3H cable (Table 3.8) was tested over a period of time (∼100 h)
while being incubated in saline solution (0.9% NaCl). Since testing in accor-
dance with pacemaker standards was successful, it was concluded that the
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TIME cables are appropriate to be implanted for the timeframe of at least 30
days.
3.6 Requirements and Steps to Transfer Preclinical
Results in Devices for the First-in-man Clinical Trial
3.6.1 Assessment of Previous Work and Pre-existing Knowledge
Assessment and documentation of previous work and pre-existing knowledge
is a mandatory task in writing a so-called investigator’s brochure to prove
conformity with the essential requirements. Not only own work but also
published studies have to be taken into account.
One clinical trial was already published in 2012 when this investigator’s
brochure was prepared and written. Colleagues had implanted four longitudi-
nal intrafascicular multichannel thin-film electrodes (tfLIFE) with platinum
stimulation sites in one amputee subject in December 2008 with the aim
of controlling a cybernetic hand prosthesis (Rossini 2010). The fLIFE have
been longitudinally implanted in median and ulnar nerves (two for each
nerve) using percutaneous cables with connectors outside the body. Afferent
stimulation was performed with trains of cathodal rectangular pulses with
repetition rates ranging from 10 to 500 Hz, current amplitudes between
10 and 100 µA, and pulse widths between 10 and 300 µs to stay in the
electrodes’ safety limits. The results achieved show that 3 out of 4 implanted
intrafascicular multicontact electrodes were able to elicit sensations that were
related to parts of the missing hand in the fascicular projection territories of
the corresponding nerves and that the sensations were modulated by varying
the pulse frequency and width (Benvenuto 2010). However, the maximum
allowed safe charge increased over time and sensory threshold exceeded the
safe limits after 2 weeks, that is, no sensations could be further elicited. In
detail, the charge threshold increased during the first 13 days from 0.1 to
2.5 nC, and no sensation had been elicited through any of the electrodes
despite the 75% of maximum charge (∼4 nC) at later points in time. In
order to avoid irreversible electrochemical processes of the Pt electrodes,
stimulation procedures were stopped. The charge increase was mainly due
to fibrotic reactions around the electrode and to a progressive “habituation”
of the patient moving from an initial “hypersensitivity,” due to long-lasting
sensory deprivation (subjective sensory threshold below maximum stimu-
lation), then decreasing and stabilizing toward more physiological levels
(subjective sensory threshold above maximum stimulation). These results
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made clear that a platinum coating is not sufficient to stimulate afferent
fibers in humans for a longer period, due to its low charge injection capacity
(4 nC ∼= 75 µC/cm2). Therefore, sputtered iridium oxide films (SIROF)
were suggested and introduced as active coating, because of its comparably
high charge injection capacity of about 100 nC (∼=2.3 mC/cm2) inside
electrochemical safe regions.
Results of finite element method (FEM) modeling and ex-vivo insertion
force measurements of TIME-2 devices into porcine peripheral nerves (see
Chapter 4) guided the design of the human TIME-3H devices. Optimum
platinum thickness for tracks and electrode sites was suggested to be at least
500 nm to let von Mises stress not exceed certain thresholds. However, this
thickness could not be chosen due to process technology restrictions but
platinum with iridium oxide (SIROF) was thicker than 1 µm in total. The ex-
vivo measurements of TIME-2 insertions into porcine median nerve gave the
maximal insertion forces and allowed to quantify the effects of geometrical
parameters of the electrodes on maximal insertion forces. The aim was to
limit the insertion forces necessary to transversally implant the electrode,
in order to reduce the probability of breaks at the loop level (polyimide)
and at the active sites level (platinum) as well as to reduce local stress and
deformations of neural tissue during insertions.
Two geometrical parameters were evaluated: final electrode width (WE)
and angle α between Wloop and WE (Figure 3.32).
We transferred the results of the simulations (Chapter 4) into the electrode
design. TIME-3H should have sufficient material strength for implantation
into the nerve by designing the width of the substrate (WE) to 350 µm, the
loop length (L) to 8 mm, and the loop width (Wloop) to 100 µm.
Final dimensions of the geometrical shape of TIME-3H were derived
from human cadaver studies at the Universitat Autónoma de Barcelona. Five
human median nerves were carefully dissected following the fascicles of
the nerve trunk innervating the fingers/hand and the fascicles innervating
the tributary muscles at the forearm. The number of fascicles dissected at
about 5 cm proximal to the elbow was counted. Cross-section samples of the
Figure 3.32 Schematic view of polyimide loop parameters to be optimized.
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nerves were histologically processed at 5 and 10 cm proximal to the elbow for
light-microscopy examination. Nerve diameters were in the range between
2.4 and 4.6 mm and contained between 8 and 17 fascicles. Proximal to the
elbow, the fascicles innervating the hand and the muscular fascicles are not
intermingled. The fascicles innervating the muscles of the forearm tend to
remain at the dorsal aspect of the median nerve surrounding the fascicles
of the hand, which are mostly formed by sensory fibers. Diameters were
similar or larger than those of pig nerves (2.9 ± 0.4 mm) from large animal
studies. Numbers of fascicles were less in human than in pig nerves (36± 4).
Insertion forces were evaluated in the pig experiments with different custom-
made (tungsten,∼75 to 100 µm diameter,∼20◦ tip angle) and commercially
available stainless steel needles (Ethicon, 125 µm diameter, ∼26◦ tip angle)
with a pre-swaged filament. The higher diameter of the Ethicon needle causes
a slightly higher insertion force needed to place it inside the nerve; however,
from a mechanical point of view, there appear to be no difference between
the two. The Ethicon needle was preferred for the human experiments since
it is commercially available for human use.
Acute and chronic implantations in the pig forearm nerves improved the
implant in the design phase. Three flaps with anchoring holes have been
included in the latest design (TIME-3) to secure adequate device fixation
opportunities within the nerve. The change from 14 single leads of Cooner
wires (stainless steel) to helically wound MP35N cables in a single silicone
rubber hose made handling during surgical intervention much easier due to
the flexibility of the cables.
3.6.2 Final Electrode Design and Fabrication Technology
for Human Use
The electrode design for the human clinical trial (TIME-3H) was derived
from the pig version (TIME-3). Since TIME-3 electrodes were easy to handle,
to fixate to surrounding tissue, and to implant transversally through the nerve,
the overall design was transferred to TIME-3H electrodes and only adjusted
to the larger diameter of human median nerves (Figure 3.33, Table 3.9) and
the number of fascicles. Process parameters were kept unchanged for the
complete fabrication and assembling technologies, since these were success-
fully tested in vitro and in vivo. Due to this larger nerve diameter (∼4 mm in
humans compared to ∼2.5 mm in pigs), two additional active electrode sites
could be implemented by increasing the electrodes width by merely 70 µm
(from 280 to 350 µm). In comparison, the nerve diameter is enlarged by a
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Figure 3.33 Schematic design of TIME-3H.
Table 3.9 Specifications of TIME-3 and TIME-3H designs
TIME-3 (Pig Model) TIME-3H
Insertion part
Number of active sites 6 per side/12 total 8 per side/16 total
Pitch of active sites 440 µm 400 µm
Ø of active sites 80 µm 80 µm
Coating SIROF SIROF
Charge injection capacity 2.3 mC/cm2 2.3 mC/cm2
Impedance 6 kΩ @ 1 kHz 6 kΩ @ 1 kHz
Length of insertion part 2.2 mm 4 mm
Width of insertion part 280 µm 350 µm
Loop length 5 mm 8 mm
Loop width at folding point 100 µ m 100 µm
Ribbon part
Width (without tabs) 1 mm 1 mm
Length 22 mm 22 mm
Number of tabs 3 3
Diameter of tabs 500 µm 500 µm
Dimension of ground electrode 1 mm× 250 µm 1 mm× 250 µm
Note: Only dimensions are changed to fit the larger human nerve. Process parameters remained
unchanged.
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factor of 1.6, while the electrodes width is increased by only a factor of 1.25.
To keep the insertion forces still low, the loop length was increased by 3 mm
from 5 to 8 mm, which is in accordance with recommendations from simu-
lations (see Chapter 4). Since this part of the loop will not remain inside the
nerve but merely acts as a guiding structure of the device during implantation,
it will not influence the structural biocompatibility of the device. An increased
thickness of the platinum layer, also a recommendation from simulations,
could not be implemented because of technological restrictions during metal
deposition. The deposition of iridium oxide (SIROF), however, results in
a total layer thickness of >1,000 nm (300 nm Pt + 800 nm SIROF) and
should therefore meet the requirements. These electrodes with this Pt-SIROF
sandwich were those already evaluated in chronic rat and pig experiments and
proved to be stable and biocompatible.
Manufacturing of the TIME-3H remained unchanged (see Section 3.2.1)
to obtain the devices with platinum tracks sandwiched between two poly-
imide layers and electrodes coated with SIROF. The produced devices were
left on the wafers to get introduced into the quality management (QM) of the
laboratory. Batch numbers were assigned and series of tests were applied to
ascertain reproducibility and quality requirements.
Cable, connector, and ceramic adapters were assembled. This complete
part is consigned to the following protocol to ensure an overall immacu-
late surface (Donaldson 2008), since all the steps performed later, given as
follows, are conducted in a class 10000 cleanroom:
1. Removal of flux residues from soldering with flux-remover (de-flux 160
by Servisol, Iffezheim, Germany)
2. Removal of flux-remover residues by washing with isopropyl alcohol
(IPA)
3. Prevent IPA residues by washing in deionized water
4. Slew device five minutes in Leslie’s Soup1
5. Removal of residues by rinsing with deionized water
6. Wash in deionized water till the conductance value of DI water settles
again
7. Dry on lint-free cloth at 60◦C in an oven for at least 3 hours.
The thin-film electrode was then microflexed to the ceramic adapters
(Meyer 2001). In the next step, the needle with attached loop-thread (STC-
6, Ethicon, Johnson & Johnson GmbH, Norderstedt, Germany) was inserted
1Leslie’s Soup is named after a British researcher and consists of the glass cleaner “Teepol-
L” (0.5%), Na3PO4 (2.5%), and deionised water (97%).
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into the insertion part of the electrode, and the ceramic adapters were placed
back to back together and glued via a droplet of silicone rubber. Following the
curing period, which hardens the polymer, the ceramic adapters were encap-
sulated in medical grade silicone (MED-1000, PolyTec GmbH, Waldbronn,
Germany). Special attention is hereby dedicated to ensure a void-free film,
firstly, by applying, a swelled silicone tubing around the ceramic adapter
sandwich and, secondly, by filling up the complete tube with silicone rubber.
Within these processes, each batch and wafer receives a unique batch number
and can, henceforth, be tracked individually. Single device of the wafer was
assembled with the ceramic adapters, and the helically wound cables and
individual series numbers were assigned. The ceramic adapters, Omnetics
connectors, and electrode devices can be traced back by their corresponding
batch number; devices were identified by their serial number on the cable.
After the device is completely assembled, it is again cleaned and sterilized
according to the following protocol:
1. Transfer device into dedicated washing bag
2. Slew in ethanol for 5 minutes
3. Dry on lint free cloth for 10 minutes without washing bag
4. Transfer device into implant washing machine (Miele Disinfector
G7735) for cleaning and disinfection
5. Transfer device into a sterile pouch (double packed) and label
accordingly
6. Steam sterilize packed pouch at 2 bar and 134◦C for 20 minutes
(prion program) using an autoclave (Superior 24B, Medesign GmbH,
Holzwickede, Germany).
The cleaned, packaged, and sterilized devices were ready for implantation
in a human clinical trial.
3.6.3 Quality Management System
The main idea behind a quality management system (QMS) is to be able to
relate any given product or product group to the single part it is made of and,
hence, how this specific part was manufactured and to trace back possible
failures in vivo to the manufacturing process. In addition, risk management
that accompanies the development process will minimize possible hazards to
the patient. To achieve this, processes, procedures, and documents have to
be created, implemented, and controlled. They are hierarchically ordered and
comprise all process steps and parts needed for manufacturing.
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In 2010, the Laboratory for Biomedical Microtechnology at the Uni-
versity of Freiburg (Germany) received accreditation for its laboratory for
electrode manufacturing (LEF) to manufacture medical devices according
to ISO 13485:2007 (certificate number CQ103013-13). A general documen-
tation scheme was established, reviewed, and finally certified. The quality
management is currently becoming updated to the actual ISO 13485:2016
requirements.
Development of devices in accordance with such a QMS needs to cover
many aspects during different phases, from the idea to a clinical trial.
3.6.3.1 Documentation of device development
Device development has to be done in close collaboration with the clini-
cal partners from the very first idea. Discussion has to be documented to
fix decisions and document target specifications. Our QMS followed the
four-stage development model. Since we did not intend to apply for CE
mark but perform an investigator-initiated clinical trial to address research
hypotheses, we did not completely develop a device dossier but preferred a
lean technical documentation to comply with the essential requirements and
meet the needs of the responsible ethical committee and the legal authori-
ties in Italy. Therefore, an investigator brochure was written containing all
the available information of the design and development process including
results from literature and preclinical studies. A user manual for the TIME
system was written including specifications like system dimensions, electrode
impedance, maximal possible charge injection capacity, and a guide for
handling the TIME system. This manual was delivered with each electrode.
3.6.3.2 Risk management
Possible risks and measures to minimize potential risks in critical points have
been identified and were handled according to the procedures described in
the ISO 14971:2009. We used risk analysis and FMEA to assess and manage
risks in the design and manufacturing part of the implantable device. Medical
partners contributed to the risk assessment during handling, surgery, and
implantation/explantation period.
3.6.3.3 Quality management system for device manufacturing
Manufacturing instructions for the TIME-3H have been written and imple-
mented (Figure 3.34). For each assembly group or product, a working order
with a unique number has to be written. This working order contains three
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additional documents: (1) the working plan, which specifies the single man-
ufacturing steps to be carried out and records the performing person; (2) the
progress procedure, which gives a detailed description of the single manufac-
turing steps according to the working plan; and (3) the list of parts, which
lists all parts used within the manufacturing and records all batch and/or
LOT numbers. Through this documentation scheme, it is always possible
to trace back: the materials used, the procedure used to manufacture this
specific part, and the person who manufactured it. Furthermore, fabrication on
stock becomes possible, for example, for assembly groups, since all working
numbers are unique and retraceable.
The TIME implant can be divided into five general assembly groups
(AG), whose fabrication is monitored via the above-mentioned procedures
(Figure 3.35).
On the lowest level, the AGs “ceramic adapter” and “helix cable and
tubing” are situated. Here, the ceramic adapters are manufactured via screen
printing of thick films onto ceramic substrates and labeled according to the
batch number. Similarly, the helix cable and tube are assembled as stock
articles and labeled accordingly. With these two assembly groups, the cable
itself can be built up and cleaned (AG Cable). Since the electrode itself,
that is, the polyimide thin film, is manufactured within the micromachining
cleanroom (without quality management system), it has to be introduced into
the QMS (AG Electrode). Therefore, an entry control was established that
Figure 3.34 Basic tree of documentation according to ISO13485.
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Figure 3.35 Scheme of the quality management system for TIME electrodes.
includes specific tests to reassure and maintain the quality of the polyimide
structures. Included tests are Fourier transform infrared spectroscopy (FTIR)
to control the amount of solvent within the polyimide layer, electrochemical
impedance spectroscopy (EIS) to assert that the metal coating is stable, and
optical characterizations to ensure pattern accuracy.
As a last step, the complete TIME system can now be assembled (AG
TIME-3H). Here, the “AG Electrode” and “AG Cable” are joined together and
encapsulated with silicone rubber. Thereafter, the electrode system is tested
for functionality and subsequently cleaned and disinfected.
This final test of operation is done via electrochemical impedance spec-
troscopy (EIS), whereas specific limits for electrode impedance have to be
met, and pulse testing, in which the limit of maximal injectable charge has
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to meet minimally the defined value within the electrodes manual. Dis-
infection of the electrode is achieved by washing the TIME system in a
certified machine (Desinfektor G7735 by Miele AG, Gütersloh, Germany)
using different disinfection agents. Afterwards, the complete TIME system
becomes double-bagged in sterile pouches, and labeled and sterilized in
an autoclave (Superior 24B by Stärker-MEDESIGN GmbH, Holzwickede,
Germany) using the prion program (135◦C, 3 bar, 20 min).
The resulting TIME system has a unique serial number with which all
the above-mentioned steps can be retraced and material batches identified.
Labeling of sterile devices will be done according to EN 554, 556 (steril-
ization with moist heat) and EN 868 (packaging materials and systems for
medical devices). The system will be shipped (or brought in person) with the
accompanying documents like electrode manual and results of the final test
of operation to the hospital in which the implantation takes place.
3.7 Discussion
It has been a long way from first ideas of a transversal intrafascicular
multichannel electrode (TIME) array to an implantable device that has the
potential to investigate new treatment options in human clinical trials. A lot
of experience has been gained in close collaborations with partners in a
multidisciplinary consortium on the impact of design changes on stability and
selectivity, biocompatibility and foreign body reactions, selectivity and stabil-
ity of the whole system and matching electrode and stimulator performance.
The reward has been the transfer of a batch of samples to clinical partners for
a first-in-man clinical trial and its success. Many lessons have been learned to
get an implant stable over months and more will have to be learned to get it
stable over years and decades. However, at a certain point in the development
phase, one has to take the responsibility to enter first-in-human clinical trials
since only humans can give feedback whether the stimulation is useful and
pleasant to be integrated in the activities of daily life. For one subject in one
trial with four TIME being implanted and another four being the “backup
safety solution”, all in all more than 100 devices had to be manufactured to
validate manufacturing and cleaning procedures as well as sterilization. This
translational research needed a long breath and showed the huge potential
of microsystem technologies and the TIME concept. The longest part of the
road, however, is still ahead as such systems are available as medical devices
in clinical practice and get reimbursed by general health insurances.
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Neuroprostheses are becoming widespread clinical solutions, addressing
human nervous system at different levels. This technology can significantly
improve the quality of life of people who have suffered from different neu-
rological disabilities. Despite the large number of peripheral nervous system
(PNS) electrodes available and their good performances, the ever-growing
complexity of neuroprosthetic devices trying to mimic the natural hand
implies a constant need to improve electrode selectivity. This is particularly
true for stimulating electrodes whose aim is to mimic the natural sensory
feedback from the hand arising from a very dense network of afferents serving
different modalities (especially in the fingertips) by only stimulating at dis-
crete, restricted locations on a given nerve (Riso, 1999). Hence, an important
goal for a PNS electrode is to achieve the highest selectivity for a high
number of nerve fascicles while minimizing the invasiveness and potential
nerve damage. In this context, experimental studies have been conducted
in order to compare the selectivity performances of different types of PNS
electrodes (Badia et al., 2011). Animal models are common developmental
tools for testing peripheral nerve interfaces. However, the complexity of the
nerve tissue upon which stimulation is applied, as well as the anatomical
differences between animal models and humans, induce great variability
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regarding the neural response (Grinberg et al., 2008). Furthermore, the wide
range of design factors that can influence the outcome of the stimulation,
such as electrode type and position or the stimulation pattern (amplitude,
pulse width, frequency, monopolar, or multipolar stimulation), needs to be
explored in order to optimize a stimulation protocol and the neural interfaces
for a given application, thus requiring a large number of experimental trials
and subjects. Even so, the interaction with living tissue induces an inevitable
variability in experimental results due to several factors that cannot always be
identified, thus rendering the problem even more complicated.
The use of computer models to study the electrical stimulation of neural
systems appears to be an inexpensive and efficient way to tackle this issue and
thus assist in the development of neural devices or applications, by exploring
the high dimensional space of design parameters while minimizing animal
use. Among the first explorations of an influence of external electrical fields
on the neurons, by analytical modeling, was performed by McNeal (1976),
who developed the concept of so-called “activating function.” He used a fact
that even though neural devices and neurons have different communicating
currents, they both share same electric field. The modulation of it by the
injected electrical currents can depolarize the external membrane of neurons,
provoking the ionic currents flows, and finally the generation of spikes, which
are the basic carriers of information in the human nervous system. Activation
function is proposing that the likelihood of neural activation by external
stimulation is proportional to the second derivative of external field respect to
neuronal spatial extension. This idea is extended and analytically improved
in Rattay’s works (1986, 1989), which extended the concept from the point
sources of current to the realistic, similar-to-electrode sources. Although the
activation function is yet used as a most rapid and intuitive indicator of the
approximate estimation of axonal responses to electrical stimuli, the recent
works (Zierhofer, 2001; Moffitt et al., 2004) have shown that it is introducing
the important mistakes. The main reasons for these errors were that approach
based on the activation function, was neglecting of high nonlinearity present
in axonal answers and the realistic anisotropy of a medium in which neurons
are placed. Recent computational models do account for both the anisotropic
extracellular conductivity present in the nerves, and for the dynamic response
of neuronal cells and axons to the extracellular electrical stimulation. For
calculating the voltages induced by means of electrical stimuli injected by
electrode into the anisotropic medium, the finite element method (FEM) are
exploited. The estimation of the axonal responses to the external stimuli
was investigated by means of software dedicated for efficient calculus of
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neuronal dynamic (McIntyre, 2002) and cable equations, NEURON (Hines
and Carnevale, 1997). Finally, the FEM results are interpolated into the NEU-
RON model, obtaining together what can be called a “hybrid electro-neuronal
model.”
Initial concept of hybrid modeling was proposed in the studies regard-
ing the electrical epidural stimulation (EES) of spinal cord (Coburn, 1985;
Coburn and Sin, 1985). Then, similar idea has been exploited in works
that model extracellular stimulation of central nervous system neurons, and
in particular for the purpose of deep brain stimulation (DBS) modeling
(McIntyre and Grill, 2002; Miocinovic et al., 2006). In the recent past, it has
been also used in human peripheral nervous system to optimize the design of
extraneural cuff electrodes (Schiefer et al., 2016) for the neural stimulation
in effort to make a motor rehabilitation of spinal-cord-injured patients. Intra-
neural electrodes have been simulated (Raspopovic et al., 2011) and validated
(Raspopovicet et al., 2012) in the rat nervous implants, using the same hybrid
modeling approach. Successful translational use of models in the CNS, as
the development of software CICERONE (Frankemolle et al., 2010), which
is used in the DBS practice, or in model for spinal cord simulation (Moraud
et al., 2016), which was the fundamental for the development of sophisticated
stimulation paradigms, that enabled unseen level of mobility in fully Spinal
Cord Injured (SCI) rats. These models were not only important from the
translational viewpoint: by indicating the electrodes placement and paradigm
of optimal stimulation, but also enabled the deep understanding of interac-
tions, which is the fundamental of these intervention computer simulations
(Rattay et al., 2000; Capogrosso et al., 2013) provided evidence that EES
primarily engages large myelinated fibers associated with proprioceptive and
cutaneous feedback circuits during the SCI rehabilitation.
Pivotal role of modeling in all these complex systems, increases the need
for the implementation of similar realistic models also for the human PNS,
to be exploited within the neuroprostheses (Raspopovic et al., 2014; Tan
et al., 2014) development. Neural interfaces are an important component of
these systems, which allow direct communication with the nervous system.
Several neural interfaces for the PNS have been developed during the past
year. They range from epineural electrodes, having low invasiveness and low
selectivity, to regenerative electrodes, having higher selectivity but at the
same time, also higher invasiveness (Navarro et al., 2005). A good trade-
off between the two previous solutions can be found in intraneural interfaces
(as transverse intrafascicular multichannel electrode (TIME) (Boretius et al.,
2010) or self-opening intraneural peripheral interface electrode (SELINE)
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Figure 4.1 Hybrid modeling: nerves sections are taken at the appropriate level for the
implantation, and then used within the hybrid electroneuronal models for the development
of the optimized neural interfaces for selective, gradual, and minimally invasive use.
(Cutrone et al., 2015). Raspopovic and his collaborators (Raspopovic et al.,
2017) were depicting the prominent use of models of human median
and sciatic electrical nerves stimulation (ePNS) within the framework of
development of innovative neuroprostheses (Figure 4.1).
The efficacy of neuroprostheses can be improved by increasing the pos-
sibility of neural interfaces used to stimulate specific subsets of neurons,
while not stimulating the untargeted ones, the concept which is measured
by the electrode’s selectivity. Models could help to reach the scope of having
devices that are enhancing selectivity, while reducing invasiveness and also
decreasing the amount of current to be injected into the neural tissues.
Selectivity is mainly influenced by interface design, and more in particular
with dimensions of whole device, its shape, number, and distance of active
contacts, used for the stimulation of the neural tissue. Models can indicate
the optimal number of devices to be implanted into an individual nerve, and
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therefore they should give hints regarding how the neurosurgery should be
performed (Raspopovic et al., 2017).
In the past years, the neural interfaces were tested in vitro or in animal
preparation by single-channel stimulation and measurements of same type of
output measure (Badia et al., 2011). This conceptual framework together with
time limitation during the effective use, have restricted the clinical application
of peripheral nerve stimulation to continuous, single active sites injected
stimulation patterns. However, this strategy does not exploit optimally, all
the possible capability offered by implanted devices, particularly does not
allow to address subject-specific deficits which is pivotal to maximize the
outcome of rehabilitation protocols. The use of more sophisticated stimula-
tion paradigms (Fang and Mortimer, 1991; Grill and Mortimer, 1995, 1997;
Vuckovic et al., 2004; Hennings et al., 2005), or combinations of single
active sites stimulations into the complex multipolar stimulation, could be
promising, and should be extensively explored by use of models (Schiefer
et al., 2012; Saal and Bensmaia, 2015; Oddo et al., 2016; Saal et al., 2017).
Finally, among the biggest problems encountered during the use of differ-
ent neural interfaces, is the temporal change of charge necessary to guarantee
the therapeutic use. This is most probably due to the tissue complex reaction,
and some aspects of it can be interpreted by use of models, rather than
extensive animal sacrificing and following histological analysis.
Computer models can be useful for exploring the high dimensional
space of design parameters with the goal to provide guidelines for the
development of more efficient neural electrodes, with minimal animal use
and optimization of manufacturing processes.
4.1 Hybrid Model
The use of computer models to study the electrical stimulation of neural
systems appears to be an inexpensive and efficient way to assist in the devel-
opment of neural devices or applications. The state of art in models accounts
for anisotropy of extracellular conductivity, present in real nerves, and also
for the nonlinear response of cells to the extracellular stimulation. Those two
aspects are solved separately: by means of the FEM which solves the voltage
distribution generated by injected currents, and by using calculations of neu-
ronal dynamics to estimate the axonal response to the electrical stimulations.
This kind of model has been called hybrid field-neuron models (or hybrid
FEM/Neuron models). To couple the external electric fields with the fiber
or cell, proper models to account for external stimulation were developed.
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The state of the art most used approach is the so-called compartmental
modeling of fibers, which is based on the subdivision of fibers and cells into
elementary circuit representation used to model the different parts of the cell
or fiber, like axons, somas, and nodes of Ranvier.
4.2 Finite Elements Model
As a first step, the correct heights of the nerve for implantation have to
be determinate, and corresponding histological picture needs to be found.
Considering upper and lower limb implants, the correct height to consider is
above the elbow for the transradial (under-elbow) amputees, while the level
at the ischial tuberosity for transfemoral (thigh-level) leg amputees.
Secondly, anatomically shaped geometrical model of the nerve and fas-
cicles are segmented by using the freeware software ImageJ (by freeware
software ImageJ with NeuronJ plug-in) obtaining an anatomically shaped
geometrical model. Coordinates of the image segmentation are then exported
to MATLAB (livelink COMSOL-MATLAB), where a 2D recreation of the
nerve is constructed. Since the fascicles are surrounded with a connective
tissue sheath called perineurium and it can influence the final results of
potential distribution, it was crucial to separate it from the fascicles’ contour.
As reported in Grinberg et al. (2008) perineurium thickness being determined
by the size of fascicle and it is equal to 3% of fascicle’s radius. Then the coor-
dinates were interpolated with interpolation curve. The segmented geometry
is imported into the FEM software, COMSOL (COMSOL S.r.l., Italy) and
extruded along the longitudinal axis achieving a 3D structure (Figure 4.2).
Very important aspect is a correct assignment of different electrical values
to the separated tissue classes: epineurium, perineurium, and endoneurium.
These values are available from literature, however, need to be critically
revision, and adapted to the particular model. Indeed, the intrafasicular
endoneurium, debt to the longitudinal disposal of axon within, has an
anisotropic conductivity tensor with a longitudinal value of 0.571 S/m and
a transverse value of 0.0826 S/m. The epineurium is assumed to be an
isotropic medium with a conductivity of 0.0826 S/m (Schiefer et al., 2008).
The perineurium is modeled as an isotropic conductor taking into account
the thickness of the perineurium as 3% of the approximately diameter of the
fascicle (Grinberg et al., 2008), and the difference temperature between frog
and humans, with a value of 0.00088 S/m (Raspopovic et al., 2017). Gen-
erally, the surroundings of nerves are implemented as homogeneous saline
solution (2 S/m), which is emulating the intraoperative environment, with
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Figure 4.2 FEM solution. (a) Picture of cross-section of human median nerve. (b) 2D cross-
section in COMSOL. (c) Final mesh of the entire structure in 3D. (d) Solution of the fem.
Electric potential in plan xy (z = 0).
saline solution, but should be corrected in the future works about chronically
implanted interfaces.
Models of electrodes are implemented separately and merged with the
neural structure. Since the frequency range, which is of interest in sensing
prosthetic applications, is low, we can assume a quasistatic approximation
of Maxwell’s equations within the nerve volume (Bossetti et al., 2008).
Therefore, the electromagnetic problem can be expressed through Laplace
formulation for the extracellular electric potential (Veltink et al., 1988;
McIntyre and Grill, 2002):
∇ · σ∇Ve = 0 (4.1)
To optimize the model from the computational load standpoint, an infinite-
length/infinite-diameter to finite-length/finite-diameter approximation has to
be considered. While in physics the 0-voltage is defined in infinity, within
FEM model, in order to emulate the proper boundary conditions of the
problem, the ground condition is set to the outermost surface of a finite
model (McIntyre and Grill, 2002). Taking into account limited resources
and time constraints, a minimal sufficient boundary dimensions had to be
found calculating appropriated indexes (Raspopovic et al., 2011). Sufficient
meaning the solution needs to be electromagnetically correct.
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4.3 Neuron Fiber Model
To model the dynamics of nerve fiber, MRG (McIntyre Richardson Grill)
model was used (McIntyre, 2002). This model represents the nonlinear modi-
fied Hodgkin–Huxley equations for the active compartment of the axons (the
nodes of Ranvier) and a detailed realistic representation of the myelinated
tracts. The success of this model is debt to its capability to reproduce several
experimental aspects of cells dynamics, and to its availability: it can be found
in model repository of NEURON. The difference between state-of-the-art
models resides basically on two aspects: the first is the membrane dynam-
ics and the second is the representation of the compartments. Membrane
dynamics refers to differential equations of the membrane potential and extra-
cellular potential relation (i.e., numbers of ion channels implemented). While
compartment representations refer to the number and type of compartments.
In this case, MRG model introduced Na+, K+, leakage channel, and nap
channel for reproducing the hyperpolarization on the recovery cycle. The
sensory axons population were simulated in NEURON 7.3 as implemented
in (McIntyre, 2002). For a fiber of diameter D, a model made of 21 nodes of
Ranvier with internodal spacing L = 100 D was built.
On the other side, it is unknown where are placed the fibers groups, which
convey a specific sensation: either over the whole fascicle, or only within a
very limited area of it. Fibers vary in diameter and position within the fascicle.
To address this issue, multiple populations could be generated to account for
fascicles’ anatomical variability. In sensory human nerves, the probabilistic
distribution for fibers diameter resulted in two Gaussian distributions, which
differentiated nociceptive fibers from fibers responsible for pressure/touch
sensation. Furthermore, nodal length was fixed at 1 um and nodal diameter
was scaled from (McIntyre and Grill, 2002). A total amount of 100 fibers,
were placed randomly in the specific target fascicle (Figure 4.3). Finally, we
considered that fibers within a specific fascicle innervate the same portion of
the hand (Jabaley et al., 1980).
4.4 Hybrid Model Solution
The FEM was solved with a stationary solver considering the quasistatic
approximation for the electromagnetic problem, i.e., an electrostatic problem.
The linear system obtained by FEM is symmetric and positive definite, there-
fore it can be solved by the Conjugate gradients method which applicable to
sparse systems that are too large to be handled by a direct implementation.
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Figure 4.3 2D nerve cross-section with electrode and the fibers positioned inside the
fascicles (red; left). 3D placement of Ranvier nodes for each fiber inside the nerve (right).
This method is an iterative solver that requires a preconditioner in order to
improve its convergence. The preconditioner used was an algebraic multigrid,
which is a numerical method that increases the computational speed by
decreasing the complexity of the computations and then leading to a faster
convergence. The convergence criterion is reached when the relative error
becomes smaller than 1× 10−6.
Electric potentials generated inside the nerve by means of electrical
stimulation were computed for the whole structure and then interpolated
on the proper fibers positions and then neurons answer was computed
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Figure 4.4 Active site of TIME close to three fascicles. (a) Recruitment curves (%).
(b) Electric potential distribution (fixed 0–1.9 µV).
(Figure 4.4). Electric potentials were interpolated along the position of the
nodes of Ranvier for each fiber in the model. Then, they were extracted from
the FEM solutions and used as an extracellular mechanism for membrane
depolarization. Fibers were stimulated by cathodal bipolar square current
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pulses of variable pulse-width (this is correct under quasistatic approxima-
tion). A fiber was considered recruited when a generated action potential
traveled along its whole length (i.e., reached the last node of Ranvier).
4.5 Model-driven Electrode Design, Dimensions,
and Number of Implants
The first, straightforward exploitation of models is for understanding of
which type of electrode geometry is the most prominent for the selective
stimulation of the discrete sensations. To do so, it is possible to implement
different models of several electrodes type, which were successfully used
in human applications, as intraneural and epineural electrode (Figure 4.5).
Intraneural electrodes by design ensure closer distance to its targets then cuff-
type electrodes. Results indicate that the most striking advantage of use of
intraneural electrode is its one order of magnitude lower necessary charge
threshold to elicit any fiber response respect to the case of epineural electrode
(Raspopovic et al., 2017). On the other side, it is also possible to stimulate
selectively the deep target fascicle by means of intraneural stimulation, while
it is impossible to do so by means of epineural electrode. Finally, as regarding
the dynamic of elicitable axonal response, it is possible to fine-modulate
Figure 4.5 Different electrode geometries (top). FEM solutions according to different
electrodes type (bottom).
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Figure 4.6 Isopotential curves regarding different fibers dimensions related for each active
site inside the same fascicle (1–5).
the sensation by use of intraneural active site (TIME) and simple charge
modulation, while the same is not feasible by epineural electrodes.
Appropriate electrode dimensions, number of active sites and their
respective distances are essential for the manufacturing process. Models
are ideal candidates for the proper addressing of this set of dimensions of
electrodes. Total number of fascicles stimulated selectively is in a correlation
with a number of contact sites, although some of them are recruited by more
than one active site (Figure 4.6). The limiting factor, when having many active
sites, is that the leads, necessary to connect them to the stimulator, are making
the dimension of electrodes’ substrate bigger, and therefore more invasive.
The optimal number of electric active contacts for a neural electrode could be
obtain using hybrid neuron model (Raspopovic et al., 2017).
In order to achieve the maximal performance (defined as the maximal
possible number of fascicles elicited selectively) during the stimulation, with
limited nerve damage, it is crucial to understand the optimal number of elec-
trode for implant. This could be possible studying it with the models; indeed,
it is possible to simulate different possible scenarios of implantation at the
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Figure 4.7 Double TIME implant in the same nerve and example of different stimulation
positions.
same time (Figure 4.7). The most important goal is to reach the access to the
maximal number of the fascicles using different active sites of the electrode.
Technically, an implantation of many electrodes can be useful to stimulate
every fascicle within the nerve, but too many electrodes could damage the
nerve of the patient, put hard demand on the implantable electronics and
transcutaneous communication implementation, and therefore this outcome
of model is of essential value for neurosurgeon.
Using the hybrid computational model, it could be possible to design
optimal configuration to stimulate the target nerve. Traditionally, the neural
interface, even if having several stimulating contacts is generally used in
paradigms concerning a single-channel: monopolar use. Monopolar stimu-
lation consists in an activation of only one active site at time, while bipolar
protocol enables to use two contacts in any configuration (with opposite or
same polarity). This represents an example depicting the potentiality of the
stimulation protocol design, guided by model findings.
4.6 Simulation of Biological Reaction to Electrode
Optimization
Modeling framework is not only useful for the design of the neuroprostheses
and their use. It can be successfully exploited also for the interpretation and
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investigation of scientific questions, which are not easy, or are impossible to
face, by experimental empiric approach, that are of paramount importance for
successful chronic use of neural interfaces.
One among the biggest issues with long-term use of neural interfaces in
the neuroprosthetic devices is the decay/change of the stimulating capability
over the time (Liu et al., 1999; Grill and Mortimer, 2000; Huang et al., 2004;
McConnell et al., 2009; Polasek et al., 2009; Leach et al., 2010; Winslow
Figure 4.8 Modeling of the fibrotic tissue growth over weeks.
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and Tresco, 2010; Raspopovic et al., 2014; Tan et al., 2014). Even though
a significant amount of studies has been performed (Liu et al., 1999; Grill
and Mortimer, 2000; Huang et al., 2004; McConnell et al., 2009; Polasek
et al., 2009; Leach et al., 2010; Winslow and Tresco, 2010), the mechanisms
of the thresholds change during the chronic neural stimulation are yet not
elucidated. Between many possible hypothesis and interpretations, there is
no consensus about the main factors; however, the nerve model can be an
excellent instrument for testing some of these. It is possible to test several
plausible hypotheses, which aim to explain the change of charge necessary
to stimulate the nerve. For example: (i) Nerve fibers are in dysfunction/dying
when electrode is placed intrafasciculary. (ii) Fibrotic tissue pushes electrode
away from nerve fibers when electrode is placed intrafasciculary (Huang
et al., 2004). (iii) Fibrotic tissue shifts electrode away from fascicle when
placed extrafasciculary. (iv) Perturbation of the electric field by means of the
fibrotic tissue generates the change in the axonal recruitment (Miocinovic
et al., 2006). (v) Fibrotic encapsulation (Figure 4.8) changes over time the
resistivity around the electrode.
4.7 Discussion
The hybrid modeling is a mandatory step in order to propose the optimized
electrodes, and also to perform the most efficient manufacturing, avoid
unnecessary animal experimentation, understand the unexpected changes and
finally propose the hints for the neurosurgical procedure. It is of paramount
importance to understand that, when dealing with models, they can be used
properly only when addressing a clearly defined issue, and for what are
tailored: it cannot be intended to explain all the aspects of such a complex
system as neural system stimulation in every its aspect. Therefore, the models
have to be customized toward the peculiar application of feature of interest.
All of models account with specific limitations, and these should be clearly
studied and stated, since could help in the correct interpretation of model
results, their future exploitation and upgrading.
We believe that by the future development of the technologies, and spe-
cially imaging techniques, the sophisticated and widespread neuroprosthetic
devices will go toward the ad hoc, ad personam modeling-based approach:
starting from the high detailed images of structure of interest, and anatomical
knowledge, by use of powerful computers, and efficient modeling computa-
tion we could have the patient-specific neural interface, and protocol of use.
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5.1 Introduction
A key component for the clinical applicability of neuroprostheses is the
neural electrode, intended to bidirectionally exchange information with the
nervous system, thus allowing recording of nerve signals and stimulation of
nerves and muscles over extended periods of time. A prerequisite for the
application of nerve electrodes is that the implant must be biocompatible.
155
156 Biocompatibility of the TIME Implantable Nerve Electrode
Biocompatibility can be defined as “the ability of a material to perform an
appropriate host response in a specific application” (Williams, 1987). The
compatibility between a technical and a biological system can be divided into
structural biocompatibility and surface biocompatibility (Stieglitz, 2004).
Structural biocompatibility refers to the adaptation of the artificial structure
to the mechanical properties of the surrounding tissue, so that the device
design and material properties should adapt to the biological structure of the
target tissue. Surface biocompatibility deals with the interaction of chemical,
physical, and biological properties of the foreign material and the target
tissue. A material can be considered biocompatible if substances are only
released in nontoxic concentrations and the biological environment reacts
only with a mild foreign body reaction and encapsulation with connective
tissue. The design and size, as well as the material choice and the interface
surface, have to ensure stable properties of the electrode-electrolyte interface
throughout the implant lifetime (Navarro et al., 2005). Once implanted, a
neural interface has to remain within the body of the subject for months
or years, so the stability of the materials in the electrode is crucial. The
electrode has to be resistant to corrosion during stimulation and to the
attack of biological fluids, enzymes, and macrophages produced during
the initial foreign body reaction. It must be composed of inert materials,
both passively and when subjected to electrical stimulation, since deterio-
ration of the device may result in implant failure and the release of toxic
products.
The first step to determine if any electrode material is biocompatible is,
on one side, the in vitro study, bringing cell cultures in contact with the mate-
rial and evaluating different parameters as morphological and ultrastructural
changes (Koeneman et al., 2004; Vince et al., 2004), and, on another side, the
in vivo subcutaneous implant of the material to investigate the tissue reaction,
evaluating the thickness of cellular layers that surround the material and the
presence of inflammatory cells (Vince et al., 2004). The following step is the
evaluation of the full electrode device implanted in the target tissue, in this
case the peripheral nerve, chronically, assessing possible functional changes
and structural damage to the nerve as a consequence of the implanted device.
The transverse intrafascicular multichannel electrode (TIME) (Boretius
et al., 2010) is intended to be implanted transversally in the peripheral
nerve and address several subgroups of nerve fibers with a single device.
Therefore, in an initial stage of the TIME project we performed extensive
in vivo studies in order to assess the biocompatibility and safety of TIMEs
after implantation in the rat and the pig.
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5.2 Biocompatibility of the TIME in the Rat Nerve Model
5.2.1 Biocompatibility of the Substrate and Components
Following the standards defined in the ISO-10993 protocol for testing
local effects after implantation of a device, pieces of polyimide substrate
containing deposited iridium oxide (IrOx) as conductor for the active sites
of the device were implanted in the subcutaneous tissue of adult rats during
4 weeks. The hexagonal pieces of polyimide substrate, with a surface of
100 mm2, containing 19 deposited circles of IrOx (occupying a total of
50 mm2) were provided by IMTEK. After shaving and disinfecting the rat
skin, four incisions 1.5 cm long were done bilaterally on the back of the ani-
mals, with a distance of 2.5 cm between incisions. Sterile pieces of polyimide
or of silicone as control, were implanted subcutaneously, one in each pre-
pared subcutaneous pocket. The incisions were then sutured and disinfected.
After 4 weeks, animals were sacrificed, and perfused transcardially with 4%
paraformaldehyde. The implanted specimens were removed with the sur-
rounding skin tissue and processed for histological and immunohistochemical
analyses.
Compared to the intact skin, samples that had the polyimide implant,
as well as silicone sheath implant as control, showed the epidermis and the
connective tissue layer, with normal organization and appearance, as revealed
by hematoxylin-eosin staining (Figure 5.1).
There were not areas of necrotic tissue in the subcutaneous and muscle
layers. However, both silicone and polyimide implants were surrounded
by a dense thin capsule of connective tissue. The thickness of the fibrous
capsule was larger in silicone sections (outer zone: 159± 35 µm; inner zone:
69 ± 21 µm) than in polyimide sections (outer zone: 107 ± 9 µm; inner
zone: 60 ± 7 µm). Immunohistochemical labeling was used to assess the
inflammatory reaction by estimating the presence of macrophages stained
with Iba-1 antibody in the capsule surrounding the implants. In samples
with silicone implants macrophages were present at the inner zone, near
blood vessels, but not at the outer and lateral zones. Sections with polyimide
implants showed also concentration of macrophages in the inner zone, and
lower amount at lateral zones.
Polyimide-based materials have been demonstrated biocompatible with
respect to toxicity (Richardson et al., 1993; Rihová, 1996) as well as to
biostable in other types of electrodes implanted in vivo (Rodrı́guez et al.,
2000; Ceballos et al., 2003; Lago et al., 2007). The histological biocom-
patibility assessment of the tissue surrounding the implants of polyimide
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Figure 5.1 Hematoxylin-eosin staining of representative sections from skin without
implant (A), with a silicone implant (B) and with a polyimide implant ((C), and detail in
(D)). (B) Silicone implants showed a cavity formed during tissue processing (asterisk). White
arrows show the superficial fibrous layer (outer zone). (C) Polyimide implants were embedded
in the fibrous capsule (white arrowheads). The deep fibrous layers of the capsule are also
shown (inner zone, black arrow). Scale bars: 500 µm ((A)–(C)) and 20 µm (D).
containing IrOx dots, selected to fabricate the TIME, indicated good integra-
tion in the skin and subcutaneous tissue of the adult rat. This is in agreement
with previous studies, describing the absence of a gross response to metal-
coated pieces of polyimide or uncoated control silicone (Cogan et al., 2003).
Although the capsule surrounding the implant was observed around both
the unprocessed silicone and the metalized polyimide samples, it was sig-
nificantly thinner in the latter. Macrophages were slightly more abundant
next to polyimide than to silicone samples, but still their density was low,
suggesting a slight degree of inflammatory response around the implanted
materials.
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5.2.2 Biocompatibility of the TIME Implanted in the Rat Nerve
The electrodes used in the study corresponded to the TIME-2 and TIME-3
designs, explained in the previous chapter, and were produced by the
Department of Microsystems Engineering (IMTEK) of the University of
Freiburg. Cleaned and sterilized TIMEs were implanted into the sciatic nerve
of adult rats. In one group (Acute, n = 7) of rats the TIME-2 was implanted
and, in order to evaluate the damage just induced by the surgical implantation
procedure, the electrode was retired after an acute electrical stimulation
protocol was performed. In two other groups (TIME-2 and TIME-3, n = 5
each) a TIME-2 or a TIME-3 were transversally implanted in the sciatic nerve
and remained for 2 months.
The TIME devices were transversally inserted across the three fascicles
of the sciatic nerve (sural, tibial, and peroneal branches) at the midthigh. The
electrode was inserted with the help of a small straight needle attached to a
10-0 loop thread that was passed between the two arms of the TIME. The
needle was inserted transversally across the sciatic nerve and then pulled the
thin-film structure through it. Once the structure was implanted, the needle
was removed by cutting the suture. The TIME-2 ribbon was routed across the
overlying muscular plane to the lateral thigh region, where the ending part
was secured under the skin. For the TIME-3 design, the ribbon was routed
along the nerve and the ending pad was accommodated under the muscle
(Figure 5.2).
All the animals were followed up with a battery of neurophysiological
tests to obtain evidence of possible functional alterations, and final histolog-
ical analysis to assess potential damage induced by the implanted TIMEs
on the nerve. The study design aimed to discriminate effects due to the
implantation procedure, to the presence of the intraneural electrode segment,
and to the mechanical motion induced by the TIME ribbon and connector
during chronic implants (Badia et al., 2011).
During the 2 months implantation time, there were no remarkable changes
in any of the parameters of motor and sensory nerve conduction tests per-
formed in any of the implanted groups, Acute, TIME-2, and TIME-3. The
amplitude of the compound action potentials (CMAPs and CNAPs) obtained
by stimulation of the right sciatic nerve after TIME-2 and TIME-3 implan-
tation did not change notably at any interval postimplantation in comparison
with the control nerve values. There was evidence of slight slowing of nerve
conduction velocity at 7 days in the implanted groups, but it was normalized
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Figure 5.2 Left: Photograph of a TIME-3 in which the intraneural portion is angled at
90◦. Right: photograph of the insertion of a TIME-3 with the ribbon accommodated to the
longitudinal axis of the sciatic nerve.
at 30 days. The implanted nerves showed similar values over time than the
contralateral intact nerves (Figure 5.3A, B).
Walking track test, used to evaluate the locomotion performance, did
not show variations between the right (TIME-2 and TIME-3 implanted)
and left (intact) hindpaw prints along the follow-up. The Sciatic Functional
Index averaged between −5 and +20 during follow-up (Figure 5.3C). The
algesimetry tests yielded similar values of the pain threshold for withdrawal
between the implanted and the contralateral sides, without evidence of hyper-
algesia that might be induced by nerve compression or injury (Figure 5.3D).
No loss of pain sensitivity was appreciated in any area of the hindpaw under
pinprick testing.
5.2.3 Morphological Evaluation of the Implanted Nerves
The macroscopic examination during final dissection at 2 months after
implantation showed that the electrodes remained in place within the sciatic
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Figure 5.3 Neurophysiological tests result in the three groups with Acute, TIME-2, and
TIME-3 chronic implant in comparison with control values. Values of the CMAP amplitude
(A) and onset latency (B) of the tibialis anterior muscle. Values of the SFI (C) and of
algesimetry (D). Modified from Badia et al., 2011.
nerve in all animals of groups TIME-2 and TIME-3. Transverse sections at
the segment that contained the intraneural TIME allowed to see the electrode
strip crossing the fascicles of the sciatic nerve, covered by a fibrous tissue that
disrupted the microarchitecture of the nerve (Figure 5.4).
Transverse semithin sections of the nerve distal to the insertion site
showed a normal fascicular organization (Figure 5.4). The numbers of myeli-
nated fibers counted in the distal level for each of the three branches of
the sciatic nerve were in all the implanted groups similar to those found in
control intact nerves. The reduction of about a 10% in the mean number of
myelinated fibers of the sciatic nerve in group TIME-2 was mostly due to a
decrease of myelinated fibers of about the 8% in the tibial nerve and 25%
in the sural nerve, the smallest of the three branches. Group TIME-3 has
only a small loss of myelinated fibers in the sural nerve (about 20%) (Badia
et al., 2011).
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Figure 5.4 Cross-sections of an implanted rat sciatic nerve. (A) At the level of TIME-3
implant crossing the tibial branch and part of the peroneal branch. Note the mild fibrous
tissue surrounding the electrode. (B) Semithin transverse section of the tibial nerve of the
same animal distal to the implant site. There are no signs of degeneration and the density of
myelinated fibers is similar to controls.
5.3 Biocompatibility of the TIME in the Pig Nerve Model
Device implantation and associated tissue injury trigger a cascade of inflam-
matory and wound healing responses that are typical of a foreign body
response (FBR) (Morai et al., 2010). The continuous presence of biomaterial
devices leads to chronic inflammation. The wound healing response depends
on the size and extent of the implant. The end stage of FBR involves shielding
the implant by a vascular and collagenous fibrous capsule (Williams et al.,
1983; Labat-Robert, 1990; Kovacs et al., 1991). The response to any implant
is wound healing comprised of hemostasis (seconds to hours), inflammation
(hours to days), repair (days to weeks), and remodeling (weeks to months)
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(Stroncek, 2008). To evaluate the biological effect of the TIME electrodes
in the large nerve animal model (chronically implanted Göttingen mini-
pigs), and particularly the fibrotic capsule formed around the electrode, we
harvested and analyzed nerves following several weeks of implant.
All experimental procedures were approved by the Animal Experiments
Inspectorate under the Danish Ministry of Justice. Female, Göttingen mini-
pigs. Under full anesthesia and using aseptic surgical techniques one or two
TIMEs were implanted in the median nerve above the elbow joint. If only
one TIME electrode was implanted, it was placed at an angle of 90◦ or
135◦. When two electrodes were implanted they were implanted with a 45◦
difference in angle. Lead-out wires were tunneled subcutaneously to the back
of the pig where they excited the skin.
To collect tissue for histological evaluation an incision was made over
the implant area and the location of the TIME and the median nerve were
identified. The animal was then euthanized and the nerve including elec-
trode(s) and lead-out wires was harvested. We performed further dissection
of the harvested tissue in order to free the nerve and electrode from the
surrounding fibrotic tissue (Figure 5.5). A specimen of approx. 5 mm of
the nerve containing the TIME electrode was taken and either immersed
in formalin or in liquid nitrogen. To maintain orientation of the nerve the
proximal cross-section was marked with green dye while the entry and the
exit point of the identified TIME electrodes were marked with blue. In one
animal, we collected control samples from the right, nonimplanted leg. We
included 11 animals in the study that were implanted during 22 ± 7.7 days
(range 8–37 days).
Figure 5.5 Example of nerve specimen retrieved from a minipig after approx. 30 days of
implant. The surrounding fibrotic tissue has been removed by careful dissection to identify the
entry and exit points of the TIME.
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Figure 5.6 Typical samples of H&E stains of the peripheral nerve, where the TIME electrode
has been identified inside the nerve. Left (×20, Pig 02): whole nerve with TIME transversing
through the nerve easily identified. Right (×100, Pig 02): higher magnification of the implant
site – the TIME electrode and a layer of fibrosis surrounding the electrode is seen. The visible
“cracks” inside the fascicles result from the processing and embedding the nerve.
Transverse sections of 5 µm thickness were cut in the nerve using a cryo-
stat. The tissue was stained with Hematoxylin and Eosin (H&E) (Figure 5.6).
To estimate the thickness of the fibrotic scarring, digital pictures were taken
through a microscope. To avoid bias we randomly chose five points and
measured the distance from the polyimide structure of the electrode to the
rim of the fibrotic capsule perpendicularly.
5.3.1 Morphological Evaluation of the Implanted Nerves
All animals were in good health state and supported weight on the implanted
leg. In approximately half of the animals we noticed signs of swelling, edema,
and tenderness at the wound following the implant, which disappeared in the
following 6–9 days. Eight of the 13 animals developed infection either at the
implant wound or at the percutaneous connector in the back. In the majority
of the cases we were able to treat the infection to a point where it was not
possible to detect it visually.
Layer of fibrosis. Complete visualization of the entire length of TIMEs placed
transversely through the nerves was not always possible. The estimated layer
of fibrosis is shown in Table 5.1. The thickness of the fibrosis averaged 108±
40 µm. A similar FBR was also identified in the histological evaluation of the
rat sciatic nerve. We found no apparent correlation between the thickness of
the fibrosis and the duration of the implant.
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Table 5.1 Estimated thickness of the fibrotic capsule formed around nine TIME electrodes
implanted in seven pigs
Pig 10 Pig 10 Pig 11 Pig 11
Animal Pig 01 Pig 02 Pig 04 Pig 06 Pig 09 TIME-1 TIME-2 TIME-1 TIME-2
Thickness
[µm]
Mean ± SD
74.3 62.0 179.6 71.4 128.3 116.4 141.6 117.9 100.4
± 8.7 ± 26.5 ± 60.6 ± 23.5 ± 42.9 ± 9.4 ± 30.6 ± 38.9 ± 21.1
# days
implant
36 19 25 20 8 31 31 37 37
Macroscopic changes. For animals included in the “Chronic selectivity”
experiments we found that typical inflammatory cells were present around
the implant (i.e., including lymphocytes, macrophages, and giant cells),
however some variation between animals was observed. Also we identified
fibrocytes/fibroblasts in all animals. There were no signs of necrosis. The
presence of inflammatory cells and fibroblasts/fibrocytes indicated that the
wound healing process was likely still ongoing at the time of explant. It is
important to note that the inflammatory response and the formation was only
found around the electrode, i.e., the remaining part of the nerves and fascicles
appeared normal and without presence of fibrosis or inflammatory response.
5.4 Discussion
Intraneural electrodes are intended to provide a good degree of sensitivity and
selectivity for stimulation and recording action potentials at the nerve fibers
of the implanted nerve fascicles. However, they have the risk of inducing
damage to the nerve. Relative motion between the nerve and surrounding
muscles during limb movement can exert forces on the electrode, and eventu-
ally extract it or damage the nerve if the electrode is unable to move with
the nerve. Lead management and connector requirements offer additional
challenges; lead wires or ribon strips can produce tethering forces on the
electrode, resulting in damage to the nerve or breakage of the device. The
materials used for the TIME, i.e., polyimide as substrate and IrOx as con-
ductive sites, are biocompatible, as corroborated in our study in subcutaneous
implants. The induced FBR was similar or slightly thinner than with a control
substrate as silicone.
In general, we found that all the animals implanted, either rats or pigs,
showed good recovery from the surgery and were in good health during the
implant period. The infections experienced are likely related to the pig model,
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since no infections were observed in the rat model. However, the risk of
infection in future human clinical experiments will be very low, since it is
much easier to keep the percutaneous lead wires and exit points clean and
protected.
From the surgical point of view, TIMEs were easy to implant in the
nerve, because of the high flexibility and small thickness of the electrode
strips, even in the small size nerves of the rat. The results of the follow-up
evaluation indicate that either acute or chronic implantation of the TIME
in the rat sciatic nerve for up to 2 months did not cause significant signs
of axonopathy, axonal loss or demyelination, as evidenced by the functional
and histological findings. Nerve conduction tests showed a mild increase in
latency time at the first week after implantation, which is likely attributable
to the surgical implantation procedure, since damage to the perineurium
leads to endoneurial edema. Nevertheless, the degree of dysfunction was low
and time limited, since the animals showed recovery toward normal values
during the following weeks. Moreover, the nociceptive responses quantified
by algesimetry tests showed a mild decrease of the threshold only at 7
days in the group TIME-2, whereas at 1 and 2 months there were no signs
of hyperalgesia or pain. The absence of differences between the animals
implanted with TIME-3 and their controls indicates that the tethering and
motion forces, produced by the surrounding muscles and transmitted through
the ribbon in the case of the TIME-2 implants, were minimized with the next
TIME-3 design.
Regarding the histological results in the rat implanted nerves, the finding
of a slightly reduced number of myelinated fibers distal to the implant site in
group TIME-2 is suggestive of damage and subsequent axonal degeneration
of a small population of nerve fibers. Nevertheless, we did not find images
of ongoing degenerating fibers at 2 months, thus pointing to a time-limited
damage, most likely occurring during insertion. Comparatively, the reduction
of about a 10% in the number of myelinated nerve fibers with TIME-2 in the
chronic group is similar to that previously reported after the implantation of
other intrafascicular electrodes such as the polyimide thin film LIFE (Lago
et al., 2007), which is coherent with the fact that the Young’s modulus of the
substrate material (polyimide, UBE U-Varnish-S) is similar between TIME
and LIFE. The Utah Slanted Electrode Array (USEA) that is also inserted
transversally to the nerve yielded results similar to the ones found for the
TIME, although we did not find images of ongoing degenerative fibers at 2
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months postimplant, in contrast with the results for the USEA (Branner et al.,
2004); the difference may be attributed to the stiffness of the silicon USEA
structure.
The reduction in the number of myelinated nerve fibers in the tibial nerve
of the group TIME-2 was not observed in the group TIME-3. This difference
can be explained because of the absence of traction forces with the TIME-
3 design, this conclusion is reinforced by the fact that the nerves of the
Acute group did not show fiber loss. The minor loss of myelinated fibers
in group TIME-2 was not extensive enough to affect the animal function
or electrophysiological responses. Since in group TIME-3 we did not find
significant histological abnormalities, we can attribute most of the axonal loss
in group TIME-2 to the effects produced by the traction forces for some days
after implantation during the animal motion, and not to the material itself.
The refinement in the geometrical design of the TIME-3 allows for a better
adaptation of the structure to the anatomical properties of the nerve and to
reduce the tethering forces to which the electrode may be subjected.
These conclusions were proved by the subsequent study of TIME-3
implants in the pig median nerve. There were no clinical evidences of nerve
damage or dysfunction during several weeks of implant. The histological
study of the harvested nerves did not show any appraten abnormality on
the microstructure of the nerve, except for the presence of the transversal
electrode, which was covered by a fibrous capsule, as corresponds to a
normal FBR. The overall mean of the fibrosis was 108 ± 40 µm, which is
comparable to what is found in the literature (Williams et al., 1983; Labat-
Robert, 1990; Kovacs et al., 1991). A similar reaction and layer of fibrosis
was also identified in the histological evaluation of the rat sciatic nerve.
Interestingly, there was no apparent correlation between the thickness of the
fibrotic scarring and the duration of the implant, thus suggesting that the FBR
occurs during the first 1–2 weeks after implant, and thereafter remains stable,
helping also to maintain the implanted electrode in place. The inflammatory
response and fibrosis was only found around the electrode, i.e., the remaining
part of the nerves appeared normal.
Altogether our results indicated that the TIMEs are biocompatible and
safe after chronic implantation even in a small peripheral nerve, such as the
rat sciatic nerve. The mild effects of the TIME on the nerve will be minimized
when implanting the electrode of the same dimensions in larger nerves of
humans.
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6.1 Introduction
For restoring the lost function of organs innervated by damaged peripheral
nerves or to control a prosthesis substituting a lost organ, it is necessary to
provide an array of electrodes with good capabilities for both stimulation
and recording neural activity. Ideally, a bidirectional interface for the control
of a bionic prostheses in amputees should allow on the one hand, recording
of neural efferent motor signals to be used for the motion control of the
mechanical prosthesis, and on the other, stimulating afferent sensory nerve
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fibers within the residual limb to provide sensory feedback to the user
from tactile and force sensors embedded in the prosthesis. In amputees, the
nerves in the stump, which previously innervated the missing limb, are still
functional, even years after the amputation has occurred (Dhillon et al., 2005).
If these nerves could be selectively interfaced, it would be possible to translate
the motor signals into adequate actions and to provide the amputated subject
with sensory input, perceived as originating from the missing limb.
The selection of a suitable nerve electrode has to consider a balance
between invasiveness and selectivity, with the ultimate goal of achieving
the highest selectivity for a high number of nerve fascicles by the least
invasiveness and potential damage to the nerve. For controlling an advanced
neuroprosthesis, multiple functions, either motor or sensory, conveyed by
separate fascicles or bundles of axons in a peripheral nerve have to be inter-
faced. To adequately reproduce motor and sensory functions, it is, however,
necessary that the interface achieves two conditions: topographical selectivity
and functional selectivity. The knowledge of the fascicular topographical pat-
tern of peripheral nerves of interest (Gustafson et al., 2009; Badia et al., 2010;
Delgado-Martinez et al., 2016) will improve the implantation of electrodes in
adequate positions, by placing at least one active site within each fascicle of
interest. Regarding functional selectivity, for example, to induce a particular
sensory input, e.g., touch sensation from the thumb, it is needed to selectively
activate the specific nerve fibers that before amputation mediated touch infor-
mation from the thumb to the brain. This should be done without recruiting
fibers mediating information related to other sensory modalities or limb areas,
which might overshadow the intended sensory input. The more individual
parts of the nerve that can be selectively interfaced without recruiting other
parts, the higher chance is that a specific part of the nerve can be targeted in
a functional relevant way and the more selective the interface is. An intrinsic
drawback, however, is that the invasiveness and the risk of the surgical
implantation procedure tend to increase the more contact sites are placed in
or around a nerve and the closer they are placed to individual nerve fibers.
The design of the transversal intrafascicular multichannel electrode
(TIME) aimed to maximize the number of contact sites and their proximity to
different populations of nerve fibers, while keeping the risk and invasiveness
of the implantation low. The TIME is intended to be implanted transversally
in the nerve and cross several fascicles or subgroups of nerve fibers with
one single device (Boretius et al., 2010). By placing a number of active
sites distributed along the intraneural implant, a single TIME is thus able
to interface several fascicles, reducing the number of implanted devices with
respect to other intrafascicular electrodes.
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The TIME was extensively tested in computer simulations and animal
studies. These studies had several purposes: (1) to develop and test surgical
techniques, (2) to ensure the durability and biocompatibility of the electrode
when exposed to the biological environment (see Chapter 5), (3) to evaluate
the selectivity performance for stimulation and recording neural activity, and
(4) to evaluate the performance over time. The current chapter focuses on the
two last objectives.
6.2 Evaluation of TIME in the Rat Sciatic Nerve Model
6.2.1 Stimulation Selectivity
The testing in preclinical animal models is obliged before translation into
human subjects to avoid any risk, and also to obtain adequate information
regarding implantation and performance of the electrode. However, one
disadvantage is that it is not possible to get a subjective description of
the percepts induced by activating the nerve in these models, and thus the
selectivity performance of the implanted electrode must be quantified by
neurophysiological methods. In the following studies, for practicality, the
tests for selectivity were performed in an inverse way to what it is pretended
in human amputees, i.e., selectivity of stimulation of motor nerve fibers, and
selectivity of recording of sensory nerve fibers.
6.2.1.1 Methods
Acute experiments were made on adult rats in which the sciatic nerve
was implanted with an electrode for assessing selective electrical stimu-
lation at the fascicular and subfascicular levels. We compared the results
obtained with three types of neural electrodes: TIME, LIFE, and cuff (Badia
et al., 2011). The three types of electrodes had adequate dimensions for
the rat sciatic nerve and were made on polyimide substrate with platinum
active sites and contact lines. In one group of rats (group TIME-A) the
TIME (Boretius et al., 2010) was transversally implanted traversing the
tibial and peroneal fascicles of the sciatic nerve. With the aim of assessing
the selectivity of TIME just in the tibial nerve (subfascicular selectiv-
ity) the TIME was implanted in dorsoventral direction across the tibial
nerve (group TIME-B). To compare the results of TIME with Cuff and tf-
LIFE devices, cuff electrodes of 12 poles (four tripoles) (Navarro et al.,
2001) were implanted around the sciatic nerve (group Cuff), and tf-LIFEs
(Lago et al., 2007) were implanted longitudinally in the tibial nerve (group
LIFE).
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Stimulation was provided by a STIM’3D stimulator (Andreu et al., 2009),
delivering series of monophasic rectangular pulses of 10 µs at 0.5 Hz,
increasing the intensity in steps of 20 µA from 20 to 300 µA for TIME and
LIFE and to 800 µA for cuff electrodes. Pulses were delivered through each
of the active sites of the TIME and tf-LIFE against a small needle electrode
placed near the nerve. For the cuff, stimulation was applied to each one of the
four tripoles in the cuff, using the central pole as cathode and the outer poles
as anodes.
The activation of tibialis anterior (TA), gastrocnemius medialis (GM), and
plantar interosseus (PL) muscles was studied to verify if it was possible to
stimulate one of the three muscles without producing significant excitation
of the other two. The fibers innervating the TA muscle are located in the
peroneal branch, whereas those innervating the GM and the PL muscles are
in distinct locations in the tibial branch (Badia et al., 2010). The compound
muscle action potentials (CMAPs) were recorded by small needle electrodes
placed in each muscle, amplified and filtered (5 Hz, 2 kHz). The amplitude
of the CMAP (M wave) was normalized to the maximum CMAP amplitude
obtained for each muscle in the experiment. For each active site (as), k, a
selectivity index (SIas) was calculated as the ratio between the normalized
CMAP amplitude of that muscle, CMAPni, and the sum of the normalized
CMAP amplitudes elicited in the three muscles (Veraart et al., 1993):
SIasi,k =
CMAPni∑
j CMAPnj
. . . (6.1)
this index ranges from 0 (no activation of the target muscle) to 1 (activation
of only the target muscle).
In order to compare the stimulation selectivity of the three devices, a
selectivity index of the device (SId) was calculated. The SId was the product
of the highest SIas for each muscle with one given electrode, and may range
from 0.0307 (no selectivity; each SIas = 0.333 for three muscles considered)
to a maximal of 1.0 (maximal selectivity; each SIas = 1).
SId = SIasP l × SIasGM × SIasTA . . . (6.2)
6.2.1.2 Results
At low stimulation intensity selective stimulation of one muscle could be
detected, due to the close contact of one electrode site with the corresponding
muscular nerve fascicle. By progressively increasing the intensity of the
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Figure 6.1 Examples of CMAPs recorded in plantar (PL), gastrocnemius medialis (GM),
and tibialis anterior (TA) muscles with stimulation (st) at increasing pulse intensity, delivered
from two different active sites of a TIME implanted in the rat sciatic nerve. Selective activation
of GM (center block) and selective activation of PL muscle (right block) can be observed.
stimulus, the amplitude of CMAPs increased to reach the maximal value
(i.e., activation of the whole muscle); however, the stimulus spread to other
surrounding fascicles, therefore activating two or the three muscles tested
(Figure 6.1).
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The TIME device allowed selective activation of the PL, GM, and TA
muscles when stimulating through different active sites. Selective activation
using a multipolar cuff electrode was only possible for two muscles, GM and
TA, whereas with the tf-LIFE it was not possible to activate selectively more
than one muscle (either PL or GM for the implants in the tibial nerve). The
intrafascicular electrodes TIME or LIFE provided excitation limited to the
implanted fascicle, but did not extend stimulation to other nearby fascicles
crossing the perineurial barrier (Badia et al., 2011).
The threshold for muscle activation was found at intensities between 24
and 66 µA similar for TIME and LIFE devices, and at higher levels ranging
180–330 µA with cuff electrodes. The mean thresholds with the TIME did
not differ significantly between the three muscles. Cuff minimum threshold
for the PL muscle was significantly higher than the threshold for GM and TA
muscles, likely indicating a deep vs. superficial location of the corresponding
motor fibers within the nerve.
With the LIFE implanted in the tibial fascicle good selectivity was
obtained for the GM, moderately for the PL, but no activation of the TA
muscle was possible. With the cuff electrode good selectivity was found
for the GM and TA muscles, i.e., between different fascicles in the same
nerve trunk, but it was not possible to separately activate PL from GM
muscle, at the subfascicular level. In contrast, with the TIME different active
sites selectively activated each one of the three muscles evaluated, indicat-
ing potential selectivity at fascicular and subfascicular levels (Figure 6.2).
Calculation of the SId showed that the TIME has higher selectivity in the
three muscles model tested than the cuff and LIFE electrodes.
Figure 6.2 (A) Plot of the threshold of activation of the motor fascicles innervating PL, GM,
and TA muscles, with TIME, LIFE, and cuff electrodes. (B) Plot of the Sias (best active site in
each electrode) obtained for each of the muscles tested with TIME, LIFE, and cuff electrodes.
(C) Plot of the SId corresponding to TIME, Cuff, and LIFE devices. Bars are mean and SEM.
* p < 0.05 vs. Cuff; # p < 0.01 vs. LIFE. Data from Badia et al., 2011.
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In order to evaluate the changes in selectivity depending on the relative
location of the implanted TIME within the sciatic nerve, after performing
the stimulation protocol with one TIME, we moved the TIME a distance
of about 0.1 mm in the same direction that it was implanted and repeated
the stimulation protocol. The comparison of the recruitment curves and the
SIas showed variations as high as 100% in the SI for individual active sites
between the two trials. This observation is a proof of concept that, once
implanted, the intraneural TIME can be carefully repositioned to obtain the
optimal stimulation selectivity of different fascicles and subfascicles in the
nerve.
6.2.2 Recording Selectivity
To verify that the TIME was able also to serve as an adequate bidirectional
interface, acute experiments were made on adult rats in which the sciatic
nerve was implanted with a TIME for assessing its properties for recording
neural activity. The aims of this work were: (1) to characterize the recording
capabilities of the TIME in an experimental model, (2) to assess the spatial
selectivity of the TIME for recording sensory neural activity at the sub-
fascicular level, and (3) to assess the potential of TIME-recorded signals
for discriminating neural activities evoked by stimuli of different sensory
modalities (Badia et al., 2016).
6.2.2.1 Methods
The TIME was transversally inserted across the two main fascicles of the
sciatic nerve, the tibial and peroneal branches, proximal to the knee, as
reported in the previous section. The insertion was monitored under a dis-
section microscope to ensure that the TIME active sites were located as: the
first three of the right and left branches inside the tibial nerve, and the fourth
ones within the peroneal nerve (Figure 6.3).
For assessing the spatial selectivity, compound nerve action potentials
(CNAPs) were evoked from the digital nerves of toes 2 and 4, and recorded
with the TIME. The digital nerves were stimulated by means of two small
needles at the side of toes second and fourth, delivering pulses of 200 µs at
1 Hz, with increasing amplitude 1–10 V at steps of 1 V. Ten CNAPs obtained
for each voltage pulse were averaged to determine the initial latency and the
peak amplitude. The CNAP peak corresponding to Aαβ fibers was identified
from its conduction velocity, and the mean maximal amplitude plotted as
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recruitment curves. A CNAP was considered when its amplitude exceeded
two times the maximum value of the root mean square of the background
noise. For each active site, a selectivity index (SIas) was calculated as the
ratio between the CNAP amplitude exhibited for one stimulated digital nerve,
CNAP toe i, and the sum of the CNAP amplitudes elicited in the two digital
nerves (Veraart et al., 1993) as in the formula [1].
With the aim of assessing the capabilities of TIME for recording
functional neural signals preferentially in different active sites and the
possible discrimination of sensory modalities, two different experiments were
performed. The first was designed to evaluate the spatial selectivity of afferent
signals recorded with the TIME. For this purpose, a pressure stimulus was
applied with a Von Frey filament on pad A, toe 2, and tip 2 in the medial
side of the paw, and on pad D, toe 4 and tip 4 in the lateral side of the paw.
The signal-to-noise ratio (SNR), expressed as the ratio of the signal RMS
to the noise RMS, was calculated for each of the six active sites implanted
within the tibial fascicle, that innervates the plantar surface of the rat hindpaw.
In the second experiment, the objective was to assess the SNR values for
stimuli of different sensory modalities. Three tactile, one proprioceptive, and
one nociceptive mechanical stimuli were applied in this order: (1) soft tactile
stimulus by brushing the sole with a small brush, (2) pressure on a plantar pad,
(3) fast scratch on the midline of the hindpaw, (4) flexion of the toes of the
paw, and (5) light prick of the plantar skin with a small needle (Raspopovic
et al., 2010). Each test was repeated 10 times with intervals of at least 10 s
between stimuli.
The recorded neural signals were then bandpass filtered by means of a
finite impulse response (FIR) filter with 0.4 and 2.2 KHz cut-off frequencies,
preserving the main power of the ENG signal. The mean absolute value
(MAV) was extracted from the preprocessed data using a bin width of 100 ms
and an overlap of 50% (Raspopovic et al., 2010). Finally, a Support Vector
Machine (SVM) classifier was used to discriminate between the different
stimuli. Data were divided in a Training set (Tr) consisting in a random
selection of 50% of the trials, and in a Testing set (Tt) consisting in the rest
of the data. The SVM classifier was trained with Tr using the optimal param-
eters, and tested with Tt during the discrimination of: (i) one stimulus vs.
background activity, (ii) two stimuli and background activity, and (iii) three
stimuli and background activity.
6.2.2.2 Results
Different active sites of the TIME selectively recorded the CNAP evoked
by stimulating the digital nerves of toe 2 or toe 4, indicating that it was
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possible to obtain topographically selective recordings of neural signals from
different targets at the subfascicular level with the TIME. The mean onset
latency of the measured CNAP peaks was ∼2.0ms, which corresponds to
a mean conduction velocity of ∼40m/s, as expected from a population of
large myelinated mechanoreceptive fibers (Harper and Lawson, 1985). The
stimulation threshold for recordings in AS1 and AS2 of both branches of the
TIME was 5–7 V whereas for AS3 it was above 12 V. This fact is related with
the position of the electrode inside the nerve trunk. Active sites placed near
the target stimulated nerve bundle record the evoked CNAP at lower levels
of stimulation than active sites placed at more distance that would require
stimulation of more nerve fibers.
From the recruitment plots of the amplitude of the CNAP recorded in the
tibial nerve with increasing magnitude of stimulation, we calculated the SIas.
In three animals, it was possible to discriminate the CNAP coming from toe 2
and toe 4 with a SI higher than 71%. In other two rats, the SI was 100% for
toe 2 but only 55% for toe 4, while in the remaining rat the SI was 73% for
toe 2 and 56% for toe 4. The selectivity indices for active sites AS3, which
were probably implanted in the region of the tibial nerve occupied by nerve
fibers innervating muscles of the hindlimb, were lower than for AS2 and AS1,
which were located within the subfascicles of the tibial nerve going to the
plantar nerves (see Figure 6.3) (Badia et al., 2016).
During sensory stimulation of the plantar aspect of the hindpaw, we
recorded bursts of action potentials from the TIME active sites. Afferent
neural activity elicited by tactile, proprioceptive, and nociceptive stimuli did
not show significant differences in the SNR level. The mean value of the
SNR, being higher with the application of fast scratch stimulation than static
pressure or pricking stimulation. For the same type of stimulus applied in
one of the stimulation spots, the SNR of the evoked recordings varied in
amplitude between different ASs; the SNR was highest at AS1, and lowest at
AS3. These results are attributed to the location of AS1 closer to the bundle
of sensory fibers that innervate the hindpaw than the other ASs (Figure 6.3).
Thus, the TIME may give spatial discrimination of source of the recorded
neural activity.
The capacity to discriminate different sensory activity was tested by
using an automatized classifier. Considering the mean classification accuracy
for the best channel in each of the rats, it was possible to robustly dis-
criminate between different stimuli and background activity from the ENG
signals recorded with the TIME. Mean values of 95.4%, 96.0%, and 85.2%
were obtained when discriminating pressure, proprioceptive and nociceptive
stimuli vs. background, respectively.
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Figure 6.3 Microphotograph of a transverse section of a sciatic nerve immunolabeled
against cholin-acetyl transferase (ChAT, dots stained in black) to label motor axons, and
counterstained with hematoxilin to visualize the tissue. The narrow strip occupied by the
intraneural portion of the TIME has been overlaid with a thin line (brown) and the active
sites (AS, in black) marked in a possible position.
6.2.2.3 Discussion
The results of these works made on the rat model indicate that the TIME
allows highly selective stimulation of different small muscular fascicles and
even parts of the same fascicle within the sciatic nerve of the rat (Badia et al.,
2011), and that it also offers good capabilities for selective recording of neural
signals elicited by electrical and mechanical stimulation delivered at discrete
areas of the foot of the rat (Badia et al., 2016). Furthermore, the post hoc
processing of the signals recorded from the TIME allows the identification
of the corresponding stimulus pertaining to different functional modalities.
Relative comparison of the SI obtained suggests that the TIME may be more
selective for stimulation of nerve fibers than for recording neural activity. The
neural signal recorded is the superposition of all the afferent signals corrected
by the distance factor, whereas in the case of stimulation, since an axon is not
activated until the threshold of stimulation is reached, only the nearest axons
to the active site will be activated at low levels of current, and therefore spatial
selectivity will be present (Raspopovic et al., 2012).
Because of the careful insertion inside nerve fascicles, TIMEs and
LIFEs achieved muscle activation at a considerably lower intensity than the
extraneural cuff electrodes, further supporting the advantage of intraneural
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electrodes for reducing the amount of current needed for axonal stimula-
tion. The intraneural placement of the active sites also allowed meaningful
recordings of neural signals evoked by functional stimulation of afferent
axons in the rat sciatic nerve. The recordings were usually of integrated
action potentials, with seldom spikes, comparable to those obtained with
other intrafascicular electrodes (Branner and Normann, 2000; Yoshida et al.,
2000; Navarro et al., 2007).
In the comparative study for stimulation, the TIME was the only electrode
tested that provided good stimulation selectivity at interfascicular and also at
intrafascicular level with one electrode implanted, even in a small size nerve
such as the rat sciatic nerve. In contrast, the LIFE allowed only selectivity at
the intrafascicular level, and the multipolar cuff electrode only interfascicular
selectivity. Thus, the TIME has advantage in the relation between selectivity
and invasiveness. Even when the targeted muscle was stimulated above
30% of the maximal CMAP, a functionally relevant magnitude (Bao and
Silverstein, 2005; Paternostro-Sluga et al., 2008), the SId of TIME remained
higher than those of LIFE and cuff electrodes. These results suggest that the
optimal application of TIME device may be in the portions of the peripheral
nerve where different bundles of axons innervating different organs are in the
inner part of the nerve forming or not a fascicle encircled by perineurium.
By repositioning the TIME short distances in the transversal direction, the
selectivity of single active sites may be considerably improved, suggesting
the possibility of measuring the SIas of the TIME implant and then slightly
adjust its position in the nerve to optimize stimulation outcome. Once the
optimal position is achieved, the electrode can be fixed in place to the nerve
to avoid undesired displacements.
The works here summarized provide evidence that the TIME is a
good intraneural electrode to be used as a bidirectional interface between
neuroprostheses and the peripheral nerves. The TIME may be appropriate
for neuroprosthetic applications at mid and proximal levels of the nerves,
reducing the number of electrodes to be surgically implanted and thus mini-
mizing the risk of damage and the complexity of the interface connections.
6.3 Evaluation of TIME in the Pig Nerve Model
The pig nerve model was used for testing the TIME electrodes, because of
pig nerves anatomical resemblance to humans nerves in terms of number of
fascicles and nerve diameters. Two studies were conducted: (1) Initially acute
studies were performed to develop and test implantation techniques and with
the purpose to assess selectivity performance and required recruitment current
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of the TIME electrode; (2) Chronic studies were later conducted to assess the
selectivity performance, recruitment current, stability and biocompatibility of
the TIME (see chapter 5 also) during periods of implantation.
6.3.1 Acute Study of Stimulation Selectivity
TIMEs and tfLIFEs were implanted into the median nerve of the left
foreleg of farm pigs (Kundu et al., 2014). The TIMEs were implanted
transverse through the center of the nerve and the tfLIFEs were implanted
parallel to the nerve direction. Patch electrodes were sutured to the seven
muscles innervated by the median nerve distally for recording the evoked
electromyogram (EMG). Stimulation was performed using monopolar rect-
angular 100 µs duration current pulses, gradually increased in intensity from
40 to 800µA, with individual TIME/tfLIFE active sites as cathode. The
evoked EMG responses from the monitored muscle were used as an indirect
assessment of the nerve recruitment evoked by the tested TIME and tfLIFE
electrodes. The EMG recruitment level in percentage (EMGRL) for each
muscle, was calculated by taking the normalized root mean square value of
EMG response. The selectivity for each muscle (SIm), was then calculated
using the same selectivity index as in the rat experiments described above.
As a constrain to reduce the influence of noise in the EMG recordings,
SIm was calculated only when the target muscle was activated > 30%. The
specific 30% limit was defined as a minimum requirement for the recruitment
to be functionally relevant (Bao and Silverstein, 2005). To evaluate the
performance of a whole TIME/tlLIFE electrode a device selectivity index
(SId) was defined as the average of the maximal SIm achieved for each of
the seven monitored muscles. Finally, the required recruitment current was
calculated as the average current used, when achieving the maximal SIm.
After ending the stimulation protocol, the pig was euthanized. For eight
TIMEs and four tfLIFEs the location of the electrode inside the nerve
was determined via histology. For these instances the nerve was carefully
dissected free and harvested after which it was frozen in liquid nitrogen,
sectioned into 5 µm cross-sections and stained with Hematoxylin and Eosin.
6.3.1.1 Results
Results showed that individual muscles could be most selectively activated at
the lower current levels. When using higher currents, the selectivity dropped,
as more parts of the nerve were recruited. The TIME was on average capable
of recruiting 2.2 ± 0.9 muscles to a SIm > 0.5 whereas the tfLIFE on average
only selectivly activated 1± 0.0 muscles. Overall the TIME had a higher SId
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Figure 6.4 Heat maps indicate the selectivity achieved for individual muscles (M1–M7), 0
corresponding to white and black corresponding to 1, when using the different contact sites of
the TIME (1–6 and 1’–6’, corresponding to the contact sites on each side of the TIME loop
structure) and tfLIFE (1,1–4,4’). The histology images show the corresponding traces of the
inserted electrodes. In general, the TIMEs were better at activating several different muscles,
whereas the tfLIFE tended to activate a single muscle selectively. Reprinted with permission
from Kundu et al. 2014.
than the tfLIFE (p = 0.02) and performance was not found to be related to
the angle with which the electrodes had been implanted into the nerve (see
Figure 6.4). With respect to the required current, Id, no differences were found
between the two type of electrodes. Histological assessment, showed that all
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the electrodes had been placed between fascicles, and not inside the fascicles
as intended.
6.3.2 Chronic Study of Stimulation Selectivity
Four female Göttingen mini-pigs (25–40 kg) were implanted with a total
of six TIMEs over a period of >30 days (Harreby et al., 2015). TIMEs
were always implanted through the center of the nerve; when implanting two
electrodes in the same nerve, they were inserted at different angles to cover
different subsections of the nerve. TIMEs were sutured to the epineurium
using the anchoring points just at the entry point and at the ribbon, which con-
nected it to the ceramic connector, see Figure 6.5A. The ceramic connector
was fixed to tissue close to the nerve.
EMG patch electrodes were sutured onto five muscles innervated by the
median nerve and a cuff electrode was attached to the median nerve to provide
supramaximal stimulation.
The ceramic connector of the TIME implant was connected to a
16 channel circular connector (Omnetics Inc., Minneapolis, USA) via heli-
cally coiled MP35N wires enclosed in silicone tube shielding. The lead out
wires from the EMG and cuff electrodes were also connected to a 16 channel
circular connector. The silicone tube cables from TIMEs, cuff and EMG
electrodes were tunneled subcutaneously to the back of the pig and mounted
in a custom made stainless steel capsule, which was sutured to the skin.
Figure 6.5 (A) picture of the TIME implant. (B) Illustration indicating the TIMEs were
located inside the nerve. (B) Example was TIME electrodes are placed at 135◦ and 90◦. As
in the acute pig study, post-mortem findings showed the TIMEs had been located between the
fascicles. Reprinted with permission from Harreby et al. 2014.
6.3 Evaluation of TIME in the Pig Nerve Model 185
6.3.2.1 Follow-up methods
Follow-up sessions were performed two to three times a week for the duration
of the implantation period. During these events stimulation and recording
equipment was connected to the lead out wires via the Omnetics connectors
at the back of the pig.
All stimulation was conducted at 2 Hz using rectangular 100 µs current
pulses. Stimulation current gradually increasing up to 1200 µA, correspond-
ing to the maximal charge capacity of the TIME (Boretius et al., 2012). A total
of 22 stimulation configurations were evaluated for each TIME electrode:
12 corresponding to monopolar stimulation using each contact site (1–6
and 1’–6’). Then 10 nearest neighbor bipolar configurations were used (1–2
. . . 5–6 and 1’–2’ . . . 5’–6’).
In some instances EMG channels became unstable, in these cases
monopolar EMG recordings were made when possible. If monopolar record-
ing could not be satisfactorily obtained, the specific channel was omitted from
the analysis.
During offline analysis three different techniques were applied to clean
the EMG recordings for noise: (1) Stimulation artifacts were blanked out
and replaced by a linear interpolation, (2) the signal was band pass filtered
between 0.1 and 2 kHz, and (3) power line noise was reduced by subtracting a
“quiet” but noisy recorded signal segment 20 ms (period of powerline noise)
prior to the segment of interest. Evoked EMG activity was now quantified
using the RMS value as in the acute rat and pig studies.
The required current for activating a particular muscle, (Im30%) was
determined as the minimal current for any TIME contact configuration to
obtain a recruitment level of 30% (EMGRL30%). The minimal required
current for recruiting all monitored muscles using a single TIME device
(Id30%), was simply calculated as the average Im30% for each of the individual
muscles monitored.
The selectivity index used in this study was based on the one used in
the acute rat and pig study, but with a couple of adaptations/improvements.
Initially the constant weighting SI (SICW) was defined as:
SI(I)CW,j =
EMG(I)RL,j
EMG(I)RL,j + (NC − 1) ∗
(∑NA
i=1|i 6=j EMG(I)RL,i
NA−1
)
Here NC , is a constant corresponding to the number of muscles intended to
be monitored, and NA is the number of muscles from which EMG could
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actually be recorded. This reduces the bias induced if EMG could not be
recorded from all muscles, and thus the number of EMG channels changed.
If NC = NA,SICW simply corresponds to the selectivity indices used in [1]
and [2].
To ensure SIm = 0 when all muscles were equally activated, the following
correction was applied to SICW:
SI(I)m,j =
NC
NC − 1
∗
(
SI(I)CW,j −
1
NC
)
if SIm,j < 0 then SI(I)M,j = 0
This function can be calculated for each contact combination. SIm≥30%,j was
now defined as the highest SIm value which could be achieved by a single
TIME contact combination, when the recruitment level was EMGRL30% or
above. A muscle was defined as being selective activated when SIm > 0.4,
corresponding to an average nontarget recruitment of 1/4 of that of the target
muscle. To quantify the overall selectivity performance of a whole TIME
device the SId>30% was defined as the mean of all SIm≥30% values.
6.3.3 Results
Six TIMEs were implanted in four pigs for a total of 33.8±2.4 days. Current
pulses evoked EMG responses, occurring mainly between 3 and 10 ms after
the stimulation pulse onset, see Figure 6.6. Recruitment of muscles in general
started at the same current level, but individual muscles often differed in how
they were recruited at higher currents, these differences meant that some
muscles became more selectively recruited than others. Recruitment curves
were in general not smooth sigmoid curves, but rather increased with a mix of
increases and plateaus (see Figure 6.7b, c). In general monopolar stimulation
evoked more muscle activity than bipolar stimulation did at similar current
levels. During the first follow-up around half of the bipolar configurations
were able to evoke EMGRL > 30%, however, during the final follow-up
session only 3/60 could evoke such EMG. Initially, in five out of six TIMEs
all channels could evoke at least one EMG channel to EMGRL > 30%. Two
TIME electrodes gradually stopped being able to recruit muscles, however,
the remaining electrodes could recruit to EMGRL > 30% on nearly all
contact sites until last follow-up. The average Id30% was initially 488±68µA
and increased to 769± 128 µA during the last follow-up.
The SId≥30% started at 0.25 ± 0.04 during the initial follow-up and
gradually decreased to 0.14 ± 0.05 during the last follow-up (P = 0.12).
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Figure 6.6 (a) The raw evoked EMG response when stimulating in P2T1 at day 7 from
the five monitored muscles when stimulating monopolar using 3’. The dotted vertical lines
indicate 30% EMG recruitment (EMGRL30%). (b) Shows the recruitment EMGRL for each of
muscles during monopolar stimulation (G–Ground) with a subset of six contact sites of P2T1.
Note that the recruitment curves are not smooth, but rather have consist of steep increases
and plateaus. (c) Shows the recruitment curves related to a subset of bipolar stimulation
configurations. Note that the recruitment level is significant lower for bipolar stimulation than
for monopolar stimulation. Reprinted with permission from Harreby et al. 2014.
Based on our definition of selectively activated muscles, each TIME could
initially activate 1.17 ± 0.37 muscles, which dropped to 0.67 ± 0.38 dur-
ing the last follow-up (P = 0.18). Neighboring contact sites on the
TIME (same side and on opposite sides), tended to recruit the same mus-
cles, with only small variations in the recruitment curves. Electrodes P2T1
and P2T2 which were both implanted in the same nerve, recruited dif-
ferent subsets of muscles (Figure 6.7a, b). During the initial follow-up
bipolar stimulation configurations were selected at the best stimulation
configuration in 1/3 of cases, when calculating the SId≥30%, however,
if these configurations were left out of the overall SId≥30% calculation
(i.e., based only on monopolar stimulation) the value dropped only by
0.005, indicating that bipolar configurations contributed insignificantly to the
selectivity.
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Figure 6.7 The selectivity of individual muscles is shown as a function of muscle
recruitment level for a subset of monopolar stimulation configurations from electrodes P2T1
and P2T2 during the last follow-up session at day 37. The vertical and horizontal dotted lines
indicate the limits for EMGRL30% and SIm = 0.4, thus based on our definitions a muscle is
selectively recruited if it enters the upper right quadrant. In P2T1 muscles: M5 and M2 are
selectively activated, in P2T2 M3 and M1 are selectively recruited. Reprinted with permission
from Harreby et al. 2014.
6.3.4 Discussion
The acute pig experiments showed that the TIME design was more effective
than the tfLIFE to selectively activate different parts of a large polyfascicular
nerve. This is not surprising as the tfLIFE was designed to be placed in
parallel to the nerve, meaning that all the contact sites of one tfLIFE would
be placed close to the same few fascicles in the nerve. In contrast, the TIME
was implanted transversal through the nerve, which means that the contact
sites were placed along the whole cross-section of the nerve.
Although different methodologies were used and thus it is difficult to
compare directly, the selectivity seen in the pig model seem to be lower as
those achieved by implanting TIMEs in rats (Badia et al., 2011). There may
be several reasons for this. Badia et al. were able to insert the TIMEs directly
into the target fascicles of the small rat nerve, this resulted in a much smaller
recruitment current and a better selectivity. In the large nerve of the pig it was
not possible for us to insert into specific fascicles. Furthermore, the location
of the specific fascicles which innervated the muscles from which EMG were
recorded was not known. This meant that electrodes were inserted “blindly”
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through the epineurium. Inside the nerve, the needle then glided of the
tough perineurium of individual fascicles which resulted in the extrafascicular
placement. This location both increased the required recruitment current
needed and reduced the achievable selectivity. Methods to overcome the
extrafascicular location in the future could be to make previous neurolysis
of the nerve to separate the fascicles or to insert the guide needle at high
velocity, as have been done when placing the Utah array (Warwick et al.,
2003).
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7.1 Introduction
The human functions are controlled through different ways among which
both central and peripheral nervous systems (CNS, PNS) play a major
part. Within this complex network, the information code is based on action
potential (AP) generation. Then, when a sensory function is deficient,
inducing APs provides for a partial restoration of the lost function.
Electrical stimulation (ES) induces APs by depolarization of the
membrane of the targeted cell, i.e., axons or muscle fibers. From the fifties,
ES has been successfully used in a growing set of applications linked to motor
and sensory impairments including pain management.
Attempts to use this approach have been made in movement
rehabilitation, such as drop foot syndrome for hemiplegic patients (Liberson
et al., 1961) and more complex movements or functions for para- and
quadriplegic patients (Kralj et al., 1989; Davis et al., 1997; Kobetic et al.,
1997, 1999; Rijkhoff, 2004; Guiraud et al., 2014). In the latter case, the func-
tional results could prove to be substantial, including, for instance, recovery
of the grasp function for quadriplegic patients, who might then be able to grab
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hold of objects, eat, and even, in the best cases, write with a pen (Smith et al.,
1998).
In the sensory area, cochlear implants allow to recover sound perception
for deep deaf persons. The principle is basically the same as for motor restora-
tion with a set of electrodes that increased from one to more than twenty over
the thirty past years, located in the cochlea in order to activate the remaining
auditory neural circuits (Djourno et al., 1957). It allowed equipped deaf
people to understand speech and in the best case speak as healthy subjects.
However, available implanted stimulators dedicated to humans, remained
too limited to explore widely all the possibilities that new techniques could
provide (Mastinu et al., 2017). In particular, the selective approach applied
to nerves through either multicontact cuff (Schiefer et al., 2008) (Dali et al.,
2018) or, in the present work, intra fascicular electrodes, needs for advanced
multichannel stimulators. The TIME approach, proved to be quite efficient
(Badia et al., 2011) but needs for a synchronous 12 outputs stimulator design.
The selectivity was a mandatory feature as the project aims at inducing very
specific sensation’s feedback whereas the whole nerve obviously contains
multiple sensory targets, but also, even unused, motor ones. Moreover, as
the stimulator was used on humans, intrinsic safety was further needed. The
chapter describes the design, the use and the main important results issued
from this first-in-man test with multicontact TIME electrode.
7.2 Bench-top Stimulator
7.2.1 Design of the Bench-top Stimulator (Stim’ND)
Stim’ND is based on two main parts, a digital part and an analog one. The
analog part of Stim’ND is dedicated to stimulus generation and the digital
part, corresponding to the stimulation controller, embeds the functionalities
required for the stimulation execution and its remote programming and
control. This Stim’ND, whose global architecture is schematically repre-
sented in Figure 7.1, relies on the FES distributed architecture paradigm con-
sisting in decentralizing stimulation control close to the electrodes (Andreu
et al., 2009).
7.2.1.1 From specifications to design of the stimulator
Globally, the stimulator must allow the generation of multichannel current
pulse stimulus patterns, with the possibility to modify waveform, amplitude,
pulse duration, pulse rate, number of pulses, number, and timing of active
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Figure 7.1 Schematic representation of Stim’ND architecture.
Table 7.1 Stimulator specifications
Stimulation Parameter Range Step Size
Pulse waveform Fully programmable 1 µs step
Pulse amplitude 5 mA 1.3 µA (using 1/15 ratio) 20 µA
without ratio programming
Pulse duration Fully programmable 1 µs
Time between two
stimulation sequences
Fully programmable 1 µs
# Pulses in a pulse train Fully programmable Application software dependent
Frequency of pulses in a
pulse train
Fully programmable Single pulse mode, 10–500 Hz
# Sites activated in full
synchrony
Up to 12 Individually as anode and cathode
but at least one of each type, total
simultaneous current limited to
5 mA
channels. Moreover, the modification of the pattern’s amplitude and dura-
tion, must be allowed “on-line,” i.e., while the stimulation is running.
This functionality is called real-time modulation and is performed using an
experimenter-dedicated computer.
From a technical point of view, its specifications are given in Table 7.1.
Since the stimulator must be able to execute different kinds of stimulation
waveforms on different electrode configurations, we thus designed it accord-
ing to two main concepts: 3D electrodes and microprograms (MPs).
3D electrode: The stimulator drives the thin-film intrafascicular multichannel
electrode array (TIME-3H) with a maximum number of simultaneous poles
to be driven set to 12. Since active channels can correspond to any TIME-
3H configuration, the stimulus generator must be fully configurable, both
in terms of poles’ electrical configuration (active poles and their polarity)
and in terms of accurate current repartition between active poles. Such a
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configuration is called “3D electrode” (VE). A VE is thus an entity that
can be specified through the software environment and executed, from an
analog device configuration point of view, by the stimulator. The possibility
to specify different VEs is of importance since for an electrode placed within
the same nerve a number of possible combinations of active sites are supposed
to induce different sensations. This feature is based on the hypothesis that a
somatotopy exists within the targeted peripheral nerve.
Microprogram: Since several waveforms can be tested, from a simple
pulse to a pulse train and even other waveforms than pulses, the stimulator
must offer a simple way to program pulses, ramps, and any combination
of them to define more complex waveforms like trapezoidal waveforms
or approximated exponential ones. Moreover, the polarity of the waveform
is easily defined to provide charge-balanced waveforms. The stimulator
being remotely programmable, a stimulus (i.e., a sequence of waveforms)
is described by means of a MP.
Thus the stimulator, via its embedded specific processor (cf. Section
7.2.1.3), must offer a set of instructions that eases the description of
a stimulation profile. Since some parameters of the waveform must be
modulated in real-time during experiments, to find sensation and pain thresh-
olds, parameters of the stimulus – duration, amplitude, time between pulses,
and time between two stimulus (stimulation frequency) – must be externally
modifiable parameters. That means that these parameters will have an initial
value specified by the corresponding instruction of the MP and an effective
value modified by remote control, at any time while stimulation is running.
Since some parameters of the waveform can be modulated in “real-time”
during experiments, the security must be ensured on both sides:
– First, a security module embedded in the stimulator must ensure that a
specified set of constraints will always be respected. If not, this module
must immediately stop the stimulation and notify the detected violation
to the operator. Specified constraints will concern, for instance, the
maximum charge quantities that can be applied; these constraints will
be defined prior to the use of the stimulator, i.e., parameters cannot be
modified once the stimulation is running.
– Second, from the control environment in order to limit the range of
amplitude and duration values that can be applied; this feature aims at
ensuring comfortable and painless sensations.
Since different stimulus (MP) and multisite stimulations (VE) can be
achieved for sensation comparison purposes, the stimulator should allow
quick swapping between two multisite stimulations to ease experiments.
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So, the stimulator offers the possibility to remotely execute and switch
between two MP/VE (one at a time). Finally, since the stimulator must be
remotely controlled, it embeds a communication module.
7.2.1.2 The Stimulus Generator
Concerning the analog front-end, the basic idea consists in providing syn-
chronous current sources for each pole. The new idea we introduced
(Guiraud, 2011) is based on the decoupling of the ratio and the global current
control. To do so, a unique digital to analog current converter (DACC) is
used followed by a programmable current divider. In this case the current is
controlled in a completely different manner.
The most interesting benefits of such structure are that it allows:
• A constant step size of the global current amplitude Iref and a constant
maximum amplitude 255*Iref, whatever the ratios are if their sum is
constrained to 16.
• An independent control of ratios and global amplitude.
However, equivalent structures between both solutions may be found but
the cost is high. In a solution with 12 DACC, if we want to guarantee the
specifications in the worst case, we have to provide for DACC with 12-bit
resolution that leads to 144 bits word length. Moreover, DACC are much
more power supply demanding than dividers. An ASIC for a 12-pole structure
has been developed (Figure 7.1). This structure is able to provide sinking or
sourcing currents in order to allow each pole to be configured either as a
cathode or an anode (Figure 7.2). The programmed current divider at each
output stages, allows to map the VE concept to the hardware directly.
Indeed, this advanced output stage allows for a higher level of software
abstraction. In fact, on a functional point of view, both features mean different
things. The ratios configuration determines on which zone of the nerve the
current lines that induce action potentials are focused, whereas the global
amplitude is linked to the extent of this area around the focus point. Our
structure further optimized software design and data-flow.
7.2.1.3 The stimulation controller
The stimulation controller is the digital part of the stimulator. Its architec-
ture relies on a set of interconnected modules; each one corresponding to
previously mentioned functionalities.
The execution module, called “micromachine,” can be seen as a specific
and very small processor, similar to an application-specific instruction-set
processor (ASIP) that runs MPs written in a FES-dedicated, reduced 32-bit
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Figure 7.2 Principle of the output stage. Each channel can be configured as shunt (anode) for
passive discharge, anode controlled current or cathode controlled current. One current source
is used and spread over the 12 poles through ratios (Iai, Ici).
instruction set (summarized in Table 7.2). Doing so, it set the output configu-
ration (VE) and drives the analog subsystem by calibrating the current pulse
(waveform, amplitude, duration) to be applied to the multipolar electrode
(Figure 7.3).
The instruction set is limited to four basic instructions:
– SIT. This instruction generates a positive or a negative pulse with a given
intensity I during a given time T. A RT SIT instruction is a SIT where
T and I can be remotely modulated (during execution). In Figure 7.4,
the seventh instruction is a SIT generating a positive pulse of 5 mA
amplitude and 300 µs width.
– RP SIT. This instruction generates a positive or negative ramp with a
given step magnitude I, a given step duration T, during a number of
steps N. It can also indicate that the starting intensity is dependent on the
preceding instruction. A RT RP SIT instruction is a RP SIT instruction
where T and I can be remotely modulated. In Figure 7.4, the third
instruction is a RP SIT generating a train of 21 positive pulses (steps)
with a 200 µA variation of amplitude and a 10 µs pulse width.
– NST. This instruction sets the high impedance state or generates a limited
passive discharge on active anodes and cathodes during a given time T.
A RT NST instruction is a NST where T can be remotely modulated.
In Figure 7.4, the ninth instruction is a NST enabling a passive discharge
during 20 ms.
– Loop. A Loop instruction is interpreted as a termination marker for the
MP. At termination it generates a limited passive discharge followed by a
7.2 Bench-top Stimulator 199
Table 7.2 Instruction set of the Stim’ND micromachine
Name Description Possibilities Parameters
NST Discharge
instruction
Passive discharge or Inter
stimulation
Time (0–16 777 215 µs)
SIT Basic stimulation
instruction
Intensity (0–255 µA)
Time (0–511 µs)
LOOP Loop instruction Finite or infinite
Passive discharge or Inter
stimulation
1–32 768 loop
Conf P Pole configuration Anode, cathode, shunt
(anode), high-impedance
Conf R Ratio configuration Ratios K/16 K (1–16)
RT NST Real-time discharge
instruction
Passive discharge or
interstimulation
Time (0–16 777 215 µs)
RT SIT Real-time
stimulation
instruction
Modulation of I and T Intensity (0–255 µA)
Time (0–511 µs)
RP SIT Ramp stimulation
instruction
Current intensity
dependence with previous
instruction
Initial intensity (0–255 µA)
Initial time (0–255 µs)
Step number (0–255)
Intensity step (0–255 µA)
Time step (0–255 µs)
RT RP SIT Real-time ramp
stimulation
instruction
Current intensity
dependence with previous
instruction
Modulation of I and T
Initial intensity (0–255 µA)
First step duration (0–255 µs)
Number of steps (0–255)
Intensity step (0–255 µA)
Time step (0–255 µs)
global passive discharge for all poles or puts the poles in high impedance
state. It also embeds a jump operation addressing a previous instruction
in the sequence, to generate a loop in the MP. This back jump can be
repeated many times or infinitely until program explicit stop, as it is the
case of the last instruction of the MP given Figure 7.4.
Two other instructions are used to configure the analog output stage, since
this configuration is separated from the stimulation profile itself:
– CONF P is the instruction used to configure active poles. For each pole
to be used, it defines whether a pole is a cathode, an anode, a shunt (not
controllable anode) or is in high impedance state. The unique CONF P
in Figure 7.4 specifies that poles 1 and 3 are cathodes and pole 2 is an
anode.
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Figure 7.3 Four different stimulation waveforms generated by the miniaturized stimulator
in bipolar mode (left-up). Rectangular biphasic charge balanced waveform (20 µs, 1 mA)
with interstim (right-up) biphasic with passive discharge (1 ms, 4 mA) (left-down) biphasic
trapezoı̈dal pulse with passive discharge. Train of pulses on a tripolar configuration with
different current ratios, followed by a passive discharge (right-down). The signal is generated
on a 1 kΩ resistor.
Figure 7.4 Example of 48-byte MP (left). Resulting stimulus with ch1 being cathode 1, ch3
cathode 3, and ch2 a trigger (right).
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– CONF R is the instruction used to configure ratios of current between
active poles (controlled anodes and cathodes). In Figure 7.4, the unique
CONF R specifies that 75% of the current will be generated by cathode
1 and 25% by cathode 3.
– If CONF P and CONF R instructions must be used at the beginning
of MPs, they may also be inserted anywhere else in the sequence of
instructions to dynamically reconfigure poles and ratios, in order to
apply different waveforms to the selected poles.
The interface module supports the interface with the stimulus generator.
It ensures the effective electrical configuration of the analog device corre-
sponding to the VE on which the stimulation has to be applied. It also maps
control signals used by the micromachine with input signals of the analog
device.
The monitoring module is based on a reference model in charge of
monitoring in respect of neurophysiological constraints. These constraints are
described Table 7.3; for instance, Qmax is set to 120 nC which is the safe limit
of charge injection that the TIME-3H electrode can support. The monitoring
of these constraints is based on simultaneous application of the stimulation
to the nerve (via the stimulus generator) and to the reference model. Each
time the micromachine sends a command to the stimulus generator, it sends
the same command to the reference model. If any constraint is violated, the
reference model forces the micromachine to immediately stop the stimulation
and commute to a safe state. Thus, any error detection puts the stimulator
into a safe mode regarding the physiological system under control (putting
the output stage into a discharge mode). The micromachine then must be
remotely rearmed by the experimenter in order for the stimulation to be once
again authorized.
The stimulator does not perform any embedded diagnostic; it only
indicates the type of error that has been detected. Note that any error due
to the MP itself (e.g., coding error) is directly detected and managed within
the execution module.
The communication module contains a three-layer protocol stack
structured according to the reduced OSI-model with application, MAC
(medium access control) and physical layers. The MAC layer provides
logical addressing (and thus packet filtering) and deterministic medium
access control mechanisms, based on a master/slave model (Godary et al.,
2013). The application layer decodes the incoming packets, executes
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Table 7.3 Parameters of the monitoring module
Name Description Parameters
QMax Maximum quantity of electrical charges
injected by “stimulation” (SIT > 0), or
by “active discharge” (SIT < 0)
Electrical charges limit
(0–6.5535 µC) with a
100 pC step
QThreshold Maximum accepted residual quantity of
electrical charges after passive
discharge (after the end of a
microprogram)
Electrical charges limit
(0–6.5535 µC) with a
100 pC step
Min LPD duration Minimum passive discharge time (after
the end of a microprogram)
Duration limit (0–65 535 µs)
Figure 7.5 12-pole ASIC that can be seen in the center, about 4 mm × 4 mm, 0.35 µ HV
technology.
the request by controlling the micromachine and the reference model,
and it also encodes responses. From an application point of view, the
application layer supports all the communication with the experimenter-
dedicated computer (cf. Section 7.3.1): download/upload of MP and VE,
start/stop/commute/rearm of MP, notification of error detection, moni-
toring parameters’ initialization, and remote modulation of stimulation
parameters.
7.2.2 Prototyping of the Stimulator
The prototype of bench-top stimulator Stim’ND is essentially based on the
assembly of two chips, a digital chip and an analog one. The analog chip is
an ASIC (Figure 7.5) and the digital one is an FPGA, both being detailed
afterward.
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7.2.2.1 Prototyping of the stimulus generator
This is the heart of the device. It is connected to the patient via the charge
balancing capacitors and the electrodes. It consists in analog stages only, and
mainly a digitally driven current sources and digitally configurable switches.
The current sources are based on a patented method (Guiraud et al., 2010)
that allows performing synchronous multipolar stimulation with fixed ratios
whatever the total current is. The global current source is based on a 10-bits
resolution DACC, and the ratios can be programmed with a 4-bit resolution.
As the DACC is controlled by the micromachine with a resolution of 8 bits,
we used the 2 remaining bits to further improve the accuracy of the stimulator.
We thus divided the relative error over the whole scale by a factor of 3 leading
this error below 5% (Figure 7.6). It is able to source and sink up to 5 mA
under a 16 V DC voltage, on capacitive load. The pulse width is externally
controlled; the ASIC is able to manage pulse widths as short as 500 ns, but a
step of 1 µs is first proposed according to the needs.
7.2.2.2 Prototyping of the stimulation controller
Four modules constitute the stimulation controller, described in Figure 7.1.
Modules are specified by means of Petri nets (PNs) based components and
analyzed. Their implementation on programmable electronic device (FPGA)
is done using HILECOP tool1 (Leroux et al., 2015). For illustration, the PN
model of the monitoring module is shown in Figure 7.7 (the PN models of
the other modules being too complex to be shown).
Once modules have been composed and this composition analyzed, the
full digital architecture is automatically translated in VHDL [c1]2 using
HILECOP; the global PN, resulting from the assembly of the PNs of the
modules, contains about 700 places and 800 transitions. This digital architec-
ture constitutes a GALS system (globally asynchronous locally synchronous)
since its components have their own clock and are interconnected by means
of asynchronous signals. Two memories, directly described in VHDL (i.e.,
not generated by HILECOP), are used: the first memory is used to store the
MPs, and the second one is used to store stimulation parameters that are
on-line modified (remote stimulation modulation). Then this digital archi-
tecture is validated by simulation at RTL [c2]3 level using industrial tools,
1High-level hardware component programming tool, ensuring automatically the model
transformation from PN-components to VHDL, language from which a FPGA can be
programmed.
2Very high speed integrated circuit hardware description language.
3Register transfer level.
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Figure 7.6 As the DACC is on 12 bits but only 8 bits are finally coded, the 4 lower bits are
used to compensate the current error following an affine linear law. It cuts down the error from
about 20% to less than 5% error over the full scale.
directly implemented on a programmable electronic component (FPGA) and
functionally validated according to a set of validation-dedicated scenarios.
The stimulator controller embeds two memory zones to store two MPs
(the configuration of the VE being included in the MP). The stimulator
reacts to the following commands: Start (starting the stimulation according
to the selected MP, i.e., start z0 or start z1), Stop (stopping the ongoing
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Figure 7.7 PN model of the monitoring module (reference model).
stimulation), Rearm (rearming the stimulation after an error detection), and
Commute (changing the active MP). It also reacts to commands used to
change values of stimulation instructions (intensity, duration, etc.).
7.2.2.3 Prototypes of stim’ND
First of all, the bench-top stimulator (Figure 7.8, left) integrates safety aspects
in terms of power supply and connectivity. The power supply of Stim’ND is
based on batteries whose recharge system ensures that no stimulation can be
performed while batteries are recharging. It terms of connectivity, Stim’ND
is based on an optically insulated USB link. Moreover, to avoid any DC com-
ponent all output channels (to electrode contacts) are capacitively coupled.
Last, Stim’ND embeds a safety device allowing, if required, isolating the
Figure 7.8 Stim’ND prototypes (left) the benchtop version (right) the miniaturized version.
206 Synchronous Multichannel Stimulator with Embedded Safety Procedure
patient and the stimulator outputs; this full emergency insulation of the
patient from the stimulator relies on a global switch that opens all the circuits
between electrodes and the stimulator, and makes a short circuit between all
the electrodes to ensure no floating differential voltages. Besides, at all the
software levels from the embedded digital controller (the reference models)
to the remote configuration and control application, safety is considered to
ensure robust and redundant checking.
7.3 Software Suite
Several software tools have been developed during the project. The first soft-
ware is SENIS Manager: it allows configuring, programming, and controlling
all stimulators that are connected to the controller-like computer. The second
software, based on SENIS Manager API, has been developed for impedance
measurement purpose in order to verify the condition of the electrode and the
quality of the contact between the electrode and the neural tissue. The third
software is the psychoplatform described Chapter 9. These three software
applications remotely control the stimulator thanks to the embedded protocol
stack that makes any stimulator a communicating unit.
To allow for such remote control of the stimulators from any of those
software, the architecture has been designed and developed according to a
multitier architecture. It exploits a “runtime module” that acts as a middle-
ware in charge of communicating with stimulators (Figure 7.9); an applica-
tion programming interface is provided to connect the different software to
this runtime module.
Figure 7.9 N-tier architecture allowing remote control of the stimulators.
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7.3.1 SENIS Manager
SENIS Manager (Passama et al., 2011) is a software environment allowing
for FES architecture configuration. It consists in configuring each stimulator
that is connected to the dedicated network mastered by this controller-like
computer (i.e., that running SENIS Manager). The network can be a bus or
serial link. Discovering connected stimulators is based on a dedicated service
that checks if any stimulator is present (64 possible nodes).
Figure 7.10 (left) shows a simple architecture composed of the PC with its
associated control-box and one stimulator connected to the computer through
an isolated USB link in this case.
• Functionalities associated these entities are given in Figure 7.10 (right):
On the PC node the AutoChecker is used to periodically check (at
runtime) that each unit is still connected and the RTStimController is
used to control the stimulation process at runtime. On the stimulator
node, the Stim’ND functionality corresponds to stimulation facilities of
this kind of stimulator.
• Stimulation profile editing (Figure 7.11). It permits a graphical
specification of the stimulation profile, from which it generates the
corresponding MP. Depending on the instruction used some parameters
of the profile can be modulated.
• Electrode configurations (Figure 7.12, left). It allows describing config-
uration of the 12 channels (poles), setting active poles, their polarity and
ratios of current repartition between active poles knowing that the sum
of current ratios for cathodes must be 100% (as for anodes).
• Stimulators programming consists in downloading MPs in its memory
areas as well as setting the parameters of its reference model (safety
Figure 7.10 Example of simple architecture (left). Functionalities associated to entities
(right).
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Figure 7.11 Stimulation profile editing (left). Correspondence between icons and instruc-
tions (right).
Figure 7.12 Electrode configuration (left). Configuring reference model parameters (right).
module), as, for instance, the maximum quantity of injected charge
(Figure 7.12, right).
• Once configured and programmed, any stimulator can be remotely
controlled. Stimulation control relies on two main facilities that are
commands and stimulation modulations through online modification of
the stimulation parameters. This can be done through the HMI as well as
from a dedicated control-box (Figure 7.13) with four push-buttons and
eight rotary ones; association of push-buttons to RT commands (start,
stop, commute, rearm) and rotary ones to RT updates of parameters
(I, PW) is simply done through the software. For each rotary button,
the user has to associate: the concerned entity (i.e., stimulator), the
concerned MP, the RT instruction and the parameter to be modulated,
as well as min and max values for the given parameter (i.e., min and
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Figure 7.13 Configuring the control-box (left). Configuration of buttons (right).
Figure 7.14 Following of the stimulator and control-box states.
max values of the button). Using a control-box allows the practitioner to
keep attention on the stimulated target when controlling the stimulation
rather than on the screen.
Once started, the stimulator state and control-box parameters are
continuously monitored as shown Figure 7.14 where the stimulation is run-
ning and parameters are modulated, and Figure 7.15 where a constraint
violation has been detected by the stimulator that immediately went to a safe
state, waiting to be rearmed.
Different stimulations can be specified playing with the MPs’ internal
repetition and computer-driven sequencing of MP execution (Figure 7.16).
SENIS Manager can deal with individual entities (unicast addressing)
and groups of entities (multicast addressing), belonging to the same network.
Thus it allows for synchronized remote control of stimulators (RT commands
only) for multisite coordinated stimulation.
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Figure 7.15 Notification of a constraint violation to the control environment.
Figure 7.16 Example of microprogram sequence.
7.3.2 Impedance Follow-up Software
In order to verify the condition of the electrode and the quality of the contact
between the electrode and the neural tissue, during the implantation of the
TIME electrode and at few time instants after the implantation, the impedance
of each site of the four implanted TIME electrodes has been measured using
indirect method. For that purpose a small controlled-current stimuli (biphasic
rectangular pulses of 40 µA, 300 µs duration of each phase) were generated
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using each of the TIME electrode stimulation sites as a cathode and the
reference (GND) site of each electrode as the anode. While the stimuli were
generated the voltage drop between the cathode and the reference site as well
as the voltage drop on the 1 kΩ resistor inserted in series with the TIME
electrode have been measured. Based on those two measurements it was
possible to determine the impedance of each electrode site versus each of the
two reference sites (left and right) of the same electrode as well as between
the two reference sites of each electrode.
In order to facilitate those measurements and to ensure that the measure-
ments during follow-ups are performed in the same way, two applications
have been developed. The first one has been developed using the Microsoft
Visual Basic Express programing language (Figure 7.1) and allowed to gen-
erate a sequence of stimuli for various sites of the TIME electrode using
the Stim’ND stimulator. It also allowed pausing stimulation after generation
of stimuli for the particular site, leaving the time for the experimenter to
evaluate the results. The second application was developed using the National
Instruments LabVIEW Signal Express programing language and allowed to
record the voltage drops in the moment of stimulation and also to immediately
display results of the measurements for up to eight different stimulation sites
combinations (Figure 7.17 – example of the results obtained right after the
surgery for the TIME electrode implanted into the median nerve, results
Figure 7.17 The screenshot shows the control of the stimulator on the left and the resulting
current-voltage curves from which the estimation is performed (ratio of U and I at the end of
the active phase).
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obtained for the stimulating sites on the right side of the electrode versus
the right reference site).
Each of the implanted TIME electrodes had 16 contacts: seven on the
left side, seven on the right side, and two reference sites (one on the left
side – LGND and one on the right side – RGND). Therefore, for each TIME
electrode four measurement series were performed:
• Seven contacts on the left site and the right reference site versus the left
reference site
• Seven contacts on the left site and the left reference site versus the right
reference site
• Seven contacts on the right site and the left reference site versus the right
reference site
• Seven contacts on the right site and the right reference site versus the
left reference site
The measurements for each site has been performed versus each of the
reference sites in order to determine the reference site with lower impedance
and to be able to estimate impedance of all the stimulating sites even if one
of the reference sites was broken.
The developed application allowed performing each measurement series
(i.e., measurements for eight combinations of stimulating sites) in less than
0.0
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Figure 7.18 The four graphs represent the rough estimation of impedances (kohms) of all the
56 contacts. Two different profiles of impedances were found (green increase then decline, red
constant increase). The references are much bigger so the impedance is much lower. Finally,
open circuits have a clear and strong increase of the impedance from day 17.
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1 min. Because for each of the four TIME electrodes four measurement series
were performed (4 measurement series × 4 TIME electrodes), using those
applications it was possible to perform the measurement of impedance for all
the stimulating sites of the four TIME electrodes in less than 15 min.
The impedance measurements have been performed during the implanta-
tion of the electrodes, in order to verify the correct position of the electrode
and to provide feedback to the surgeon, and also right after the surgery as
well as 2, 11, 17, and 30 days after the implantation in order to track the
changes of the impedance during the course of the experiment. The results of
the measurements are presented in Figure 7.18. It may be observed that at the
last day of measurement (i.e., 30 days after the implantation) only seven sites
had higher impedance than expected (i.e., above 80 kΩ).
7.4 Discussion
The stimulator Stim’ND has shown its suitability to achieve selective multi-
polar stimulations. However, the different control modalities of the stimulator,
through different software and operators, have also revealed some necessary
improvements. Modulating the stimulation profile simultaneously playing
with several parameters of several instructions still is a cumbersome and
inefficient procedure. A new processor, more particularly a new set of
instructions, must be designed to allow the modulation of all or part of the
stimulation profile with notably preservation of charge-balanced stimulation.
As stimulation often relies on executing different kinds of stimulation
waveforms on different electrode configurations, we designed the stimulator
according to 3D electrode (VE) and MP concepts. Nevertheless at this stage
the description of a 3D electrode is inserted into a MP, thus limiting the
possible reuse of each of these entities. The stimulator should be able to be
programmed via these two entities, namely the tuple {VE, MP}, constituting
so key elements of a high-level programming language.
Finally, SEF applications may require the sequencing of different stimuli
(i.e., different tuples {VE, MP} executed in sequence). Remotely controlling
this sequencing poses a performance problem in the sequence of stimulations,
the remote control necessarily inducing a latency of communication and
decoding. One of the solutions would be to decentralize this functionality,
i.e., to embed it directly into a stimulation unit, at the expense of complexity,
surface, and consumption.
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8.1 Introduction
Use of electrical stimulation through implanted neural interfaces makes it
possible to selectively activate afferent neurons and provide natural sensory
feedback. However, effective stimulation patterns for creating natural sensory
feedback are not uniquely characterized in the literature. Thus, there is often a
need to evaluate various combinations of different stimulation parameters for
specific applications, which can produce a wide range of possible stimulation
patterns in a multichannel stimulation system. It makes the use of sensory
feedback an impracticable and time-consuming task. We therefore designed
and implemented a computerized tool referred to as a “Psychophysical
Testing Platform” to easily control multichannel stimulation and characterize
the evoked sensations. The tool was tested in a clinical trial including one
amputee with the aim to relieve his phantom limb pain (PLP) by manipulation
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of phantom sensation using intraneural stimulation. The tool may also be
utilized in systems based on surface electrical stimulation.
8.2 Sensory Feedback
Amputation of a limb involves the complete transection of afferent and
efferent nerves innervated the removed limb. Sensory feedback from the
missing part of the limb is thus severely impaired. While most amputees
experience that the absent limbs still exist (Kooijman et al., 2000), artificial
activation of the residual afferent neurons likely enhances the sensory feed-
back by creating more specific sensations, e.g., joint position or finger
movement. The enhanced sensory feedback may be utilized in prosthetic hand
control or PLP treatment (see, e.g., Flor et al., 2001; Rossini et al., 2010;
Dietrich et al., 2012).
Electrical stimulation has been recognized as one of the feasible
approaches to artificially activate sensory neurons, which can, according
to where the stimulation is applied, broadly be grouped into two types:
cutaneous stimulation and direct nerve stimulation (Riso, 1999). Cutaneous
stimulation may substitute impaired sensibilities by accessing the tactile
senses in the skin (Szeto and Saunders, 1982). Users are typically provided
with coded stimuli (such as modulation of pulse rate) and learn to relate these
codes to specific sensory information, e.g., pinch force (Shannon, 1979).
However, intensive cognitive load is usually required for a user to correctly
interpret the coded signal (Prior et al., 1976).
Stimulation directly applied to the peripheral nerves through implanted
nerve-electrode interfaces makes it possible to generate natural sensations
and provide more intuitive sensory feedback (Anani and Korner, 1979;
Dhillon et al., 2005). It has been demonstrated that intraneural stimulation via
implanted microelectrodes was capable of evoking sensation of touch, joint
position, and movement referred to the amputated limb (Dhillon et al., 2005;
Rossini et al., 2010). The orientation of the stimulation sites of the implanted
electrodes is usually blinded due to complex histological characteristics of
peripheral nerves as well as due to some limitations of the current surgical
procedures (Stewart, 2003; Harreby et al., 2012; Kundu et al., 2012). As
previously mentioned, the stimulation patterns capable of producing natural
sensory feedback are not well documented in the literature. Therefore, there
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is a need to consider a variety of possible combinations of stimulation param-
eters that may generate sensations such as touch/pressure, finger movement,
and vibration (Dhillon and Horch, 2005) or tingle, touch, vibration, buzz,
pinch in cutaneous stimulation (Kaczmarek et al., 1991; Pfeiffer, 1968).
The magnitude of a sensation is commonly estimated using scaling
methods by assigning a number to the perceptual event such as sensation
(Stevens, 1957). A 10-point visual analogue scale (VAS) is widely used, with
0 representing “no sensation” and 10 “the upper limit of a sensation or pain.”
There are also a number of other types of linear scales such as Likert scale
and Borg scale. A particular scaling method may outperform the others in
specific circumstances (Grant et al., 1999).
8.3 Sensory Feedback for Phantom Limb Pain
Treatment
In 50–80% of amputees, pain occurs in the missing limb, known as PLP
(Weeks et al., 2010). There are no effective, long-lasting treatments currently
available for PLP and it has not been completely understood why and how the
phantom pain develops. However, cortical reorganization has been discussed
as a plausible cause for the development of PLP (Ramachandran et al., 1992;
Flor et al., 1995) and a positive relation was found between the amount of
plasticity in the primary somatosensory cortex (S1) and the severity of PLP
(Florence et al., 2000; Lotze et al., 2001; Karl et al., 2004).
Several studies demonstrated a positive effect of enhancing sensory feed-
back on reversal of cortical changes and relief of PLP. For instance, the
patients who received daily training in sensory discrimination of surface
electrical stimuli applied to the stump, experienced reduction of PLP after
2 weeks (Flor et al., 2001). In another study, training in control of a robotic
hand with limited amount of sensory feedback significantly reduced PLP
in a human amputee implanted with four intrafascicular electrodes in the
nerve stump. The reduction in PLP lasted several weeks after removal of
the electrodes and changes in sensorimotor cortex topography were shown
(Rossini et al., 2010). A recent study found that use of a prosthesis that
provides somatosensory feedback on the grip strength effectively alleviated
PLP (Dietrich et al., 2012). The evidence suggested the likelihood to suppress
PLP by providing intensive, natural sensory feedback to amputee patients.
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8.4 Psychophysical Testing Platform Design
Strategy and Principles
The psychophysical testing platform was designed as a part of the “TIME
prototype system” to efficiently test, deliver, and evaluate generated sensory
feedback (see introduction).
The aim of the TIME (transverse intrafascicular multichannel electrodes)
project was to develop an implantable neural prosthesis system with suf-
ficient stimulation selectivity to generate phantom sensations and explore
the possibility of using the method as a potentially effective treatment for
PLP. The project hypothesized that manipulating phantom sensations using
selective stimulation of the nerve stump may reverse cortical reorganization
and consequently mitigate PLP.
TIME electrodes, each consisting of 12 stimulation sites, were designed
and manufactured by IMTEK (University of Freiburg, Germany) based
on micromachining technologies on flexible polymeric substrates (Boretius
et al., 2010) were used as the interface for the peripheral nerves, see also
Chapter 3. A customized 12-channel stimulator was developed (Montpel-
lier Laboratory of Informatics, Robotics, and Microelectronics and MXM
Neuromedics, France) to deliver the electrical stimulation, see also Chapter 7.
The psychophysical testing platform consisted of two computers inter-
acting with each other – i.e., subject performs psychophysical tests for
characterization of the delivered sensory feedback on Computer #1 and the
experimenter controls and monitors the stimulation process on computer #2.
Definition of the system functionalities was based on the experimental
tasks to be conducted. Three main experimental tasks were identified:
(1) determination of threshold, (2) characterization of sensation, and
(3) repeated application of “useful” stimulation.
• Experimental Task 1: Determination of the sensation threshold and
upper limit of sensation. Before applying stimulation for pain relief
treatment, it is necessary to determine which of the TIME electrode
active sites are functional and how much electricity should be injected
into each active site to elicit natural sensations referred to the phan-
tom hand. Therefore, the sensation threshold and the upper limit of
a sensation first needs to be determined. The sensation threshold is
defined as the current level where subject can just barely detect that a
stimulus is delivered. The upper limit of a sensation is defined as the
current level where the nature or the location of the sensation changes, or
when the sensation becomes uncomfortable or painful. To determine the
8.4 Psychophysical Testing Platform Design Strategy and Principles 221
sensation threshold, the intensity of the stimuli presented to the subject
should initially be sufficiently weak and then increase in successive
steps. Different psychophysical methods can be adopted to identify the
sensation threshold and the upper limit of the sensation (Ehrenstein
et al., 1999).
• Experimental Task 2: Sensation characterization. After thresholds are
determined, the perceived location, type, and intensity of the sensation
should be characterized for those active sties that were defined as
functional in Experimental Task 1. This task is important to identify
the stimulation patterns that can produce natural phantom sensations
which are interpreted as meaningful by the subject. The range of cur-
rent between the sensation threshold and the upper limit of sensation
are applied. Other parameters that are interested include: pulse dura-
tion, pulse frequency, single-pulse vs. pulse train, number of pulses,
monopolar vs. bipolar, as well as stimulation site combinations.
• Experimental Task 3: Repeated application of natural sensory feedback.
Repeated application of the stimulation patterns that were identified as
“meaningful” in Task 2 may reinforce the effect of sensory feedback
on cortical plasticity and PLP. A subset of optimal stimulation patterns
selected based on the results in the Task 2 is repeatedly applied in the
experimental task.
Four main functionalities were defined according to the tasks above
described.
• Functionality 1: Decide stimulation parameters. An interface is needed
for the experimenter to configure the stimulation parameters to be varied.
Each stimulus usually needs to be repeated multiple times and random-
ized to obtain a data set that later can be statistically analyzed. The
interface should thus allow repeated configuration of one or a series of
stimuli, as well as randomization of stimuli.
• Functionality 2: Determine thresholds. Threshold is usually determined
by delivering a set of stimuli with an intensity in the vicinity of the
threshold. An interface is developed for the subject to indicate whether
or not the stimulus just delivered was perceived or perceived as the upper
limit. The subject’s response and corresponding stimulation parameters
need to be tracked for later calculation of threshold.
• Functionality 3: Characterize sensations. A sensation can be character-
ized by three main attributes: location, type, and intensity. An interface is
needed for this psychophysical testing, which comprises a questionnaire
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presented to the subject for evaluating the three sensation attributes. The
subject’s response and corresponding stimulation parameters is tracked
for later identification of optimal stimulation patterns, or analysis of the
relation between a parameter and evoked sensation.
• Functionality 4: Automated repetition of stimulation and characteri-
zation. The large amount of stimulus patterns to be investigated to
determine the thresholds or characterize the sensations requires an effi-
cient way to deliver stimuli and characterize the evoked sensation. An
automated process of stimulus delivering, sensation characterization,
and data collection is the solution to address the issue. The system
supports the automated process, in which each session proceeds as
illustrated in Figure 8.2.
8.5 Software Components
The software was developed in the LabVIEW environment (National Instru-
ments). Control of the electrical stimulator was implemented through
accessing a set of application programming interface (API) functions built
in dynamic linked libraries provided by the stimulator developer.
The specified functionalities were implemented in two subsystems,
i.e., the stimulator and experiment control (SEC) subsystem (located in
Computer #1, see Figure 8.1) and the interactive subject interface (ISI)
subsystem (located in Computer #2, see Figure 8.2).
Stimulator and experiment control (SEC): The SEC subsystem provides a
tool for the experimenter to configure stimulation parameters, and monitor
Figure 8.1 Prototype system in the TIME project. The psyschophysical testing platform
was implemented on Computer #1 and Computer #2 to interact with the experimenter and the
subject.
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Figure 8.2 Flow chart showing automated process of stimulus delivering and sensation
measurement in one stimulation session.
stimulation process and experimental progress. To secure safe delivery of
the electrical stimulation it is possible for the experimenter to override the
otherwise automated stimulation process.
Interactive subject interface (ISI): The ISI subsystem provides the inter-
face to perform psychophysical testing with the subject, i.e., threshold
determination and sensation characterization. This subsystem also collects
all the subject’s responses for later data analysis.
The functionalities defined for the SEC were implemented in five modules
physically grouped in the main graphical user interface (GUI), as shown in the
screenshot (Figure 8.3). The five modules are described in details as follow.
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Figure 8.3 Screenshot of the main GUI of the SEC software with the five modules identified
(i.e., the module numbers are shown in the center of each module box).
Table 8.1 A list of stimulation parameters implemented in SEC software
Parameter Range Step Size
Pulse waveform Monophasic (negative or positive)
Biphasic (symmetric, positive following negative)
Biphasic (symmetric, negative following positive)
Biphasic (arbitrary amplitude and pulse duration)
N/A
Amplitude 5 mA 20 µs
Pulse duration 500 µs 1 µs
Number of pulses 1–5000 pulses 1
Frequency 1–1000 Hz 1 Hz
Module 1: Stimulation parameter configuration. In this module different
parameters can be configured in a panel consisting of several pages. Table 8.1
is a summary of the range and step size of each stimulation parameter. The
panel also includes a page where the stimulation constraints can be configured
to ensure the safety. If a stimulus violates the constraints, the stimulation
session will stop.
Module 2: Progress monitoring. A progress bar is used to indicate how
far a stimulation session has progressed. A textual indicator (light blue box)
shows specific status information of the stimulation session (e.g., which
stimulus was just delivered, waiting for a response from the subject). This
information is automatically saved in a log file. In addition, four numeric
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indicators are used to respectively display: (1) the total number of stimuli
in the ongoing stimulation session, (2) the number of stimuli already deliv-
ered, (3) the current level of the stimulus just delivered, and (4) the index of
the stimulus just delivered.
Module 3: Stimulator status monitoring. Four squared “LED” indica-
tors are used to indicate the status of interaction between the software and
the stimulator. These four indicators are used for trouble-shooting if the
stimulation process accidently stops or hangs during communicating with the
stimulator. Twelve round-shape “LED” indicators are used to indicate active
cathode channels (i.e., light up when active).
Module 4: Experimental control. This module allows to control the
experiment and choose the way that the configured stimuli are delivered. The
commands include:
• Add one or a series of increasing stimuli with constant step size.
• Randomize the order of the stimuli to be delivered.
• Start/stop/continue a stimulation session.
• Save the stimulus configurations to an external text file.
• Load stimulus configurations from a previously saved file.
• Clear and reset the stimuli.
Module 5: Graphical display. This module provides a graphical display of
the stimulus waveform just delivered in the 12 stimulator output channels.
8.6 Implementation of ISI Subsystem
The ISI subsystem software includes two main user interfaces: the interface
for threshold determination and the interface for sensation characterization.
The interface for threshold determination provides the subjects with a YES or
NO choice on whether or not the stimulation was perceived, or whether or not
the stimulation was perceived as the upper limit of a sensation (Figure 8.4).
In the interface for sensation characterization, three questions are
implemented with regard to the sensation type, location, and magnitude,
respectively (see Figure 8.5).
Question 1: Please choose one or more words to describe the sensa-
tion you felt. A list of words describing possible evoked sensation types
is predefined based on previous studies (Dhillon et al., 2005; Dhillon and
Horch, 2005; Rossini et al., 2010). The list includes touch/pressure, vibration,
tugging, spider crawling, pinch, pain, wrist flexion, wrist extension finger
flexion, finger extension, cold and warm. One or more types can be selected.
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Figure 8.4 Screenshot of user interface for threshold determination.
Figure 8.5 Screenshot of user interface for characterization of the sensation type, location,
and magnitude, each corresponding to a question in the red box.
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In case the perceived sensation is not covered by the list, an option of making
a note is provided to the subject.
Question 2: Please locate the sensation. Two pictures of the front and
back view of a human hand are provided for the subject to locate the evoked
sensation. The subject needs to point the cursor to the center of the perceived
region using the mouse. A red-color rectangular box will then be marked on
the hand picture. The width, length and angle of the box can be adjusted.
Question 3: Please use a number or a visual analogue scale to indicate
how strong you felt the sensation. Two approaches of measuring the sensation
strength were implemented: visual analogue scale (VAS) and open-ended
number. A VAS is a horizontal bar anchored by word descriptors at each
end (left end: no sensation, right end: upper limit of a sensation). The subject
can mark a point by moving the slider, to indicate how strong the sensation
is. The VAS score is then determined by the distance from the left end of the
bar to the point that the subject marks. Alternatively, the subject can use an
open-end number to indicate the magnitude of a sensation.
8.7 Communication Between SEC and ISI
The SEC and ISI software are able to communicate and exchange data
through a local area network to achieve the automated process of stimulation
and evaluation. The physical substrate of the communication is an Ether-
net crossover cable, which directly connects the two computers allowing
data transfer across the network. The LabVIEW DataSocket has been used
to realize data communication between two applications residing in two
computers.
8.8 Use of the Psychophysical Testing Platform
Training of amputee subject. One amputee volunteer was recruited for the
clinical test of the TIME prototype system (see also Chapter 9). Before the
subject had the electrodes implanted he went through a training session to
familiarize him with the automated stimulation-characterization procedure,
as well as the interactive interfaces for psychophysical testing. Comparing
the use of paper-based psychophysical questionnaire, the subject reported that
the system assisted and promoted the process of the psychophysical testing,
which helped him concentrate more on the actual experiments.
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Evaluation by clinical doctors. A questionnaire was used to evaluate
the usability of the software and user satisfaction of the interfaces. It was
developed based on a modification of IBM The Post-Study System Usabil-
ity Questionnaire (Lewis, 1995) and the Questionnaire for User Interface
Satisfaction (Chin et al., 1988). Only relevant questions from the original
questionnaires were included in our evaluation. This questionnaire was given
to our clinical partner who was using the software in clinical experiments.
The response to the questionnaire helped us understand what aspects of the
software they were particularly concerned about and satisfied with.
Use in clinical trials. When the electrodes were implanted in two main
nerves in the subject’s forearm (i.e., the median and ulnar nerve), the software
part of the TIME prototype system was used for clinical tests. SEC was
used to define specific stimulation sequences, define, and control the delivery
of the electrical stimulation, and monitor the progress of the experiment.
ISI was used to perform psychophysical testing, where the subject filled in
questionnaires to describe and quantify the perceived sensation referred in
the phantom hand (see Chapter 9).
8.9 Discussion
Following amputation, the complete truncation of afferent and efferent nerves
leads to lack of sensory feedback from the missing limb, and this can produce
a phantom pain effect. Artificial activation of sensory neurons may then
be considered as a solution to recover the impaired sensibility. Microfabri-
cated neural interfaces enable direct nerve stimulation with high selectivity.
However, morphological complexity and limited knowledge about optimal
stimulation strategies make it necessary to investigate a large number of
different combinations of stimulation parameters. To overcome these limi-
tations, a computerized tool may be used to efficiently evaluate the sensory
feedback in a multichannel, intraneural stimulation setting as described here.
We sought to evaluate the usability and user satisfaction of the software.
However, the evaluation was limited due to the simple fact that the system
was only used with one amputee subject.
Based on the experience obtained from the clinical tests, we believe
that the psychophysical testing platform may be improved in the following
aspects. For instance, a resizeable, rotatable rectangular box was used to
localize a sensation, since the perceived region could be in an irregular
shape. An improved tool should instead allow arbitrary drawing to localize
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the sensation more precisely and speed up the process further. Moreover,
bilateral upper-extremity amputees may not be able to control a computer
mouse conveniently. Using a touch screen could be easier, especially for
above-elbow amputees.
The platform was designed to collect the data from threshold and sen-
sation measure experiments. However, to counteract cortical plasticity and
consequently relieve PLP, it is necessary to carry out repeated, intensive
stimulation sessions. Therefore, a set of optimal stimulation patterns should
be identified based on the results in sensation characterization. The optimal
stimulation patterns is defined as those capable of eliciting clear, meaningful,
distinct sensation referred to the phantom hand, e.g., finger movement, touch,
joint position, etc. As such, a module that can automatically select optimal
stimulation patterns can be considered in future development.
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9.1 Introduction
Phantom limb pain (PLP) is a frequent consequence of amputation and can
be defined as pain in a body part that is no longer present. Although phantom
limb pain occurs in up to 85% of patients after amputation (Sherman and
Sherman, 1983), the characteristics of this pain vary drastically. Throbbing,
piercing and needle sensations are among the most commonly used descrip-
tors of PLP. The heterogeneity of phantom limb pain is widely acknowledged,
and it is recognized that the disorder likely arises from multiple mechanisms
(Flor et al., 2006). PLP is commonly considered as neuropathic and the
general view now is that many changes along the neuraxis, both peripheral
and central, contribute to the experience of PLP. A gold standard for PLP
treatment is still lacking since several studies, including large surveys of
patients with amputations, have shown that most treatments are ineffective
(Griffin and Tsao, 2014). Available therapies include acupuncture, deep brain
stimulation (Flor, 2002), mirror/virtual reality therapies (Chan et al., 2007;
Mercier and Sirigu, 2009), mental imagery (MacIver et al., 2008), tran-
scutaneous nerve stimulation (Katz and Melzack, 1991), deep brain, motor
cortex, spinal cord, dorsal root ganglion and peripheral nerve stimulation
(Krainick et al., 1980; Bittar et al., 2005; Ahmed et al., 2011), drugs such
as carbamazepine, opioids (Wu et al., 2008), gabapentin (Bone et al., 2002),
amitriptyline (Robinson et al., 2004), calcitonin (Jaeger and Maier, 1992),
ketamine (Eichenberger et al., 2008) and memantine (Nikolajsen et al., 2000),
local anaesthesia, sympathectomy, dorsal root entry-zone lesions, cordotomy
and rhizotomy (see Sherman et al., 1980; Sherman, 1997).
Following limb amputation and, consequently, truncation of nerves at the
stump level, a part of the nerve fibers originally directed to the lost part of the
body degenerates (because of retrograde Wallerian degeneration); however, a
significant part of them survives in the residual portion of the nerve. Thanks to
the rapid development of neural interfaces for the peripheral nervous system,
e.g. intraneural multichannel electrodes (Navarro et al., 2005), it was recently
demonstrated that it is possible to induct meaningful sensations (Dhillon
et al., 2005) in the phantom hand of amputees by stimulating the surviving
fibers through these interfaces.
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Peripheral nerve stimulation was the first clinical application of the
gate control theory proposed by Melzack and Wall (1965). This technique
requires the implantation of electrodes near, across or along a nerve trunk
(see Rasskazoff and Slavin, 2012) to provide stimulation-induced paresthesia.
Anecdotical reports showed efficacy of peripheral nerve stimulation in PLP
treatment.
Some studies have demonstrated a positive effect of providing sensory
feedback from the lost part of the body to alleviate PLP, e.g. through mir-
ror/virtual reality therapies, myoelectric prosthesis or daily discrimination
training of surface stimuli, electrical or mechanical, applied to the stump
(Antfolk et al., 2010; Antfolk et al., 2012; Börjman et al., 2012).
In the frame of a European founded project (called TIME), we
implemented a system able to perform a peripheral nerve stimulation, pro-
viding, at the same time, meaningful somatosensory feedback from the lost
hand in amputees (Raspopovic et al., 2014). This is a pilot study aiming to
test the feasibility, the safety of this system and its efficacy in treating PLP.
9.2 Methods
All procedures were approved by the local Ethics Committee and, being an
experimental trial using non-CE marked medical devices, also by the Italian
Ministry of Health. An informed consent was signed by the patient before
beginning the trial.
The system that we implemented was composed of two different medical
devices:
(1) intra-fascicular multichannel electrodes (TIMEs)
(2) multichannel stimulator system (Stim’ND)
The system was tested in a 34-year-old male with a traumatic transradial
(proximal third of the forearm) amputation of the left arm in January 2004.
About a week after the amputation, the patient began to present a painful
phantom limb syndrome, which at the time of the trial was reported as a
constant sensation of “very intense painful clenched fist” of the amputated
phantom hand, almost constant, worsening with the cold. On a scale from 0
(no pain) to 10 (maximum pain imaginable), the patient reported a constant
pain intensity of 9. Apart from the amputation and consequent PLP, the
clinical condition of the patient was unremarkable.
The TIMEs consist of a 10 µm thick polyimide-based substrate with
seven active electrode sites on each side of a loop-like structure and two
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reference electrodes, connected through a ceramic adaptor with a 18 mm
long polyimide ribbon ending with a 16 pole circular connector (NPC-16,
Omnetics Inc., Minneapolis, USA). Four electrodes (Boretius et al., 2010)
were surgically implanted into the median and ulnar nerves of the amputee
at the arm level. In both nerves, the two TIMEs were implanted, one distally
(closer to the elbow) and the other proximally (closer to the axilla).
To implant the TIMEs, in the operating room, a 15 cm long incision
was made in the left arm of the patient (along the internal bicipital groove)
in order to expose the nerves. The surgical intervention was performed in
general anesthesia. The median and ulnar nerves were dissected from the
surrounding tissue along all the length of the opening. In order to implant
the TIMEs, the same following procedure was performed for each electrode.
A short incision was made in the epineurium of selected nerves to have visual
feedback on the location of individual fascicles. Then, using a guiding needle
(Ethicon needle diameter 125 µm attached to a 10-0 Prolene suture), each
polyimide loop was implanted transversally (with respect to the longitudinal
direction of the nerve) to place the active sites inside the nerve, inside or
between fascicles. In order to check the positioning of the electrodes, inside
the operating room, each TIMEs was connected with the Stim’ND stimulator
to assess the electrode–tissue impedance and verify that the active sites had
been properly placed inside the nerve. After the check, in the case of proper
positioning, the electrode was anchored to the epineurium (with 8-0 non-
absorbable Silk suture) and surrounding tissues (with 4-0 non-absorbable Silk
suture) to avoid migration. A subcutaneous pocket was created to house the
lead-out cables of the TIMEs and, after a small skin incision, the electrode
was externalized to make it available for percutaneous connection with the
stimulator. Finally, the muscle and tissue were repositioned in their original
location and the wound was closed with 3-0 non-absorbable Ethilon suture.
Each cable was fixed at the exit point (3-0 non-absorbable Silk sutures).
The surgical operation lasted 7 hours. The participant was discharged
from the hospital 48 hours later with no post-surgical complications.
The Stim’ND is a multichannel electrical stimulator that, connected with
the TIMEs, was able to deliver electrical stimulation to the nerve through
the active sites of TIMEs, individually or simultaneously, with an amplitude
range of 20 µA–5.1 mA (step size of 20 µA between current levels) and a
pulse width range of 1–511 µs (minimum step size of 1 µs).
As previously stated in the introduction, it is possible to elicit sensations
in the phantom hand by stimulating the nerve fascicles (with intraneural
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multichannel electrodes) originally directed to the hand before the amputa-
tion. However, it is impossible to know in advance which type of feedback
and where it is possible to evoke these sensations. The only possibility to
discover the potential of the system is to perform a mapping of each electrode
and corresponding contacts (a process called sensation characterization) in
order to know the following:
• the location, type and strength of the generated sensation with respect to
the active stimulation sites used to generate them;
• the lower (thresholds) and upper (saturation) limits of the current to
be delivered in order to induce meaningful sensations (defined, respec-
tively, as the lowest stimulus pulse charge at which the subject reliably
feels a sensation and the pulse charge at which the sensation becomes
close to uncomfortable or painful);
• which electrode channels are useful and able to induce reliable sensory
feelings in the patient’s phantom hand (the sensation is considered
reliable if, when using the same characteristics of current, the generated
sensation is the same considering the strength, the location and the type
in at least two out of three repeated trials of stimulation; the charge
delivered for the three repeated trials is between the lower thresholds
and upper limits).
For this purpose, each channel of each electrode was connected with the
electrical stimulator in order to deliver short trains of current of variable
intensity and duration. More precisely, monopolar, charge-balanced, biphasic
and rectangular stimulation pulses were applied; the single pulse duration
varied between 25 and 300 µs (steps of 25 µs) and the pulse amplitude
between 40 and 300 µA (steps of 20 µA), and the pulses were delivered
with a frequency of 50 Hz over a 500 ms time window. The stimulator – and
consequently the parameters of the current to be injected into the nerves –
was managed by the operators, thanks to a specific software. The procedure
was performed as follows. First, train of current of increasing amplitude from
40 to 300 µA (steps of 20 µA) with a fixed pulse duration (the lowest, i.e.
25 µs) were delivered. After each stimulus, the patient was asked to provide
his feedback on the type, strength and location of the sensation (if any)
through a computer interface properly designed for the study. If no sensation
was reported, a second train of stimuli with the same range of amplitude but
with a higher step duration of 25 µs was delivered. The same procedure was
repeated progressively increasing the duration of the current (never exceeding
the maximum chemical safe charge injection limit per electrode site, i.e. 120
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nC) until the patient felt a mild sensation in the phantom hand for the first
time. In this case, the last train of stimuli was repeated twice with the same
characteristics and, if the same sensation was reported at least once, the
pattern of electrical parameters able to generate this sensation was identified
as the lowest threshold and coupled with the type, the localization and the
intensity of the sensation reported by the patient. The active sites not able to
elicit any sensation using the maximum charge possible, i.e. 120 nC, were
discarded from further use.
In order to determine the upper limit of sensation, we continued to
deliver trains of increasing current until the generated sensation became
uncomfortable. Also, in this case, the procedure was repeated twice with the
same characteristics and, if the same sensation was reported at least once, the
pattern of electrical parameters able to generate the uncomfortable sensation
was identified as the upper limit. Since minor changes of the electrode–
tissue interface can be expected during the weeks following surgery (i.e.
formation of fibrosis around the TIME device and possible micro-motion of
the polyimide loop placed inside the nerve), this procedure was repeated once
a week to ensure that the stimulation levels were appropriate.
When the lower threshold and upper limits were identified, a level of
current (in the range previously defined between the lower threshold and the
upper limit) able to evoke sensation perceived as medium-strength (according
to a scale from 0 to 10: 0 corresponding to no sensation and 10 to pain)
was delivered and the corresponding location, quality and kind of evoked
sensation were characterized.
Finally, strategies of simultaneous synchronous multichannel electrical
stimulation (i.e. stimulation of median and ulnar nerves with two or more
channels in parallel and simultaneously) were explored. As the number of
combinations of electrode channels was extremely large and time-consuming,
we first proceeded combining two channels of electrodes implanted in the two
different nerves (i.e. one in the median and one in the ulnar nerves) choosing
channels able to generate stable and reliable sensations with a minimum
amount of charge injected (among those with the same kind of sensory feeling
generated, i.e. the channel with the lower “lower threshold”). In order to
try to cover a wider area with the evoked sensation of the phantom hand,
we proceeded adding one or more channels in different combinations with
the aim of reaching the widest surface possible according to the feedback
of the patient. Since minor changes to the electrode–tissue interface can be
expected, this procedure was also repeated once a week.
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The TIMEs were explanted 30 days after the implantation for reasons
related to ethical and legal authorization.
9.2.1 Therapy
The most efficacious train of multichannel stimulation was used for pain
treatment. More precisely, the stimulation pattern delivered to the patient
as therapy was represented by sequences of 15 biphasic pulse trains lasting
0.5 seconds. The time interval between two consecutive trains was 1 second,
while that between two consecutive sequences was 10 seconds. The therapy
consisted of three sessions of 30 minutes (9 minutes stimulation, 1 minute
rest) each separated by 5 minutes. Every session lasted 100 minutes. The
daily session of treatment was repeated with the selected set of stimulation
parameters and active sites that produced reliable, distinct and the most com-
fortable and pain-releasing sensations while injecting the minimum amount
of charge. The stimulation sessions were performed for 10 days.
Pain assessment
To assess the effect of treatment, we used three different questionnaires: the
abbreviated version of the McGill Pain Questionnaire (sfMcGill), the present
pain intensity scale (PPI) and the pain visual analogue scale (VAS). In addi-
tion, the participant’s own qualitative descriptions of his pain perception were
recorded in an open-ended session. The questionnaires were used the first
time before the surgical implantation of TIMEs, second time after implant
of the TIME devices (but before starting the treatment) and daily where we
applied repeated stimulation sessions (either after the session only or both
before and after the session), and on day 30 (the day of the removal of the
TIMEs).
9.2.2 Assessment of Cortical Organization
Cortical reorganization was recorded with two different methods: electroen-
cephalography (EEG) and somatosensory evoked potentials (SEP). Both the
examinations were performed before and after the therapy.
9.2.2.1 EEG
EEG signals were recorded using a cap with 31 recording electrodes placed
according to the positions of the 10–20 international system (excluding Fpz
and Oz). The reference was at Fz and the ground at Fpz. An automatic artifact
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rejection algorithm excluded from the average all runs containing transient
exceeding +65 mV at any recording channel. Data were processed in Mat-
lab R2011b (MathWorks, Natick, MA) using scripts based on EEGLAB
11.0.5.4b toolbox (Swartz Center for Computational Neurosciences, La Jolla,
CA). EEG signals were bandpass filtered from 0.1 to 47 Hz using a finite
impulse response (FIR) filter. Imported data were divided in 2 second
duration epochs and visible artifacts in the EEG recordings (i.e. eye move-
ments, cardiac activity and scalp muscle contraction) were removed using an
independent component analysis (ICA) procedure (Formaggio et al., 2013;
Hoffmann et al., 2008; Jung et al., 2000) performed using the Infomax ICA
algorithm (Bell et al., 1995) as implemented in the EEGLAB. Artifact-free
EEG signals were used for the further analyses.
The recordings were performed in resting state, with the patient seated in
an arm chair for 5 minutes with eyes open and 5 minutes with eyes closed.
EEG power spectral density
We selected artifact-free EEG epochs and calculated the spectral density
(EEG signal bandwidth from 0.5 to 45 Hz with a resolution of 0.5 Hz,
frequency bands at delta: 2–4 Hz, theta: 4–8 Hz, alpha 1: 8–10.5 Hz, alpha 2:
10.5–13 Hz, beta 1: 13–20 Hz, beta 2: 20–30 Hz and gamma: 30–45 Hz).
EEG cortical source analysis
We estimated the three-dimensional distribution of the EEG activity by the
use of the standardized Low Resolution Electromagnetic Tomography Algo-
rithm (sLORETA). The output of the algorithm integrates information on
localization of signal sources with the brain tomography. Selected artifact-
free EEG segments were used for calculating the sLORETA intracranial
spectral density, with a resolution of 0.5 Hz, from 0.5 to 45 Hz. All EEG data
epochs were normalized and re-computed into cortical current density time
series at 6239 cortical voxels7. The voxels were collapsed at four regions
of interest (ROI) in each hemisphere, central (Brodmann areas: 8–11 and
44–47), frontal (Brodmann areas: 1–4 and 6), parietal (Brodmann areas: 5–7,
30, 39–40 and 43) and occipital (Brodmann areas: 17–19) coded according to
the Talairach space. The signal at each cortical ROI consisted of the averaged
electric neuronal activities of all voxels belonging to that ROI. The sLORETA
has shown to provide improved results over other methodologies, such as
the LORETA algorithm. The exact, zero-error localization property of the
method has been demonstrated, and no localization bias is introduced even in
the presence of measurement or biological noise (Pascual-Marqui et al., 2002;
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Pascual-Marqui et al., 2011). Also, localization agreement has been shown
with functional magnetic resonance imaging (fMRI), structural MRI, positron
emission tomography (PET) and intracranial recordings in humans.
Functional connectivity analysis
Brain connectivity was computed by sLORETA/eLORETA software on 84
ROIs defined according to the 42 Brodmann areas (BAs: 1–11, 13, 17–25,
27–47) for each hemisphere. Among the eLORETA current density time
series of the 84 ROIs, intracortical lagged linear coherence, extracted by
“all nearest voxels” method, was computed between all possible pairs of the
84 ROIs for each of the seven EEG frequency bands (delta (2–4 Hz), theta
(4–8 Hz), alpha 1 (8–10.5 Hz), alpha 2 (10.5–13 Hz), beta 1 (13–20 Hz), beta
2 (20–30 Hz) and gamma (30–45 Hz). The values of connectivity computing
between all pairs of ROIs for each frequency band were used as measure of
weight of the graph in the follow graph analyses. The lagged linear coherence
method was originally developed as a measure of physiological connectivity
that was not affected by volume conduction and low spatial resolution. It has
been shown to provide an improved connectivity measure8 in comparison to
the imaginary coherence method (Nolte et al., 2004).
Graph analysis
A network is a mathematical representation of a real-world complex system
and is defined by a collection of nodes (vertices) and links (edges) between
pairs of nodes. Nodes in large-scale brain networks usually represent brain
regions, while links represent anatomical, functional or effective connections
(Friston et al., 1994), depending on the dataset. Anatomical connections
typically correspond to white matter tracts between pairs of grey matter
(cortical areas or subcortical relays) brain regions.
Functional connections correspond to magnitudes of temporal correlations
in activity and may occur between pairs of anatomically unconnected regions.
The nature of nodes and links in brain networks is determined by combining
brain mapping methods, anatomical parcellation schemes and measures of
connectivity. Nodes should ideally represent brain regions with coherent pat-
terns of extrinsic anatomical or functional connections (Rubinov et al., 2006;
Sporns et al., 2006). Two core measures of graph theory were computed:
characteristic path length (L) and weighted clustering coefficient, represen-
tative of global connectedness and local interconnectedness, respectively
(Watts et al., 1998). The length of a path is indicated by the number of
connections it contains. The characteristic path length L (averaged shortest
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path length between all node pairs) is an emergent property of the graph,
which indicates how well its elements are integrated/interconnected. The
mean clustering coefficient is computed for all nodes of the graph and then
averaged. It is a measure for the tendency of network elements to form
local clusters 14. The respective distributions of global (L-random) and local
(C-random) connectedness values were calculated and averaged to obtain a
mean value for each core measure. The scale-free value, Gamma (γ) was
evaluated from the normalized C (C/C-random) and Lambda (λ) from the
normalized L (L/L-random). “Small-worldness” (Sigma σ) is the γ:λ ratio
and is used to describe the balance between the local connectedness and the
global integration of a network. When this ratio is larger than 1, a network is
said to have small-world properties.
9.2.2.2 SEP
To assess the cortical topography and responsiveness to sensory stimulation,
we analyzed somatosensory evoked maps. To obtain SEP, we stimulated the
median nerve at the elbow. The SEP amplitudes were measured in relation to
baseline recordings. SEP cortical components were identified on the basis of
their latency and polarity, and we created cortical maps based on the N20
component. The N20 component corresponds to arrival of the peripheral
nerve stimulation at the primary somatosensory area.
Somatosensory evoked potentials were performed by using a Micromed
System Plus Evolution, Mogliano Veneto, Italy. The somatosensory evoked
potentials were recorded using a cuff with 31 recording electrodes placed
according to the positions of the 10–20 international system 31 electrodes,
Fp1, Fp2, AF3, AF4, F7, F3, Fz, F4, F8, FC5, FC1, FC2, FC6, T3, C3, C7,
C4, T4, CP5, CP1, CP2, CP6, T5, P3, P7, P4, T6, PO3, PO4, O1 and O2. The
common reference was placed at the vertex and the ground at the forehead.
The signal was amplified and filtered (bandpass 0.3–70 Hz). An automatic
artifact rejection algorithm was used in order to exclude all runs containing
transient exceeding +65 mV at any recording channel from the average.
Peripheral nerve stimulation was performed with a surface bipolar electrode
stimulating the median nerve at the elbow, medially to the distal tendon of
biceps brachii. The electrical stimulation was performed with the stimulator
integrated in the Micromed System, and a pulse intensity able to generate
a clear motor twitch of flexors carpi and/or finger muscles was used. The
frequency of the stimulation was 1 Hz. Two separate averages – each com-
posed by 500 stimuli – were performed. If needed, according to the operator’s
judgment on the quality of the somatosensory evoked potentials recorded,
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one or more averages were added. The whole procedure was repeated on the
amputee side before and after the therapy and on the spared side only before
the therapy.
9.3 Results
The surgical implantation and removal of TIME electrodes on an amputee
was smooth and efficient after its careful planning. No complications related
to the surgical procedure and daily stimulation were observed. In particular,
no complications related to nerve injury, infection, bleeding and relocation of
the electrodes were observed.
The four implanted electrodes functioned during all the trials. It was
possible to stimulate the four implanted nerves using all channels except
seven contacts. The intraneural stimulation was able to evoke different sensa-
tions referred by the patients as “touch”, “pressure”, “vibration”, “a touching
wave” and “warm”. The more common reported sensations were “touch” and
“vibration”. The sensations were primarily located on the palm, thumb, index
and little finger of the phantom hand. The anatomical distribution of this
sensation was always congruent with the electrode used: electrodes inserted
on median nerve generated sensation in the median nerve innervated part of
the phantom hand and electrodes implanted on ulnar nerve evoked sensation
on the ulnar innervated portion of the phantom hand. Some channels, when
stimulated, produced an evident muscular twitch of the stump. The combined
stimulation of two or more different channels usually had two common
effects:
(1) The area of the phantom hand where the patient felt the sensation was
not simply the sum of the two portions of hand stimulated by using only
one of the channels.
(2) The current threshold needed to evoke a sensation was usually lower
than the threshold of the same electrode when used alone.
The charge required to elicit a specific sensation increased over time;
however, the quality and strength of the sensation generated remained stable
over time.
Many combinations of channels were tried and a combination of five
different active sites was selected for the treatment. This combination of chan-
nels produced a reliable, distinct, pain releasing and comfortable sensation
perceived by the patient as “a touching wave” covering the majority of the
palmar side of his phantom hand (Figure 9.1).
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Figure 9.1 Schematic representation of the areas of the patient’s phantom hand involved by
the sensation during intraneural stimulation. On the left side of the picture, the areas of the
phantom hand where the patient felt the sensation stimulating with five channels individually
can be seen. On the right side of the picture, the area of phantom hand where the patient felt
the sensation by stimulating simultaneously with the same five channels can be seen.
During the 10 days of treatment, the patient described a significant and
progressive decrease of his phantom limb pain (Figure 9.2) that was referred
as less “stabbing”, “sickening”, “sharp”, “fearful”, “gnawing”, “cramping”,
“hot”, “aching” and “heavy”. The patient experienced a maximum decrease
of pain intensity from 9 to 4/5 according to the VAS. A sensation of partial
opening of the phantom “clenched fist” was also referred by the patient
together with the pain decrease. However, the effect of treatment was of short
duration lasting only some hours after therapy; during the first three days of
therapy (lowest VAS score between 6 and 7, PPI score 4 and McGill score
between 12 and 20), the pain came back to normal before the patient went
to sleep, whereas during the last days of therapy, the relief from pain lasted
until the patient went to sleep and pain came back to normal when the patient
woke up (lowest VAS score between 4 and 5, PPI score 3 and McGill scores
between 6 and 9).
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Figure 9.2 Results of questionnaires for PLP evaluation. (A) A clear reduction of PLP is
evident in all three questionnaires: VAS, McGill and PPI. (B) Results of McGill more in detail:
a clear reduction of different qualities of pain during the treatment is evident.
The TIMEs were removed 30 days after the implantation without any side
effects.
From a neurophysiological point of view, the somatosensory evoked
potentials mapping showed a modification of the cortical topography in the
central–parietal areas contralateral to the amputation site, i.e. evaluated while
stimulating the left median nerve (Figure 9.3A). For comparison, we included
a map on the evoked potentials while stimulating the right median nerve. The
EEG source analysis (Figure 9.3B–C) showed a widespread reduction of delta
activity and a significant increase of alpha activity in the central–parietal areas
in both hemispheres following the repeated stimulation sessions, indicating a
shift of the EEG activity towards normal states.
Finally, the analysis of the cortical connectivity showed a less random
architecture of cerebral networks following the repeated stimulation ses-
sions, evident as a reduction on delta band and an increase on alpha band
frequencies (Figure 9.3D).
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9.4 Discussion
To the best of our knowledge, in this study, we present for the first time
the results of a new approach, based on peripheral nerve stimulation, for
PLP treatment. Our system combines the characteristics of peripheral nerve
stimulation with the new kind of intraneural interface that makes it possible
to evoke somatosensory sensation on the phantom hand of amputees. The
philosophy at the base of this new system was the possibility to combine
two kinds of treatment that individually already demonstrated, although in
a very small number of cases, efficacy in dealing with intractable (or poorly
responsive) PLP. Paresthesias are assumed essential for pain relief when using
conventional spinal cord, dorsal root ganglion or peripheral nerve stimulation
systems (Kumar et al., 1998; North et al., 2006). The other assumption of
these kinds of systems is the possibility to cover the areas of the body involved
by pain with paresthesia generated by electrical stimulation. In the design of
the protocol, along the lines of already existing and previously cited kinds
of stimulations, we decided to choose a pattern of stimulation able to cover,
as much as possible, the phantom hand surface, i.e. the painful area in our
amputee patient. In this perspective, median and ulnar nerves were chosen for
the implantation of TIMEs because their innervation territory covers almost
entirely the palmar and the finger sensory fields. In addition to the previous
anatomical consideration, a practical aspect was also taken into account in
choosing nerves to be implanted; given the level of amputation with a single
incision at the medial aspect of the arm, it was possible to expose both median
and ulnar nerves. To implant the radial nerve would have meant a second
incision and an even greater duration of surgery.
Paresthesias can be uncomfortable for some patients and sometimes can
limit the acceptable amplitude of stimulation during conventional spinal cord,
dorsal root ganglion or peripheral nerve stimulation systems (Kuechmann
et al., 2009). One of the advantages of our system is that we are able to avoid
this unpleasant sensation by substituting it with a natural, meaningful and
pleasant sensation in the missing part of the body. Moreover, the selective
stimulation of sensory fibers bypass the difficulty to stimulate mixed sensory
and motor nerve, avoiding recruitment of motor fibers. The latter is one of
the reasons why the electrical stimulation of the end “fields” of peripheral
nerves technique was developed and, also if in its infancy, is growing as an
effective option for local generation of paresthesia. However, in amputees,
this is not an option due to the absence of the area involved from pain. All
conventional electrical stimulation treatments (spinal cord, peripheral and
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dorsal root ganglion) require implantation of a dedicated device with the only
purpose of pain treatment. The future of prosthetics is going toward the use of
new generation prosthesis that can be controlled bidirectionally by the users.
This kind of prosthesis is based on the possibility to provide a somatosensory
feedback to the amputees, and that possibility is based on the implant of
the same (or similar) electrode used in our system (Raspopovic et al., 2014;
Tan et al., 2014). So, in the future perspectives, the great advantage of our
approach is that the same system will be used both for PLP treatment and for
the functioning of this new generation prosthesis.
During the 10 days of treatment, the patient experienced a decrease in his
phantom pain intensity together with a change in the qualitative perception
of his pain. However, this was only a transient effect (only for few hours
following the treatment). It is outside the purpose and possibilities of this
work to understand the mechanism of pain decrease and at what level of the
nervous system the stimulation might have acted, but some considerations can
be made. Peripheral nerve stimulation represented the first clinical application
of the gate control theory proposed by Melzack and Wall (1965). According
to this theory, the A-beta fibers interact within the substantia gelatinosa of
the posterior horn in the spinal cord with inhibitory interneurons able to
influence the wide dynamic range neuron, where both the large and small
pain fibers synapse, closing the gate and inhibiting the conduction of pain
(Treede, 2016). Although some recent evidence has questioned this theory,
the concept of early large fiber recruitment inhibiting small fiber conduction
remains the basis of the theory of electrical stimulation for pain treatment,
and recent studies demonstrated that peripheral nerve stimulation is able to
suppress subjective complaints of pain associated with noxious laser-induced
nociception (Ellrich and Lamp, 2005). The kind of sensation mainly evoked
with intraneural stimulation in our study was touch and vibration, and for
this reason, it is possible to hypothesize that with our system, large diameter
sensory fibers, like A-beta fibers, were the most likely recruited (probably
because of their lower excitability threshold). According to this assumption,
it is possible to speculate that one of the possible effects of our system was
mediated by the activation of these fibers with a mechanism similar to what
usually happens with peripheral nerve or other kinds of electrical stimulations
(e.g. spinal cord or dorsal root ganglion stimulations). The transient duration
of pain relief seems in accordance with this mechanism. However, other
mechanisms and levels of stimulus-induced plastic changes, both peripheral
and central, cannot be excluded. In particular, our results showed plastic
changes in the primary somatosensory area and a general increase of alpha
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band power density and connectivity following the trial that could have
contributed to the pain relief.
Our study confirmed the possibility, also after years from the amputation,
to deliver intraneural electrical stimulation and to generate meaningful and
comfortable sensations perceived from the phantom hand by amputees.
The majority of the channels of TIMEs remained functional during
the whole trial and the system was safe. No side effects related to the
implant/explant of TIMEs and repeated intraneural stimulation were observed
within a three-year follow-up.
Since the implant of the TIMEs cannot be fully controlled to target
specific sensory nerve fibers, we had to perform a mapping procedure in order
to match the different channels of the four electrodes with the corresponding
potentially evoked sensations. This is a highly time-consuming procedure but,
without a conceptual redesign of described procedures, should be considered
a necessary pre-condition for the proposed treatment.
The charge of electrical stimulation increased over time, likely due to
the ongoing healing process of the tissue and formation of fibrosis. For
this reason, a quick check of threshold at the beginning of each week was
needed. This is an issue that should be taken into account for future clinical
applications. The chronic application of this kind of treatment remains a big
unsolved issue and longer studies should be performed in order to test the
stability of the system over time.
Other limitations of the study are the following. (1) Data were obtained
only from one patient and thus generalization to a population should be
cautioned. However, this was a pilot study, and it is important to underline
the strong effort, in terms of time and money, performed in order to obtain
this proof of concept. (2) Intensity and dosage of treatment were fixed, and
it was not possible, also for ethical reasons, to blind the intervention neither
for the participant nor for the experimenters. Moreover, it was not possible to
conduct a SHAM stimulation. However, regarding this point, it is important to
underline that the simple procedure of intraneural stimulation did not provoke
any modification to PLP in our patient.
This study provides the demonstration of feasibility, safety and efficacy
of a newly developed system for PLP treatment. Other studies are needed in
order to test this treatment in a larger number of patients. Using the same sys-
tem, different paradigms of stimulation, in terms of frequency and duration of
treatment, could also be tested. The ongoing process of development of new
generation prosthesis, able to provide a somatosensory feedback, should be
considered as an opportunity to test this new therapeutic approach.
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The development of TIME electrodes was driven by the goal to investigate
the treatment of phantom limb pain in upper limb amputees by selective
intraneural stimulation. Can the experience with the approach be transferred
in other applications? What lessons have been learned with the approach
of intraneural thin-film-based stimulation electrodes embedded in polymer
substrates with respect to other implantation sites, stimulation paradigms, and
even other designs?
This chapter will discuss the most obvious next applications and speculate
about transfer in other treatment and rehabilitation scenarios in which flexible
but mechanically robust nerve interfaces could be advantageous.
Electrical stimulation to deliver sensory feedback (Pasluosta, 2017) is not
only limited to patients with limb loss after amputation. Evoked somatosen-
sory potentials (Granata, 2018) of the phantom hand cannot only be used to
diminish phantom limb pain (Stieglitz, 2012) but also to deliver signals for
sensory feedback in the control of artificial hand prostheses (Micera, 2016).
While the benefit of information about grasp force and object compliance
during grasping is beyond discussion and was achieved in a subchronic pilot
study (Raspopovic, 2014), improvement of proprioception (D’Anna) and
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embodiment (Rognini, 2018) based on intraneural sensory stimulation could
be shown in chronic implantations in three patients. Since delivery of sensory
feedback by intraneural stimulation was beneficial after amputation of the
upper limb, the research question arose whether sensory feedback after lower
limb amputation would improve the use of leg prostheses. Would there be
any additional information beyond the one that leg prostheses users get by
mechanical interaction of the stump with the prosthesis socket? Preliminary
results from studies over up to 4 months in three patients indicate that sensory
feedback delivered via four TIME in the residual nerves in the stump does
not only reduce energy consume during walking and decreases phantom limb
pain (Petrini, 2017 and 2019) but also restores the dexterity, confidence, and
ownership in lower-limb amputees (Raspopovic, 2017).
Further transfer scenarios have not been studied yet but include all
approaches in which nerves allow transversal implantation by pulling from
anatomical access and structure. Linear arrangements or arrays might cover
the cross-sectional area of any medium-sized mono- or multifascicular nerve
or selectively address subset of fibers in muscles for recording (Farina, 2008)
or stimulation. These scenarios include both, control and drive of artificial
limb prostheses as well as neuroprothetic control of paralyzed limbs. While
early suggestions of double-sided electrode arrays where pure technological
design studies (Stieglitz, 2001) on the nerve interface, current technology,
and manufacturing readiness levels have matured and allowed chronic first-
in-human studies. The requirement of electrode sites on both sides of the
implanted probe can be achieved by folding of the thin substrate instead
of using complex processes that drive manufacturing costs and quite often
result in low yield (Stieglitz, 2002; Poppendieck, 2014). However, for clinical
applications wireless systems without the need of percutaneous wires have to
be developed and delivered. If the electrode array with many channels and
the hermetic package housing electronic circuitry are rather concentrated like
in cochlear implants (Lenarz, 2018), direct connection of the array and the
hermetic package can be envisioned given that reliable pad-to-pad insulation
is delivered over the life-time of the implant (Khan, 2018).
Experiences made with clinical implants that experience mechanical
forces due to limb or muscle movements like cardiac pacemakers and deep
brain stimulators indicate the necessity of solvable connections to minimize
the invasiveness of the surgical procedure and allow for replacement of
implant components in the case of (wire) failures. The lack of implantable
connectors with about 16 channels or more is currently challenging research
groups as well as companies to develop fully implantable systems that
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would be able to drive several TIMEs at a time with a single implantable
pulse generator. Stimulator, package, and feedthrough technology is available
(Kohler, 2017) desperately awaiting innovation in the connector development.
Challenges in the course of increasing the technology readiness level and
commercialization address mainly aspects of longevity. Thin-film electrodes
embedded into polyimide substrates have been working reliably over up to
5 months under electrical stimulation in human studies and for more than 2
years in recording studies in nonhuman primates (unpublished data) but they
still have to prove their stability. The transition between the micromachined
substrate and “real” cables is one of the critical transitions known from many
medical and nonmedical developments. Scalability with respect to cables
and connectors is very specific for implants since approaches from telecom-
munication and automotive lack solutions for insulation in humid and salty
environment or size restrictions. A possible solution lies in the integration of
electronics with multiplexing capabilities and wireless data transmission and
energy supply close to the electrode array. Technology is available and solu-
tions could be developed with state of the art knowledge. This work, however,
needs more time and money that can regularly be allocated in research project
based on public funding. Private-public-partnerships, for example, made in
the framework of either strategic or venture capital-based start-up companies,
look for prefer to look for application with large patient numbers and high
therapeutic need to be able to transfer research ideas into a “mass market”
product and have a realistic chance for break even. Different levels of transla-
tional research can be foreseen in the preclinical research market or in clinical
studies and application. The lowest hanging fruits include the development
of flexible probes for the neuroscientific research community that mainly
addresses cortical or subcortical structures in rodent animal models. Using
insertion tools, polyimide-based probes show foreign body reactions that
are comparable to established microprobes or even below (Boehler, 2017).
When hearing research goes beyond cochlear implants toward the acoustic
nerve (Lenarz, 2018), the TIME approach delivers a good combination of
robustness in handling and flexibility at the material-tissue interface. It has
all prerequisites to deliver spatiotemporal stimulation patterns in a resolution
adequate to restore hearing at a better quality than currently existing auditory
brainstem implants. Huge patient numbers would benefit from solutions in
the field of bioelectronics medicine (Bouton, 2017). Widespread diseases
in aging societies include diabetes, hypertension, rheumatic arthritis, and
asthma with patient numbers far above those of neuronal disorders. The
vision to interface target nerves close to the end organs or interfere with the
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autonomous nervous system via the vagus nerve opens many scenarios in
which the TIME concept can deliver highly selective nerve interfaces with
relatively low degree of invasiveness. However, proof-of-concept studies in
small animal models have to validate the general concepts in this relatively
new field or research until translational studies can bring hope and new
treatment options to these patients.
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Böhler, C., Kleber, C., Martini, N., Xie, Y., Dryg, I., Stieglitz, T.,
Hofmann, U. G. and Asplund, M. (2017). Actively controlled release of
Dexamethasone from neural microelectrodes in a chronic in vivo study,
Biomaterials 129: 176–187.
Bouton, C. (2017). Cracking the neural code, treating paralysis and the future
of bioelectronic medicine. J Intern Med 282(1): 37–45.
D’Anna, E., Valle, G., Strauss, I., Patton, J., Petrini, F. M., Raspopovic, S.,
Granata, G., DiOrio, R., Stieglitz, T., Rossini, P. M. and Micera, S.
(2017). Simultaneous tactile and proprioceptive feedback in myo-
controlled hand prostheses using intraneural electrical stimulation.
Poster presentation at the 47th annual meeting of the Society for
Neuroscience (SfN 2017), Washington, D.C., USA, Abstract # 769.03.
Farina, D., Yoshida, K., Stieglitz, T. and Koch, K. P. (2008). Multi-channel
thin-film electrode for intramuscular electromyographic recordings,
J Appl Physiol 104(3): 821–827.
Granata, G., Di Iorio, R., Romanello, R., Iodice, F., Raspopovic, S., Petrini,
F., Strauss, I., Stieglitz, T., Cvancara, P., Giraud, D., Divoux, J.-L.,
Wauters, L., Hisarray, A., Jensen, W., Micera, S. and Rossini, P. M.
(2018). Phantom somatosensory evoked potentials following selective
fascicular intraneural electrical stimulation in two amputees. Clin Neu-
rophysiol 129: 1117–1120.
Khan, S., Ordonez, J. S. and Stieglitz, T. (2018). Reliability of spring inter-
connects for high channel-count polyimide electrodes array. J Micro-
mach Microeng 28 055007 (9 p.).
Kohler, F., Gkogkidis, C. A., Bentler, C., Wang, X., Gierthmuehlen, M.,
Fischer, J., Stolle, C., Reindl, L. M., Rickert, J., Stieglitz, T., Ball, T. and
Schuettler, M. (2017). Closed-loop interaction with the cerebral cortex: a
review of wireless implant technology. Brain-Computer Interfaces 4(3):
146–154.
References 259
Lenarz, T. (2018). Cochlear implant – state of the art. GMS Curr Top
Otorhinolaryngol Head Neck Surg 16:Doc04.
Micera, S., Raspopovic, S., Petrini, F., Carpaneto, J., Oddo, C., Badia, J.,
Stieglitz, T., Navarro, X., Rossini, P. M. and Granata G. (2016). On the
use of intraneural transversal electrodes to develop bidirectional bionic
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